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Abstract 
The overall aim of this project was to design and synthesise novel Protease 
Activated Receptor-1 (PAR-1) inhibitors in order to develop a novel treatment for 
Idiopathic Pulmonary Fibrosis (IPF). After finding the commercially available, 
allosteric PAR-1 inhibitor, “Q94” inactive and insoluble, focus switched to making 
novel vorapaxar analogues. A newly published synthetic route towards himbacine 
was successfully adapted to give vorapaxar analogues with a C-9-keto group. 
These were shown to have moderate potency against PAR-1 in a FLIPR calcium 
flux assay. After further synthetic route optimisation and investigation another novel 
vorapaxar analogue was identified. Compound (-)-94 was shown to be the most 
potent of the series of compounds tested, achieving an IC50 of 27 nM. In the same 
assay vorapaxar gave an IC50 of 13 nM. This makes (-)-94 a novel, potent, PAR-1 
inhibitor worthy of further investigation and development as a potential IPF drug.  
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Chapter 1: Introduction 
Idiopathic Pulmonary Fibrosis 
Diagnosis, Epidemiology and Pathogenesis 
Idiopathic pulmonary fibrosis (IPF) is the most common of the interstitial lung 
diseases (ILDs); a family of over 200 diseases that affect the interstitial tissue in 
the lung. It is chronic, progressive and characterised by scarring on the lung that 
gives rise to a honeycomb like texture and a poor gas exchange surface1. As the 
name suggests there is no known cause so it is only diagnosed once other 
interstitial lung diseases have been ruled out.2 However, there are several factors 
that have been associated with the diagnosis of IPF. Smoking has been shown to 
increase the risk of IPF, along with a work environment that exposes you to wood, 
metal, textile or stone dust.3 Finally, it has recently been suggested that some of 
the cases of IPF could be re-diagnosed as asbestosis.  
 
IPF and asbestosis both show symptoms of shortness of breath during everyday 
activities, a dry persistent cough and, in some cases, clubbing of the fingers. 
Further, their progression can both be tracked by a decline in forced vital capacity 
(FVC). The main difference is that in asbestosis the fibrosis is focussed around 
asbestos fibres5 whilst in IPF there is no obvious cause. IPF can now be diagnosed 
based on a High-Resolution Computed Tomography (HRCT)2 of the lung. This 
shows a characteristic histopathologic pattern in IPF lungs, known as usual 
interstitial pneumonia (UIP) (Figure 1). HRCT is a non-invasive scan making it a 
preferable diagnostic tool, in comparison to diagnosis by lung biopsy. Fortunately, 
there are certain characteristics that, in some cases, can mark a difference 
between IPF and asbestosis.6,7 Despite this, asbestosis is still often only diagnosed 
if the patient reports known asbestos exposure.8 This neglects the possibility of 
unknown asbestos exposure.9 A study which looked into the regional distribution of 
IPF and asbestosis diagnosis found that there were higher mortality rates, caused 
by IPF, in areas with a history of shipyard work. Around shipyards there would be 
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increased potential for unknown exposure to asbestos.10 This supports the idea 
that some of the IPF diagnoses could actually be asbestosis. 
 
 
Figure 1: Transverse high-resolution computed tomography (HRCT) image of IPF lung 
showing the characteristic usual interstitial pneumonia (UIP) pattern.11 
 
The potential mis-diagnosis of asbestosis as IPF highlights two issues. One, that 
the fibrotic response, seen with IPF, is observed in other related diseases and, two, 
that IPF is very difficult to diagnose.12 Consequently, the prevalence of IPF stated 
in different sources varies. A recent study suggested that there are over 5000 new 
cases of IPF a year in the UK alone. This may not sound like very many but, 
considering that the average life expectancy is only 3-5 years (post-diagnosis), it 
means that more people in the UK will die from IPF per year than from ovarian 
cancer, leukaemia, lymphoma or several other cancers. Further, the number of 
diagnoses is still on the increase.13  
 
Evidently, IPF is a growing concern. The post-diagnosis life expectancy is shorter 
than for many cancers whilst the prevalence, in some cases, is greater. Finally, the 
quality of life for sufferers is very poor. As a consequence, one may expect that 
there would already be a reasonable treatment for IPF available. Sadly, this is not 
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the case. Further, IPF research does not receive much in the way of funding, 
especially in comparison to the billions spent on cancer related studies.14 Despite 
this, over the last 15 years there has been a huge increase in the understanding of 
the pathogenesis of IPF, and consequently, a rise in the number of potential drugs 
reaching clinical trials. 
 
It was previously hypothesised that IPF was initiated by an inflammatory response 
in the lungs, as is the case for many of the non-IPF ILDs.15 However, it is now 
thought that IPF results from an aberrant wound healing process. The type I 
alveolar epithelial cells (AECs), which line most alveolar surfaces, are thought to 
be damaged upon lung epithelial injury. In the healthy lung, type I AECs regulate 
pulmonary structural mesenchymal cells. However, when they are damaged, type 
II AECs proliferate to cover the basement membrane and avoid alveolar collapse. 
The type II AECs should then undergo controlled apoptosis or differentiate into 
type I AECs.16  
 
It is thought that in the diseased state the type II AECs undergo uncontrolled 
apoptosis and release pro-fibrotic compounds, such as transforming growth factor-
β (TGF-β). The dying type II AECs can also attract fibroblasts which are known to 
differentiate into α-smooth muscle actin-expressing myofibroblasts. The end result 
is secretion of collagen, and other extra-cellular matrix proteins, which can be 
deposited at the site of injury.17 It is at this stage that the inflammatory response is 
thought to be initiated, attracting monocytes, macrophages and fibrocytes, which 
develop the fibrosis further. The dense collection of myofibroblasts and scarring 
create a “fibroblastic foci” around which, it is thought, AECs remain abnormal, 
helping to explain the fast rate of disease progression.18  
 
Past and Present Treatments 
In the past, glucocorticoids or immunosuppressive agents had been used to treat 
IPF, guided by the outdated belief that IPF was initiated by inflammation. Typically 
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a dual therapy of prednisone (Compounds 1a) and azathioprine (Compounds 1b) 
or a triple therapy of prednisone, azathioprine and N-acetylcysteine (NAC) 
(Compounds 1c) were given.19 Prednisone is an immunosuppressing synthetic 
corticosteroid used to treat certain inflammatory diseases and in high doses certain 
cancers.20 Azathioprine is an immunosuppressing purine analogue frequently used 
in organ transplant and for treating auto-immune diseases.21 Finally, NAC is a 
cysteine derivative which in itself is a mucolytic agent but is also a precursor to 
glutathione.22 Glutathione is an important anti-oxidant agent in the lung that 
becomes depleted in IPF patients which potentially allows oxidative stress 
mediated AEC injury. Small scale studies had shown that orally administered NAC 
increased the concentration of glutathione in the lung.23  
 
 
Compounds 1a, b and c: Prednisone, Azathioprine and N-Acetylcystiene; combine to give 
the triple therapy. 
 
The Idiopathic Pulmonary Fibrosis International Group Exploring N-Acetylcysteine I 
Annual (IFIGENIA) study was the original clinical trial which tested the triple 
therapy. The triple therapy was compared to the dual therapy because, at the time, 
that was the standard IPF treatment. It led to a significant reduction in absolute 
FVC and a decline in diffusion capacity (DLCO) suggesting that it was more 
effective than the dual therapy.24 Nevertheless, the study was criticised as (i) there 
was no placebo arm, (ii) the results had not been replicated and (iii) few patients 
completed the year-long study.25  
 
The prednisone, azathioprine, and N-acetylcysteine: a study that evaluates 
response in idiopathic pulmonary fibrosis (PANTHER-IPF) clinical trial compared 
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the triple therapy with NAC mono-therapy and to a placebo. The triple therapy arm 
of this trial was terminated early due to an excess in the number of deaths, 
hospitalisations, and serious adverse events among patients.26 This was pretty 
conclusive and stopped the prescription of immunosuppressants to IPF patients. 
The monotherapy and placebo arms were continued until study completion. 
Unfortunately, the recent results showed that NAC was no more effective than a 
placebo for reducing IPF development or decreasing the number of deaths.27  
 
The IFIGENIA study had been the first clinical trial to show a positive result for an 
IPF treatment. The negative results of the follow-up PANTHER-IPF trial gave the 
conclusion that immunosuppressants and NAC, like many other drugs that had 
been trialled for the treatment of IPF, were actually not effective. Warfarin (an 
anticoagulant) showed increased mortality.28 everolimus [a mammalian target of 
rapamycin (mTOR) inhibitor] gave increased disease progression29 and bosentan 
and macitentan (dual endothelin receptor antagonists) showed no significant 
results in comparison to placebo.30 These are just a few examples of the 
unsuccessful therapy options trialled; nevertheless, it highlights how difficult IPF is 
to treat. 
 
Until 2008, there were no drugs registered for the specific treatment of IPF. 
Patients were either given the dual or triple therapy or long-term oxygen therapy 
(LTOT). LTOT does nothing to the rate of disease progression but it helps to 
reduce the hypoxemia and thus increases the patients’ quality of life.31 The final 
treatment option was to have a lung transplant which may not always be viable.32 
Not only would there be long transplant waiting lists, but IPF is a seriously 
debilitating disease that usually affects 60-70 year olds. As a consequence, having 
an operation could be very risky for the patient. In 2008, however, pirfenidone 
(Compound 2) was registered as the first IPF treatment in Japan.33  
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Compound 2: Pirfenidone 
 
Pirfenidone is a small molecule which acts to reduce fibroblast proliferation, reduce 
the production of TGF-β, TGF-α and interleukin 1-β and inhibit collagen production 
promoted by TGF-β. This gives it anti-fibrotic and anti-inflammatory properties.34 It 
was developed by several companies; InterMune Inc. in the US, Shionogi Ltd. in 
Japan and GNI Group Ltd in China. Pirfenidone was registered in Japan in 2008, 
but, was only approved in China and Europe in 2011.35,36 The delayed approvals 
were prompted by the publishing of the results of the phase III, multinational, 
randomised, double-blind, placebo-controlled trials; Clinical Studies Assessing 
Pirfenidone in IPF: Research of Efficacy and Safety Outcomes 1 and 2 (CAPACITY 
1 and 2), results which prompted the delayed approvals. 
 
The results from the trials were slightly conflicting. CAPACITY 1 met its desired 
primary end-point, showing that pirfenidone slowed the decline in FVC when 
compared to placebo. CAPACITY 2, unfortunately, failed to meet this primary end-
point, but did show improvements in some of the secondary end-points.37 A final 
phase III trial was conducted to try and confirm the efficacy of pirfenidone. The 
Assessment of Pirfenidone to Confirm Efficacy and Safety in Idiopathic Pulmonary 
Fibrosis (ASCEND) study confirmed that pirfenidone is effective at increasing 
progression-free survival in IPF patients.38 The supporting data from the extra 
study was enough to warrant FDA approval in the US.39  
 
The success of the clinical trials and the growing market of pirfenidone should be 
good news to IPF sufferers. Regrettably, the patients who received the drug on the 
trial reported no improvements in how they felt. Further, pirfenidone causes 
gastrointestinal upset and skin photosensitisation. These side-effects were enough 
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to cause drug discontinuation in some of the study patients.40 Clearly, pirfenidone 
is a step in the right direction but it is not the solution. Inhalable pirfenidone is being 
investigated to try and overcome the photosensitisation issue but there is still 
clearly room for improvement.41  
 
Whilst InterMune were battling to get US approval for pirfenidone,42 Boehringer 
Ingelheim were racing to get their IPF drug to the market. Nintedanib (Compound 
3) targets and inhibits tyrosine kinases that act as growth factor receptors, 
especially platelet-derived growth factor receptor (PDGFR), fibroblast growth factor 
receptor (FGFR) and vascular endothelial growth factor receptor (VEGFR).43 
These have all been shown to contribute to the pathogenesis of pulmonary 
fibrosis.44 Subsequently, nintedanib has been shown in two parallel, randomised, 
double-blind, placebo-controlled, phase III clinical trials (INPULSIS-1 and -2) to 
reduce the rate of decline of FVC over a 52 week trial period.45 In other words, both 
trials met their primary end point, along with most of their secondary end-points. 
 
 
Compound 3: Nintedanib 
 
Nintedanib, although behind pirfenidone in coming to market, appears to offer 
superior treatment. Unlike pirfenidone, nintedanib shows no significant side-effects 
except for diarrhoea. Moreover, in one of the INPULSIS trials, the patients’ quality 
of life was said to be improved, based on a St George’s Respiratory 
Questionnaire.46 However, neither drug can claim to reverse the progression of 
IPF. A small Biotech, Fibrinogen, is planning further phase II trials for FG-3019. 
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This is after the initial data from one phase II trial which showed FG-3019 to 
reverse the fibrotic process based on forced vital capacity measurements and 
quantitative HRCT.47 FG-3019 is an antibody which targets connective tissue 
growth factor (CTGF). CTGF can induce excess fibrosis in combination with TGF-
β.48 Therefore, inhibiting CTGF can slow down the progression of fibrosis 
explaining the results seen with FG-3019. This is exciting progress for the field of 
IPF treatment. 
 
It is clear that there has been an expansion in IPF research. The understanding of 
how the disease is initiated and develops has advanced considerably. As a result, 
the standard pharmaceutical treatment that would have been given 10 years ago 
has been discontinued. In its place many potential drug candidates that target 
different receptors within the vast and complicated disease pathway have been 
trialled. As a result, pirfenidone has recently come to market as the first specific 
IPF drug, whilst nintedanib is likely to be approved for the treatment of IPF in the 
US within the next year. Despite all of this, there is still room for further research, 
as evidenced by Fibrinogen investing heavily on their novel antibody treatment, 
FG-3019.49  
 
Protease Activated Receptor-1 
Activation and Signalling 
The research presented in this thesis pertains to the protease activated receptor-1 
(PAR-1). PAR-1 belongs to a family of 7-transmembrane G-Protein Coupled 
Receptors (GPCRs) which were first cloned in 1991.50 There are currently four 
subclasses known, three of which; PAR-1, PAR-3 and PAR-4, are primarily 
activated by the protease thrombin.51 PAR-2, on the other hand, is typically 
agonised by trypsin. Thrombin has long been known as an important mediator in 
the coagulation pathway. Activation of this pathway is essential, upon tissue injury, 
to limit blood loss by promoting the formation of a fibrin clot. It was only in the last 
20 years that it was shown that thrombin exhibited its pro-coagulation effects, 
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along with its inflammation mediation and tissue repair, through the activation of 
PAR-1. As can be expected, PARs exist throughout the body and some cells 
express more than one type of PAR. Furthermore, PAR distribution appears to be 
species specific. 
 
γ 
β 
 
Figure 2: PAR-1 Signalling Pathways. LHS: Thrombin activated PAR-1- Gα12/13 
preferentially activated. RHS: TRAP activated PAR-1- Gαq preferentially activated All 
modes of activation are available in both cases. 
 
The discovery of the PARs uncovered a novel mode of receptor activation. In the 
case of PAR-1, thrombin binds to the specific amino acid sequence LPDR41-S42 
found on the N-terminal. Upon binding, it cleaves the amide bond between R41 and 
S42 leaving a new extracellular N-terminus. This acts as a tethered ligand by 
wrapping around to the PAR-1 active site (Figure 2).52 The affinity and potency of 
thrombin to PAR-1 is increased by a secondary interaction. This interaction is 
between the anion-binding exocite I, found on thrombin, and an acidic region, 
termed the “hirudin-like” domain, found on the PAR-1 N-terminus. Experimentally, 
PARs can be agonised by short peptide chains which are based around the 
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specific tethered ligand amino acid sequence. These are known as Thrombin 
Receptor Activating Peptides (TRAPs). Once activated, PAR-1 can couple to one 
of three classes of guanine nucleotide-binding proteins (G-proteins); Gα12/13, Gαq or 
Gαi. Evidence suggests that the mode of PAR-1 activation can influence which 
G-protein is coupled. Thrombin activation tends to lead to Gα12/13 association whilst 
using TRAP as the agonist will give predominantly Gαq coupling.53  
 
The activated G-proteins can initiate many different signalling pathways (Figure 2). 
The Gα12 and Gα13 subunits stimulate Rho GTPases which can cause shape 
changes in platelets and increase permeability and migration of endothelial cells. 
The Gαq subunits can activate phospholipase C-β (PLC-β) causing the hydrolysis 
of phosphoinositide (PI) and subsequent mobilisation of calcium (Ca2+) stores. In 
addition protein kinase C (PKC) can be activated by Gαq to give cellular responses 
such as granule secretion, integrin activation and platelet aggregation. The Gα i 
subunits act to promote platelet response by inhibiting adenylate cyclase (AC). 
Further, the Gβγ subunits, which are released from all of the G-protein subtypes, 
can alone activate a range of lipid-modifying enzymes, protein kinases and ion 
channels. Finally, the activated PAR-1 itself can cause the liberation of receptor 
tyrosine kinase ligands which can affect receptors associated with cell growth and 
differentiation.53  
 
It is becoming increasingly evident that the process of PAR activation is more 
complicated than originally thought. Although activation can occur via the tethered 
ligand, or using a TRAP, it is now clear that PARs can exist as dimers or oligomers 
and thus activate their partner intermolecularly or act as co-factors. This in turn can 
modulate the receptor response often by effecting which signalling pathway is 
activated. Human (h)PAR-1-PAR-1 homodimerisation has been observed; equally, 
hPAR-1 can also form heterodimers with hPAR-2, hPAR-3 and hPAR-4.54  
 
An experiment was carried out on an hPAR-1 homodimer made up of one 
signalling deficient receptor and one thrombin-resistant receptor. Normal 
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downstream signalling was shown when the mutant homodimers were stimulated 
with thrombin. This means that the thrombin-generated tethered ligand, on the 
receptor which could not itself signal, must have intermolecularly bound to the 
tethered ligand active site on the partner receptor to elicit a response. Naturally, 
the intermolecular agonism was less efficient than the standard intramolecular 
mechanism of activation; nevertheless, the type of downstream signalling did not 
appear to be affected.52 On the other hand, in the case of hPAR-1-hPAR-2 
heterodimerisation, hPAR-2 could also be intermolecularly activated by the PAR-1 
tethered ligand but the activated heterodimer conveyed different downstream 
signalling effects to those seen with monomeric hPAR-1 activation. An example of 
the modulated signalling can be seen in the pathogenesis of sepsis. In early phase 
sepsis, thrombin promotes vascular disruption via the PAR-1 activation of Gα12/13 
and Gαq signalling; whereas, in late stage sepsis, thrombin activation of PAR-1 
results in a PAR-2 downstream effect; Rac1 signalling. This suggests that the 
heterodimer offers increased functionality for thrombin activated PAR-1.55 
Heterodimerisation between hPAR-1 and hPAR-3 seems to cause activated PAR-1 
to preferentially couple to Gα13, in other words PAR-3 acts to modulate the activity 
of PAR-1.56 Finally, hPAR-1-hPAR-4 heterodimers appear to allow co-
factorisation.57  
 
The first example of PARs acting as co-factors was shown in mice. Murine (m) 
platelets express both mPAR-3 and mPAR-4, but not mPAR-1. PAR-3, like PAR-1, 
has the “hirudin-like” domain giving it high affinity for thrombin; PAR-4, on the other 
hand, does not. As a consequence, monomeric PAR-4 can only be activated in the 
presence of high concentrations of thrombin. However, it has been shown that, 
whilst mPAR-3 cannot cause thrombin-induced platelet activation and aggregation 
alone, when it is co-expressed with mPAR-4 low concentrations of thrombin can 
elicit platelet activation.58 It was later shown that thrombin remains bound to the 
“hirudin-like” site, on cleaved mPAR-3, with its active site free, thus allowing the N-
terminus, on the dimerised mPAR-4, to be subsequently cleaved.59  
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On human platelets there are also two types of PAR expressed; hPAR-1 and 
hPAR-4. These appear to also act as co-factors. Unlike mPAR-3, hPAR-1 can 
cause platelet activation, independently, at low concentrations of thrombin; whilst, 
monomeric hPAR-4 still requires high concentrations of thrombin to elicit a 
response. However, when co-expressed with hPAR-1, activated by thrombin but 
inhibited by a TRAP mimetic (RWJ-56110; Compound 5), hPAR-4 can be activated 
with low concentrations of thrombin. During the process of determining the specific 
contributions of each of the PARs, throughout platelet activation, it was shown that 
there was a rapid increase of intracellular Ca2+ upon thrombin activation of hPAR-
1. Interestingly, this was followed by a sustained Ca2+ flux response mediated by 
hPAR-4. Further, hPAR-4 was shown to sustain other secondary signalling 
responses essential for late phase platelet aggregation.57 This suggests that 
hPAR-4 has the important role of prolonging thrombin induced platelet activation, 
via hPAR-1-hPAR-4 co-factoring, rather than just being a PAR-1 back-up, as was 
originally hypothesised.60  
 
PAR-1 and Disease 
The extensive network of PAR-1 signalling pathways associates the receptor with a 
wide variety of disease states. Some of the lesser explored disease implications 
include the link between the PAR-1 gene and the genetic disorder 5q syndrome 
and the role of PAR-1 in cancer and in some neurological disorders.50 The most 
explored medical implication of the PAR-1 cascades involves the formation of 
thrombi. Thrombi are blood clots that reside in the blood vessels blocking blood 
flow. They may lead to further complications such as acute coronary syndrome 
(ACS), atherosclerosis or restenosis; the re-occlusion of blood vessels following 
invasive surgery. 
 
Anticoagulants such as warfarin, which inhibit thrombin directly, and antiplatelets 
like aspirin and clopidogrel, which inhibit platelet aggregation, have been used 
therapeutically to block the formation of thrombi.61 However, these medicines tend 
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to be non-selective and thus inhibit the homeostatic function of thrombin causing 
unwanted side-effects such as excessive off-target bleeding. Consequently, in the 
last 10 years, there has been a huge drive towards developing PAR-1 antagonists 
to treat the formation of arterial thrombi. PAR-1 inhibitors are predicted to be 
selective for a variety of reasons. For one, arterial thrombi are platelet rich giving 
rise to target selectivity due to the extensive role of PAR-1 in platelet aggregation. 
Moreover, PAR-1 is up-regulated in atherosclerotic plaques and, following vascular 
injury, in vascular smooth muscle cells. This increases the concentration of target 
receptors at the therapeutic site.62  
 
Idiopathic pulmonary fibrosis (IPF) involves lung inflammation and fibrosis following 
lung injury. It has been shown in knockout mice studies that PAR-1 was associated 
with fibrosis formation. It was seen that PAR-1 deficient mice were protected from 
bleomycin-induced pulmonary fibrosis.63 PAR-1 is responsible for the rapid 
proliferation of fibroblasts along with the overproduction of extracellular matrix 
proteins.64 These are both associated with the pathophysiology of pulmonary 
fibrosis. Further, as PAR-1 is associated with many activation pathways which give 
rise to profibrotic effects, such as cell migration and the secretion of profibrotic 
growth factors and cytokines, it follows that, in the absence of PAR-1, the fibrotic 
response will not be activated. 
 
Many of the potential drug candidates for IPF treatment target proteins 
downstream of PAR-1. However, the knockout mouse study highlights PAR-1 as a 
potential therapeutic target in itself. This is further supported by a study which 
showed that P1pal-12 limited the development of bleomycin-induced pulmonary 
fibrosis in mice.65 P1pal-12 is a pepducin that blocks the interaction between PAR-
1 and the relevant G-protein, explaining its inhibitory effects. PAR-1 is expressed in 
endothelium and in smooth muscle, both of which are found in the lung airways. 
Additionally, primary adult lung fibroblasts, and human pulmonary artery 
endothelial cells, also express PAR-1. Finally, it has been shown that PAR-1 
expression is up-regulated in inflammatory pulmonary diseases.66 In combination, 
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these factors make PAR-1 a promising drug target for the selective treatment of 
IPF. 
 
Protease Activated Receptor-1 Inhibitors 
There have been a number of PAR-1 inhibitors developed; however, to the best of 
our knowledge, none for the treatment of IPF. PAR-1 inhibitors have been used as 
research tools to help determine the biological pathways through which PAR-1 
gives its effects. Furthermore, several PAR-1 inhibitors have been evaluated in 
drug trials, predominantly, as target specific arterial antithrombotic agents. The 
most successful of these inhibitors has recently made it to market. Detailed below 
are some of the notable, literature PAR-1 inhibitors. 
 
RWJ-58259 
 
Compound 4: RWJ-58259 
 
One of the earliest effective PAR-1 inhibitors was developed by Johnson and 
Johnson. RWJ-58259 (Compound 4) was designed as a mimetic for the PAR-1 
tethered ligand amino acid sequence, Ser-Phe-Leu-Leu-Arg-Asn (SFLLRN). During 
the development process, the tethered ligand sequence was computationally 
modelled to find the lowest energy conformations. The results gave rise to the 
three-point receptor binding model (Figure 3). This dictated that the distance 
between the amino terminus, the benzene ring of the phenylalanine and the central 
carbon of the arginine guanidine group was important.67  
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Figure 3: SFLLRN and the three-point binding model. 
 
The series, which culminated in RWJ-58259, started with a 6-amino linked indole 
scaffold. The indole scaffold displayed a spatial arrangement which fulfilled the 
three-point receptor binding model.67 Following an extensive optimisation 
programme, which highlighted several significant structure activity relationships, 
the compound RWJ-56110 (Compound 5) was deemed a lead compound. 
Unfortunately, like some of the other early indole compounds, it displayed 
hypotensive effects when tested in guinea pigs.68 This led to the indole being 
replaced by an indazole to finally give RWJ-58259. 
 
 
Compound 5: RWJ-56110 
 
RWJ-56110 and RWJ-58259 showed comparable inhibition of thrombin induced 
human platelet aggregation (IC50 = 34 and 37 µM respectively). RWJ-58259, 
however, was better in most other respects. It showed improved PAR-1 binding in 
a binding assay previously developed by Johnson and Johnson (IC50 = 15 µM), 
improved potency in a rat aortic smooth muscle cell Ca2+ mobilization assay (IC50 = 
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0.07 µM) and in a rat vascular smooth muscle cell proliferation assay (IC50 = 2.3 
µM).69 Importantly, it also showed an improved toxicity profile in relation to the 
hypotensive effects seen with the indole compounds. 
 
In order to further develop the pre-clinical data profile for RWJ-58259 it was 
assessed in a number of different animal models. In a rat arterial balloon-injury 
model it showed a dose dependent reduction in neointimal thickness. On the other 
hand, the results were insignificant for the arteriovenous (AV) shunt, and the 
photochemically-induced thrombosis models, when conducted in guinea pigs. This 
was thought to reflect the additional presence of PAR-3 and PAR-4 found on 
guinea pig platelets.70  Finally, RWJ-58259 was tested using an electrolytic injury-
induced carotid thrombosis model in cynomolgus monkeys. Cynomolgus monkeys 
have a similar PAR-1 expression pattern to humans thus providing a very relevant 
model. Intravenously administered RWJ-58259 was shown to significantly reduce 
the time it took to form an occlusive thrombus in this model. Further, there was 
roughly a three-fold reduction in the relative area made up of platelets. Better still, it 
did not alter the composition of the blood or effect coagulation. 
 
The positive biological results would lead one to believe that RWJ-58259 would 
have been a suitable drug candidate. However, it is not orally bio-available which 
would limit it to use for acute treatments after events such as heart attack or stroke. 
In addition, there is some evidence to suggest that it has a very short half-life (t1/2). 
It was shown to be rapidly metabolized in an in vitro human liver microsome assay 
giving a t1/2 of only 9.2 min. It showed a slightly improved t1/2 of 30 min in rats 
following IV administration.71 These drawbacks made it unviable as a therapeutic 
drug. Still, given that it was amongst the first of the PAR-1 inhibitors, it received 
widespread use as a research tool. It was, and still is, used as a positive control for 
early stage target validation. Additionally, the development of suitable biological 
and animal models helped pave the way to better PAR-1 inhibitors. 
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Atopaxar (E5555) 
 
Compound 6: Atopaxar 
 
Atopaxar (Compound 6) is a 2-iminopyrrolidine derivative, developed by Eisai, 
which displays potent oral PAR-1 inhibition. There does not appear to be significant 
literature regarding the early development of atopaxar. The structure was claimed 
in a patent filed in 2002.72 It can be assumed that the scaffold, which led to 
atopaxar, was found via a high throughput screen. This is owing to the fact that the 
2-iminopyrrolidine scaffold is a common motif found in drug compounds. The 
patent literature shows thousands of example structures. This suggests that a vast 
library of 2-iminopyrrolidine derivatives were synthesised and tested allowing the 
structure activity relationship (SAR) at most positions to be explored before the 
structure of atopaxar was finally decided upon as a viable drug candidate.  
 
Atopaxar was evaluated in many of the same pre-clinical tests used with RWJ-
58259. In most respects it showed a better profile. It inhibited thrombin induced, 
human platelet, aggregation with an IC50 of 64 nM; this makes it 1000 times more 
efficient than RWJ-58259. Equally, atopaxar was found to inhibit the binding of 
[3H]-high-affinity (ha) TRAP to PAR-1, in human platelet membranes, with a 1000 
times greater potency (IC50 = 19 nM). The fact that atopaxar competes with TRAP 
suggests that it, like RWJ-58259, must bind at or close to the tethered-ligand 
binding site. 
 
In the rat smooth muscle cell proliferation assay atopaxar exhibited an IC50 value of 
0.16 µM.73 This makes it about 15 times more potent than RWJ-58259, in this 
model. Atopaxar, like RWJ-58259, showed a significant reduction in neointimal 
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formation in the rat arterial balloon-injury model.74 However, unlike RWJ-58259, a 
100 mg/kg oral dosing of atopaxar prolonged the arterial occlusion time 2.4-fold, in 
comparison to the vector alone, in the guinea pig photochemically-induced 
thrombosis model. Importantly, it gave this result without increasing bleed time or 
effecting coagulation.75 These results led Eisai to believe that atopaxar had the 
potential to treat arterial thrombosis in humans. 
 
Atopaxar had shown great potential in animal studies. The next stage was to 
assess the safety and pharmacodynamics (PD) within humans. The first phase I 
study had three randomly assigned groups of twelve healthy volunteers. The 
participants of each group received a once daily dose of 50, 100 or 200 mg 
atopaxar, or the placebo equivalent, over a period of 14 days. The results from this 
study showed atopaxar to have a Tmax of 3.5 h, a t1/2 of 23 h and to reach a steady 
state after 11 days. Further, there was significant ex vivo platelet aggregation 
inhibition and no adverse side-effects at all dose concentrations.76  
 
A second slightly larger phase I trial was conducted. In this study there were eight 
randomly assigned groups of eight healthy male volunteers. Five of the groups 
received a single oral dose of 20, 50, 100, 200 or 400 mg of atopaxar. The final 
three groups were randomly assigned to receive a once daily oral dose of 50, 100 
or 200 mg atopaxar over a period of 10 days. Some of the volunteers, within the 
repeated dose groups, were randomly assigned to receive a placebo giving a 
double-blind, placebo-controlled trial. The inhibitory effect on platelet aggregation 
was determined ex vivo. It was found that in all but the 20 mg dosing thrombin 
induced platelet aggregation was inhibited by over 80%. Furthermore, in the 
repeated dose groups, it was seen that this inhibitory effect was maintained with 
subsequent dosing. Even at 24 h after dosing 100% inhibition of platelet 
aggregation was observed in those receiving repeat doses of 100 or 200 mg 
atopaxar. This highlighted the long t1/2 shown by atopaxar. Importantly, atopaxar 
again appeared to be well tolerated at all doses and showed no changes in 
coagulation time and bleeding time.77  
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The success of the phase I trials led Eisai to progress atopaxar to assess it in a 
larger population in Phase II trials. They completed two dual-arm, multicentre, 
randomised, double-blind, placebo-controlled studies. The first; Japanese-Lessons 
From Antagonizing the Cellular Effects of Thrombin (J-LANCELOT) recruited 504 
Japanese patients.78 One arm of the study was made up of 241 patients who had 
ACS. The remaining patients had high-risk coronary artery disease (CAD) and 
were assigned to the second arm. The patients in the J-LANCELOT-ACS arm were 
randomized into one of four dose groups; placebo, 50, 100 or 200 mg atopaxar. 
The patients were given once daily dosing, for 12 weeks following a 400 mg load 
dose or placebo equivalent. The patients in the J-LANCELOT-CAD arm were 
randomized into the same dosing groups but did not receive the load dose and 
were treated for 24 weeks rather than for 12. The trial therapy was given in addition 
to the patients’ personal standard of care which, in 75% of the cases, was the dual 
therapy of aspirin and clopidogrel. In both groups, the primary end-point was the 
number of bleed events, the secondary end-point was the number of major 
adverse cardiovascular events (MACEs) and finally, an ex vivo, aggregation 
assessment was performed. The results showed no significant difference in the 
incidence of bleed events between each of the dose groups suggesting that 
atopaxar does not cause off target bleeding. There was also no significant 
difference in the occurrence of MACEs thus, unfortunately, providing no evidence 
for the efficacy of atopaxar. Finally, the aggregation assessments reflected the 
positive results found in the phase I trials. 
 
The second phase II trial was conducted outside of Japan, using the same study 
protocol, but a larger study population; 603 and 720 in the LANCELOT-ACS and 
LANCELOT-CAD arms respectively. Again, there was no significant difference in 
the number of bleed events, or MACEs, between all of the dose groups. Of 
moderate concern was the observation of up-regulated liver enzymes; alanine and 
aspartate aminotransferase, and dose-related prolongation of the corrected QT 
interval, seen in both clinical trials. In summary, the results from the phase II trials 
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highlighted a few potential safety concerns and, due to the insufficient population 
size, did not show conclusive efficacy. It was concluded that a phase III trial would 
be needed to determine whether the significant results in the aggregation 
measurements could correlate to a real clinical effect. 
 
Since the completion of the phase II trials there have been a few further 
investigations using atopaxar. Two smaller clinical trials have been conducted 
assessing drug-drug interactions in healthy subjects. The first was between 
atopaxar and diltiazem (NCT01261156); a drug commonly used to treat 
hypertension and angina.79 More importantly, diltiazem is a mild cytochrome P450 
3A4 (CYP3A4) inhibitor. Since, atopaxar is mainly metabolised by CYP3A4, this 
study was largely focused on the effects diltiazem had on the pharmacokinetics 
(PK) and PD of atopaxar. The second trial showed the interactions between 
atopaxar and metformin (NCT01241669); an oral anti-diabetic drug used to treat 
type II diabetes.80 Metformin, is a superior organic cation transporter-2 (OCT-2) 
substrate.81 OCT-2 is the major cation transporter protein in the kidney so this 
study was primarily designed to determine the effects of atopaxar on renal function. 
However, the study was also being used to determine the effects of atopaxar on 
metformin PD. The results from these studies, although complete, have yet to be 
published. However, as patients with ACS or CAD are likely to suffer from 
hypertension, angina and/or type II diabetes, the results would greatly influence the 
decisions made by Eisai regarding the progression of atopaxar. The results may 
even promote a change in utility if atopaxar slowed the clearance of metformin. 
 
The results from the pre-clinical data suggested that, not only did atopaxar inhibit 
PAR-1 associated platelet aggregation; it also inhibited non-PAR-1 related platelet 
activation. To gain fuller appreciation of the inhibitory effects of atopaxar an in vitro 
study was conducted. The study used the blood of healthy volunteers, who had 
several cardiovascular risk factors, and of patients with known CAD. The CAD 
patients were either receiving a single therapy of aspirin or a dual therapy of aspirin 
and clopidogrel; the standard treatment options for CAD. The blood was used to 
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conduct a series of tests for standard platelet biomarkers. It was concluded that 
atopaxar exhibited moderate inhibition of platelet activation beyond that expected 
from direct PAR-1 blockade. Additionally, the study showed that atopaxar 
enhanced the anti-platelet activities of lone aspirin and combined aspirin and 
clopidogrel therapies. It also provided useful data for the determination of a 
suitable effective dose were atopaxar to be progressed to phase III clinical trials.82  
 
Despite the completion of additional post-phase II studies in 2012, Eisai 
discontinued the development of atopaxar. This decision would have been due to a 
combination of factors. The limited efficacy, shown in the phase II trials, would 
have left Eisai relying on significant results being shown with a larger study 
population. These results would be required to prove atopaxar as a useful 
treatment option. Further, the additional cost and patient compliance implications of 
having to administer atopaxar as a dual or triple therapy, with aspirin and/or 
clopidogrel, would have led Eisai to question the marketability. Finally, atopaxar 
was losing the development race with the third of the notable, literature PAR-1 
inhibitors; vorapaxar. 
 
Vorapaxar (SCH 530348) 
 
Compound 7: Vorapaxar 
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Vorapaxar (Compound 7) was the first to market oral potent PAR-1 inhibitor. It was 
initially developed by Schering-Plough before Merck and Co. took them over and 
thus obtained the patents. Vorapaxar is a derivative of an alkaloid; himbacine 
(Compound 8). Schering-Plough had a vast library of himbacine derivatives as they 
had shown promise for the treatment of Alzheimer’s disease.83 Upon screening 
their compound library against PAR-1, they discovered the further potential of 
himbacine derivatives. The series was first patented in 1999 (WO99/26943).84 
 
 
Compound 8: Himbacine 
 
The initial hit (S1.1, Scheme 1) was already more potent than RWJ-58259, 
competing with [3H]-ha TRAP, with an IC50 of 300 nM, as opposed to 15,000 nM. 
Initial SAR studies, aiming to optimize the substitution on the pyridine ring, gave 
the ethyl derivative (S1.2, Scheme 1) (IC50 = 85 nM). Enantiomer resolution of S1.1 
and S1.2 provided a hugely significant SAR development. It was shown that the 
unnatural ent-himbacine scaffold was roughly ten times more potent than the 
natural himbacine structure. The (+)-enantiomers gave IC50 of 150 and 20 nM for 
the methyl and ethyl derivatives, respectively. On the other hand, the (-)-
enantiomers gave IC50 values of 1500 and 400 nM. (+)-S1.2 showed dose 
dependent inhibition of TRAP induced platelet aggregation (IC50 = 70 nM) and ex 
vivo platelet aggregation in blood from cynomolgus monkeys dosed, at 10 mg/kg, 
with IV for 30 min. The compound was showing good potency but had a poor t1/2 
and was not orally bioavailable.85 Therefore, further optimization, to improve the 
PK, involved exploring the effects of an aromatic group at the pyridine C-5 position. 
Compound S1.3 was found to be the most potent of the series (IC50 = 11 nM). It 
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showed great potency and PK in a number of platelet aggregation and animal 
studies.86 However, a 10 day enzyme induction study highlighted significant liver 
enzyme induction in rats; notably, CYP2B and CYP1A enzymes showed an 
increase of 21-fold and 3.6-fold, respectively.87  
 
 
Scheme 1: Development of Vorapaxar.  
IC50 (in nM) of the major compounds; S1.1 = 300, S1.2 = 85, (+)-S1.2 = 20, S1.3 = 11, 
S1.4 = 17, S1.5 = 11 and vorapaxar (7) = 8 nM. 
 
In a metabolite study, the liver enzymes were shown to primarily hydroxylate at the 
C-8 position on ring III. There was also some C-7 hydroxylation product observed. 
The PAR-1 binding potencies of C-6, C-7 and C-8 hydroxy compounds were 
investigated giving compound S1.4 as the most potent (IC50 = 17 nM). Compound 
S1.4 was still shown to mildly up-regulate liver enzymes, giving rise to di-
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hydroxylated metabolites. Further SAR was completed on ring III; heteroatoms 
were incorporated in place of C-7 and/or C-8. Compound S1.5 was found to be 
very potent (IC50 = 11 nM), had great oral bioavailability, displayed ex vivo platelet 
aggregation inhibition in a cynomolgus monkey model, was selective over other 
GPCRs and showed good results in a mouse enzyme induction model and a 
cynomolgus monkey clearance model.88  
 
Finally, additional SAR was completed at the C-7 region to give vorapaxar with a 
C-7 carbamate. Throughout much of the development process the bi-aryl portion of 
the compound had a m-CF3 substituent. However, the final drug candidate had a 
m-fluoro substituent as it was shown to reduce the lipophilicity. Vorapaxar bound 
competitively and with high affinity to PAR-1 (IC50 = 8.1 nM), it also gave a long 
disassociation rate (t1/2 = 20 h). In an ex vivo, cynomolgus monkey, platelet 
aggregation inhibition model it gave 100% inhibition after 24 h, following an oral 
dosing of 0.1 mg/kg, without increasing bleed times. After 48 h considerable 
inhibition of platelet aggregation was still observed. Following a 1 mg/kg oral dose, 
to monkeys, vorapaxar exhibited a Tmax after 1 h, 86% bioavailability and an 
elimination t1/2 of 13 h. It was shown to selectively inhibit PAR-1 over other GPCRs, 
thrombin and TRAP over other platelet agonists and importantly gave no evidence 
for liver enzyme inhibition.89  
 
The excellent pre-clinical profile led Merck to progress vorapaxar into clinical trials. 
A number of phase I studies were completed to assess the safety, PK and PD of 
vorapaxar in healthy volunteers. In a series of phase I trials, designed to determine 
a suitable dosing regimen, 50 healthy volunteers were randomly allocated to 
receive a single, oral dose of 0.25, 1, 5, 10, 20 or 40 mg of vorapaxar, 36 subjects 
were allocated to receive a once daily dosing of 1, 3 or 5 mg vorapaxar for 28 days 
and 12 volunteers were allocated to receive a loading dose of 10 or 20 mg 
vorapaxar followed by a daily dosing of 1 mg for 6 days. In each of the dosing 
options several subjects were randomly assigned to receive placebo instead. The 
blood from the volunteers was used to perform several ex vivo, TRAP induced, 
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platelet aggregation studies. Dose-related inhibition was observed; a single, 5 mg, 
dose gave over 80% inhibition of platelet aggregation, by 12 h after administration. 
With a 10 mg single dose it only took 2 h to get over 80% inhibition and with the 20 
and 40 mg single doses over 80% inhibition was achieved after an hour. 
Significantly, the inhibition was maintained for at least 72 h whilst full platelet 
recovery could take several months. The daily dosing studies all gave maintained 
inhibition of platelet aggregation of over 80% throughout the length of the study 
and showed up no obvious safety concerns. It was concluded from this series of 
phase I trials that a daily dosing of at least 1 mg would be sufficient for 
maintenance therapy. Additionally, a loading dose could be used in cases where a 
fast onset of action would be required.90  
 
A similar set of studies, designed to determine ethnic differences in the PK and PD 
of vorapaxar, randomised 50 healthy Japanese and Caucasian volunteers to 
receive a single, oral, dose of 5, 10, 20 or 40 mg vorapaxar and 48 subjects to 
receive daily, oral, dosing of 0.5, 1 or 2.5 mg of vorapaxar for 28 days. Again, ex 
vivo, TRAP-induced platelet aggregation was monitored, along with several PK, 
clinical and safety assessments. The platelet aggregation results supported those 
of the studies above with no variation observed between the ethnic groups. It was 
concluded that a 40 mg loading dose was best suited to give a fast onset of action, 
whilst, a 2.5 mg daily dose was thought to be best for chronic treatment. Again, no 
significant safety concerns were highlighted in this study.91  
 
The conclusions, regarding the required therapeutic dose, were supported further 
by a slightly larger phase I study. In this study, 111 healthy volunteers were, again, 
randomly assigned to receive a single, oral, dose of 5, 10, 20 or 40 mg vorapaxar 
or a daily, oral, dosing of 0.5, 1 or 2.5 mg of vorapaxar, for 28 days. Again, the 
platelet aggregation inhibition was consistent with what had been found already 
providing strong evidence for the efficacy of vorapaxar. This study also noted the 
rapid absorption and the long mean terminal-phase t1/2 which was shown to be 
165-311 h.92 A further study investigating the effects of food and antacid on the PK 
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and PD of vorapaxar found that although food delayed the absorption of vorapaxar, 
it increased the exposure; whilst, antacid decreased the exposure. However, these 
effects were insignificant in a clinical setting. Thus, it was concluded that vorapaxar 
would be able to be used without thoughts to meals or antacid usage.93  
 
The results were looking very promising, and there did not seem to be any safety 
issues; thus Merck carried vorapaxar into phase II clinical trials. The Thrombin-
Receptor Antagonist for cardiovascular event reduction in Percutaneous Coronary 
Interventions (TRA-PCI) (NCT00132912) trial was the largest of the phase II trials 
and was designed to assess the safety and tolerability of vorapaxar in patients 
undergoing non-urgent percutaneous coronary intervention (PCI). It was a multi-
centre, international, randomised, placebo-controlled, double-blind study involving 
1030 patients who were undergoing non-urgent PCI or coronary angiography with 
planned PCI. The patients were randomly allocated to receive an oral loading dose 
of 10, 20 or 40 mg vorapaxar or the placebo equivalent. The patients who 
underwent PCI, the primary PCI cohort, received an oral, daily, maintenance dose 
of 0.5, 1 or 2.5 mg vorapaxar, or placebo equivalent, for 60 days post-procedure. 
As with the atopaxar phase II clinical trials, vorapaxar was given in addition to the 
patients standard medication, often aspirin plus clopidogrel; the primary end-point 
was the occurrence of clinically significant bleeding events, a safety end-point and 
the secondary end-point was the number of MACEs, an efficacy end-point. It was 
concluded from the study that orally dosed vorapaxar was well tolerated and did 
not increase the number of bleed events when compared with placebo.94 This 
supported the idea that it was safe. Unfortunately, although there was a tendency 
towards a reduction in the number of MACEs, the study had too few patients to 
provide statistical significance. Therefore, it was concluded that larger phase III 
studies would be required to determine if vorapaxar was efficacious.94 
 
A smaller study assessed the safety and efficacy of vorapaxar in Japanese 
patients with non-ST-segment elevation acute coronary syndrome (NSTE ACS) 
was completed. The 117 Japanese patients were scheduled to have PCI and were 
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given the standard treatment; a cocktail of aspirin, heparin and ticlopidine, 
accordingly. They were then randomised to receive an oral loading dose of 20 or 
40 mg vorapaxar, followed by a daily maintenance dose of 1 or 2.5 mg for 60 days, 
or the placebo equivalent. The primary and secondary end-points were the same 
as those in the TRA-PCI study and again no significant increase in the number of 
bleed events were observed. However, this study showed a significant decrease in 
the number of myocardial infarctions (MI) occurring throughout the PCI.95 This 
gave the first evidence of a beneficial effect of vorapaxar in humans. 
 
Another phase II study was conducted using Japanese patients who had prior 
ischemic stroke. In this study, 90 patients, who were already taking daily aspirin, 
were randomised to, additionally, receive daily, oral, 1 or 2.5 mg dosing of 
vorapaxar, or placebo, for 60 days. Again, there were no significant differences in 
the number of bleed events between any of the trial groups.96 This further 
supported the idea that vorapaxar was well tolerated even on top of the standard 
treatment. Merck clearly concluded that there was sufficient evidence to justify 
progressing vorapaxar further. 
 
Two large phase III trials were initiated; the Thrombin-Receptor Antagonist for 
Clinical Event Reduction in Acute Coronary Syndrome (TRACER)97 and the 
Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic 
Ischemic Events (TRA 2°P)-TIMI 50 trial.98 Both studies were multinational, 
placebo-controlled, double-blind and randomized; they both had an efficacy 
primary end-point which was the number of MACEs or deaths caused by 
cardiovascular issues and in both trials vorapaxar was administered on top of the 
patients’ standard treatments. The TRACER study recruited 12,944 patients with 
NSTE ACS and randomly allocated them to receive an oral, load dose of 40 mg 
vorapaxar, followed by a daily, maintenance dose of 2.5 mg or the placebo 
equivalent. The study was intended to run for at least a year; or until a certain 
number of primary end point events had occurred. Instead, the study was 
terminated early, after only 6 months, for two reasons. Firstly, the set number of 
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primary end-points had occurred and, more importantly, a significant increase in 
bleed events (particularly intracranial bleeding) had been observed in the 
vorapaxar treatment group.99 This, added to the fact that there was an insignificant 
reduction of primary end-points in the vorapaxar group, was a major concern for 
Merck. Nonetheless, the TRA 2°P-TIMI 50 study was still running. 
 
The TRA 2°P-TIMI 50 trial recruited 26,449 patients with stable atherosclerotic 
vascular disease; typically those who had suffered from myocardial infarction, 
stroke, or peripheral artery disease within the previous year. The patients were 
randomly allocated to receive a once daily, oral dose of 2.5 mg vorapaxar, or 
placebo, on top of their standard treatment; most commonly low-dose aspirin. The 
treatment was continued on average for 2.5 years. It was found that, similar to the 
TRACER trial, there was an insignificant reduction in cardiovascular death, MI or 
stroke. However, a significant reduction in hospitalisation for acute limb ischemia 
and periphery artery revascularisation was observed. A significant increase in 
bleed events was also seen in this study. Moreover, the patients with a history of 
stroke were withdrawn from the study early since the increased bleed events 
tended to be intracranial.100  
 
In summary, the two large phase III trials did not yield desirable results for Merck. 
However, they had already invested heavily in the development of vorapaxar. First, 
they had taken over Schering-Plough to obtain the licence; then they had carried it 
through extensive and expensive clinical trials. The problematic phase III results 
meant that they had a critical decision to make. They could either cut their losses 
and discontinue development, in the same way that Eisai had, or they could find a 
suitable patient group with whom vorapaxar was safe and beneficial to use. Merck 
opted for the second choice. Two years after the completion of the TRA 2°P-TIMI 
50 trial, vorapaxar was finally approved as a novel treatment for the reduction of 
thrombotic cardiovascular events in patients with a history of heart attack or with 
peripheral arterial disease.101 Significantly, it was not to be prescribed to patients 
with a history of stroke, transient ischemic attack or intracranial haemorrhage, thus, 
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vastly reducing the eligible patient population. Vorapaxar is now being marketed as 
Zontivity.102  
 
Other Series 
The three significant PAR-1 inhibitors detailed above achieved various degrees of 
clinical success and provided a proof of concept. Detailed below are some of the 
series which were discontinued along the development process to vorapaxar and 
atopaxar. In addition, some of the newer series of PAR-1 antagonists, developed 
by research groups encouraged by the success of vorapaxar, are described. In 
some cases the compounds offered completely new scaffolds whilst in others 
inspiration clearly came from RWJ-58259, atopaxar or vorapaxar.  
 
 
Compounds 9a, b and c: Pyrroloquinazoline series hit and optimised leads. 
  
Schering-Plough must have evaluated several scaffolds before they focussed their 
research efforts on vorapaxar. The pyrroloquinazoline derivative (Compounds 9a) 
was discovered in a high-throughput screen and shown to inhibit ha-TRAP from 
binding to PAR-1 with an IC50 of 300 nM. SAR investigations at N1, N3 and N7 
gave rise to Compounds 9b and Compounds 9c as the most potent of the series. 
They inhibited ha-TRAP binding with IC50s of 56 and 52 nM, respectively. They 
inhibited TRAP-induced platelet aggregation with IC50s of 300 and 150 nM, whilst 
inhibiting thrombin-induced platelet aggregation with IC50s of 3000 and 700 nM.103 
Clearly the tertiary amine was the more potent compound, but not potent enough 
for Schering-Plough to develop the series further.  
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Compounds 10a and b: Benzimidazole series hit and optimised lead. 
 
Another series Schering-Plough investigated was based on a benzimidazole 
derivative, also discovered via a high-throughput screen. The initial hit 
(Compounds 10a) inhibited [3H]-ha-TRAP in a PAR-1 binding assay (IC50 = 900 
nM). Following minimal optimisation they found Compounds 10b to be the most 
potent of the series. It gave a PAR-1 binding IC50 of 33 nM and inhibited ha-TRAP 
induced human platelet aggregation (IC50 = 575 nM).104 The structure is quite 
similar to that of atopaxar with the tri-substituted benzene ring attached to a 
heteroaromatic core. Consequently, it can be assumed that it binds to PAR-1 in a 
similar fashion to atopaxar; it potentially would have given a similar development 
profile, had it not been discontinued. 
 
 
Compounds 11a and b: Tri-substituted urea series hit and optimised lead. 
 
Before Merck took over Schering-Plough, and the development of vorapaxar, they 
too were developing their own PAR-1 antagonists. They screened their compound 
library and discovered a tri-substituted urea (Compounds 11a). It inhibited the 
TRAP-stimulated secretion of 3H-seretonin, from human platelets, with an IC50 of 
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0.6 µM. A SAR profile was developed around Compounds 11a to give Compounds 
11b as the most potent of the series. It was found that there was very little 
tolerance on the di-substituted benzene ring, however, simplification by removal of 
the two terminal ureas led to improved solubility. The potency was not significantly 
improved but the ligand efficiency was, owing to the reduction in molecular weight. 
Compounds 11b showed an IC50 of 0.23 µM, in the TRAP-induced serotonin 
secretion assay, however, when using 1 nM thrombin as the agonist it only gave 
38% inhibition. In a PAR-1 binding assay it gave an IC50 of 0.12 µM, confirming that 
it was binding to PAR-1 itself. Finally, it delayed thrombin induced platelet 
aggregation in a concentration dependant manner.105 The tri-substituted urea 
series did not appear to show much potential but it was used to direct future 
developments. 
 
 
Compounds 12 a, b and c: The most potent compounds from the proline, piperidine and 
morpholine derived urea series. 
 
Structurally constrained analogues of the tri-substituted urea series were also 
assessed. Proline, piperidine and morpholine derived ureas were investigated. The 
best compound from each series (Compounds 12a-c) gave TRAP-induced 
serotonin secretion inhibition with IC50s of 0.4, 0.5 and >40 µM, respectively. None 
of the structurally constrained ureas were developed further. Instead, a library of 
compounds, relating to the tri-substituted ureas, was screened. This led to the 
identification of the structurally distinct isoxazole lead (Compounds 13a) which 
gave an IC50 of 9 µM, in the serotonin secretion assay. After optimization at the N-
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benzyl, tertiary amine and 3-aryl group, Compounds 13b was identified. This 
showed an IC50 of 0.09 µM in the TRAP induced serotonin secretion assay but, 
unlike the lead from the tri-substituted series, it also gave full inhibition of thrombin 
induced serotonin secretion with an IC50 of 0.51 µM. It gave an IC50 of 0.15 µM in 
the PAR-1 binding assay and inhibited thrombin-induced platelet aggregation at 4 
µM.106 Despite proving more effective than the tri-substituted urea series, Merck 
did not appear to progress with the isoxazole series either. 
 
 
Compounds 13a and b: Isoxazole series hit and optimised lead. 
 
It was clear that some of the big Pharmaceutical companies were interested in 
PAR-1 antagonists but the series described in more recent publications tended to 
come from academic research groups. A group in Italy took inspiration from the 
work that culminated in RWJ-58259. They investigated two different cores to 
provide peptidomimetics.107 One set of compounds was based around the indole 
core which, in the case of the RWJ series, had shown hypotensive effects in 
guinea pigs. The group added a methyl at the indole 2-position to try and force the 
pyrrolidine to interact with the receptor more efficiently. The methylated compound 
(Compounds 14a) showed about 25% greater inhibition of TRAP-induced platelet 
aggregation when compared with the equivalent non-methylated RWJ compound, 
thus suggesting that tighter binding was afforded. The group did not show whether 
the novel compound reduced the hypotensive effects that led Johnson and 
Johnson to move away from the indole core. This means that, although they have 
moderately improved the potency, the compound is still unlikely to be a viable 
clinical candidate. The second set of compounds the group investigated was based 
around a 1,4-benzodiazepinone scaffold. Unfortunately, the best compound in this 
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series (Compounds 14b) only gave about 30% inhibition of TRAP-induced platelet 
aggregation at 10 µM. The loss in activity is possibly due to the lack of a second 
basic centre; a requirement needed according to the 3 point binding model. This 
work provided further insight into the agonist binding pocket but is unlikely to lead 
to any new clinical leads. 
 
 
Compounds 14a and b: The most potent compounds from the 2-methylindole and the 
1,4-benzodiazepinone series. 
 
More recently, a group from Spain reported the synthesis of a set of urea and 
thiourea compounds based on diversity orientated synthesis. Their aim was to 
make small, diverse libraries of different scaffolds which could display aromatic 
groups and basic groups at variable distances and orientations. This approach 
resulted in a series of analogues of RWJ-58259 which were less effective at 
inhibiting TRAP-induced human platelet aggregation. The best of the ureas 
(Compounds 15a) gave 38% inhibition; one of the two thioureas (Compounds 15b) 
gave 33% inhibition. Finally, the most potent of the compounds synthesised was 
actually an intermediate in the synthesis; an Fmoc protected amine (Compounds 
15c). It gave 51% inhibition of platelet aggregation, at 10 µM, whilst RWJ-58259 
gave 98% inhibition.108 Again this work has not provided any major hit compounds 
but it has further developed the understanding of the binding site and has given 
structurally simpler and smaller peptidomimetics. 
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Compounds 15a, b and c: The most potent compounds from the urea, thiourea and Fmoc 
protected amine series. 
 
Evidently, RWJ-58259 was used as inspiration for the development of novel potent 
PAR-1 antagonists. On the other hand, a research group from Korea clearly used 
vorapaxar as their main influence. During the development of vorapaxar, Schering-
Plough obtained a large number of patents covering many thousands of vorapaxar 
analogues. The analogues typically showed variation of the tricycle ring; 
monocyclic and bicyclic variants have been covered (US2007/0232635 A1) along 
with spirocyclic (US2006/0223808 A1) and oxazoloisoquinoline (WO2007/075809 
A2) derivatives to name but a few. This suggested that there was a high degree of 
tolerance surrounding the tricycle but that obtaining novel analogues could be 
difficult. Nevertheless, the Korean group developed a series of octahydroindene 
vorapaxar analogues. Following some SAR profiling, at the C-2 of the 
octohydroindene motif, the group found that short bulky substitutions, such as the 
N-methylmethanesulfonamide of Compounds 16a, gave better PAR-1 binding. This 
led them to make quaternary (Compounds 16b) and spiro-substituted (Compounds 
16c) octahydroindenes. Compounds 16a, b and c proved to be as potent as the 
parent vorapaxar, achieving PAR-1 binding IC50s of 1.3, 2.7 and 8.6 nM 
respectively. Equally, they inhibited TRAP-induced platelet aggregation with IC50s 
of 0.097, 0.10 and 0.21 µM, compared with vorapaxar which gave an IC50 of 0.12 
µM. Functionally the octahydroindenes proved successful; unfortunately, they 
lacked metabolic stability surviving for no longer than 5 min when incubated with 
both rat and human liver microsomes.109 Even so, the group had proved that 
designing novel PAR-1 inhibitors around the vorapaxar scaffold was both feasible 
and promising. 
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Compounds 16a, b and c: Tertiary, quaternary and spiro-substituted octohydroindenes. 
 
A group in France have explored two novel scaffolds, found via a library screening 
approach, for use as PAR-1 inhibitors. The first was based around a 
cinnamoylpiperazine motif. Following some optimisation studies they arrived at 
F16618 and F16357 (Compounds 17a and b, respectively) as the most potent in 
their series. They had respective binding affinities (pA2) of 6.49 and 6.67, inhibited 
TRAP-induced Ca2+ flux, measured in a fluorescent imaging plate reader (FLIPR) 
assay, by 99 and 93% and inhibited TRAP induced human platelet aggregation to 
give pKb equalling 5.30 and 5.52, in that order. Finally, in a rat AV shunt model, IV 
administration increased the re-occlusion time by 58% with Compounds 17a and 
28% with Compounds 17b. Following an oral dosing of 40 mg/kg the occlusion 
times were increased by 54% and 59%, correspondingly. Both compounds showed 
good absorption, distribution, metabolism and excretion (ADME) properties and 
were investigated further.110 Compounds 17b was used as a basis for further 
optimisation; several series, with linker variations, were investigated but none of 
the resultant compounds appeared to significantly improve upon the original 
piperazine linker.111 Additional biological studies were completed with Compounds 
17a. It was compared to, and investigated in combination with, aspirin and 
clopidogrel in the rat AV shunt model. Administration with clopidogrel increased the 
time to occlusion by about 70% whilst giving minimal increase to the systemic 
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bleed time.112 This suggests that it, like vorapaxar, could be a successful anti-
thrombotic agent given alongside aspirin and/or clopidogrel. 
 
 
Compounds 17a and b: The most potent compounds from the cinnamoylpiperazine series; 
F16618 and F16357. 
 
The effects of Compounds 17a on smooth muscle contraction was also 
investigated. PAR-1 activation can lead to vasoconstriction, under certain 
pathological conditions, which is thought to be associated with the development of 
vascular lesions.113 The group showed that Compounds 17a competitively inhibited 
TRAP-induced constriction of both isolated pig coronary artery and rat superior 
mesenteric artery.114 Similarly, atopaxar had been shown to be able to inhibit the 
thrombin induced vasoconstriction in a rabbit subarachnoid haemorrhage model.115  
The inhibition of vasoconstriction seen with atopaxar may have been enough to 
protect patients from the significant increase of brain haemorrhage observed with 
vorapaxar. Consequently, the promising results of this study mean that 
Compounds 17a could prove to be a synthetically simpler, potent, orally active 
PAR-1 inhibitor which shows antithrombotic activity with the added benefits of 
being able to treat vascular injury provoked vasospasm. 
 
 
Compounds 18a, b and c: Initial hit and optimised leads for the imidazole series. 
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The second series discovered by the group in France was based on a substituted 
imidazole. The initial hit (Compounds 18a) already showed 96% inhibition of 
TRAP-induced Ca2+ release at 10 µM and gave a pKb of 5.01 in the TRAP-induced 
human platelet aggregation assay. Still, further optimisation was carried out to 
obtain Compounds 18b and c. These showed 99 and 81% inhibition in the Ca2+ 
flux assay, pKb of 5.71 and 5.73 in the platelet aggregation assay and 45 and 43% 
increase in re-occlusion time, following 1.25 mg/kg IV dosing, in the rat AV shunt 
model, respectively. They both showed reasonable stability in human liver 
microsomes but poor stability in rat liver microsomes. Despite the success with the 
cinnamoylpiperazine compounds, the group claim to be further optimising this 
series.116 This highlights the continuing interest in PAR-1 antagonists. 
 
Allosteric Inhibitors 
The PAR-1 inhibitors discussed so far are all thought to antagonise the receptor in 
the extracellular domain, either at the thrombin binding site or at the third 
extracellular loop where the tethered ligand binds. This makes them non-selective 
for the type of G-protein inhibited thus causing all pathways downstream of PAR-1 
to be blocked. On the other hand, in the last few years some compounds have 
been found to inhibit Gαq selectively. These compounds could be the inspiration 
behind a new, more selective PAR-1 inhibitor. 
 
 
Compound 19: Q94 
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Compound 19, commonly known in the literature as Q94, appears to be a 
synthetically simple benzimidazole derivative. It was identified by the company 
Caden Biosciences in a library screen of compounds supplied by ChemDiv. They 
screened the compounds in competition with a high-affinity peptide, which 
mimicked the Gαq C-terminus, using an enzyme-linked immunosorbent assay 
(ELISA). Q94 blocked the Gαq mimic from binding to activated PAR-1 receptors 
with an IC50 of 916 nM. In addition, Q94 was shown to inhibit TRAP-induced Ca2+ 
flux, in human embryonic kidney (HEK) cells, in a concentration dependent 
manner; a 10 µM dose gave full inhibition. This suggested that Q94 could be used 
to directly inhibit the Gαq subunit. Consequently, it was thought to be the first small 
molecule to inhibit PAR-1 at the intracellular level with increased selectivity of PAR-
1 inhibition. 
 
Caden Biosciences offered a free sample of “Caden Biosciences Q94” to any 
research group who requested it, and the Chambers group obtained a small batch. 
They intended to investigate PAR-1 related thrombin mediated signalling in mouse 
lung fibroblasts (MLF). They were particularly interested in the pathway that led to 
the release of the chemoattractive chemokine ligand 2 (CCL2). This is because 
CCL2 levels tend to be up-regulated in patients with ILDs and thus they hoped it 
could be a good biomarker to assess the clinical progression of IPF. This was the 
first example of PAR-1 inhibitors being used in relation to IPF. They showed by 
ELISA that a 10 µM dose of “Caden Biosciences Q94” was sufficient to fully inhibit 
thrombin-induced CCL2 production in MLF. Furthermore, 10 µM of “Caden 
Biosciences Q94” was shown to cause approximately 70% reduction in thrombin-
induced CCL2 mRNA levels.117 They concluded that CCL2 production was one of 
the downstream effects of activated PAR-1 binding to the Gαq subunit. They also 
recognised the opportunity for using Q94 as a starting point to develop a selective 
PAR-1 inhibitor as a clinical candidate for treating inflammatory and 
fibroproliferative diseases. 
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Compounds 20a and b: Q94 analogues Q89 and Q109 respectively. 
 
Another group, in Italy, were inspired by the work completed by Chambers et al.. 
Initially, they screened around 10,000 ChemDiv compounds with the same 
competition ELISA used by Caden Biosciences. From the library screen, they 
identified Q89 (Compounds 20a) and used it as a template to find the commercial 
analogues Q94 (Compound 19) and Q109 (Compounds 20b). In the competition 
ELISA, the three compounds, Q89, Q94 and Q109, gave IC50s of 320, 923 and 817 
nM (respectively). It is suggested that they subsequently synthesised the three 
compounds in-house in order to complete further pharmacological tests. The 
compounds were assessed in a thrombin-induced Ca2+ flux assay in human dermal 
microvascular endothelial cells-1. Q94 and Q109 showed evidence of allosteric 
modulation which led to the inhibition of Ca2+ release with IC50s of 10.3 and 19.2 
nM, respectively. An IC50 for the original hit, Q89, was not obtained as they found 
that it did not reduce the maximum effect (Emax) of thrombin. This meant that it 
would not have an inhibitory effect. The inhibition of the Gαq pathway, observed 
with Q94 and Q109, was further supported by the fact that they inhibited thrombin-
induced inositol trisphosphate (IP3) accumulation. IP3 production is another 
downstream effect observed with the thrombin activation of the Gαq pathway. On 
the other hand, the group found that Q94 and Q109, in the absence of thrombin, 
both inhibited cAMP production. Since, cAMP is synthesised by AC, which is in 
turn inhibited by the coupling of activated PAR-1 to Gαi subunits, it can be 
concluded that Q94 and Q109 act as allosteric agonists for PAR-1 Gαi signalling.118 
This suggests that the benzimidazole derivatives are even more interesting than 
the Chambers group previously thought. 
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Compound 21: JF5 
 
Another, intracellular, PAR-1 inhibitor, named JF5 (Compound 21), was shown, by 
Flaumenhaft et al., to interact allosterically with the intracellular helix 8 (H8) of the 
PAR-1 receptor to modulate G-protein binding. It was discovered through a high-
throughput screen using a luciferin-luciferase based assay designed to identify 
compounds which could inhibit TRAP-induced platelet granule secretion. The 
assay was able to identify allosteric modulators as it is a functional test as opposed 
to a site-specific binding assay. JF5 was shown to inhibit platelet aggregation 
which, like granule secretion, is a downstream result of Gαq activation. It was 
shown to have no effect on platelet shape change, which is caused by Gα12/13 
activation, highlighting the selectivity. Even though JF5 blocks only one of the 
G-proteins, it was still shown to greatly reduce the accumulation of platelets into 
thrombi in mice that had laser-induced arterial injury. In this in vivo model, JF5 
exhibited an IC50 of about 1mg/kg. Furthermore, it was shown to more than double 
the time to 50% maximal platelet accumulation at this dosing.119 This helps to 
prove the concept that a G-protein selective PAR-1 inhibitor could be of potential 
use. Unfortunately, JF5 targets many of the GPCRs which have the H8 regions. 
Thus, although interesting, it is unlikely to be developed into a clinical candidate. 
 
Flaumenhaft et al. discovered a second PAR-1 allosteric modulator, based on a 
1,3-diaminobenzene scaffold, using the same library screening strategy as before. 
The initial hit (Compounds 22a) inhibited dense granule release (IC50 = 1-10 µM), 
did not inhibit platelet activation caused by other receptors, was reversible and 
soluble in phosphate buffered saline (PBS); the buffer used for biological assays. 
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Compounds 22a was shown to be moderately stable in human plasma with around 
80% remaining after 5 h. Unfortunately, in mouse plasma it showed unacceptable 
stability, thus making it difficult to conduct any in vivo studies. Nevertheless, like 
JF5, it was shown to exhibit non-competitive inhibition of platelet aggregation 
without inhibiting the ability for the platelets to change shape. Consequently, it can 
again be assumed that Compounds 22a blocks Gαq activation and not Gα12/13. 
Finally, it was shown to inhibit TRAP-induced surface expression of P-selectin in 
human platelets (IC50 = 0.26 µM). P-selectin is a cell adhesion molecule which 
lines the inner surface of activated platelets. It is released from α-granules, when 
the platelets become activated, which means that it again is related to Gαq 
activation. 
 
 
Compounds 22a and b: Initial hit and optimised lead of the 1,3-diaminobenzene series. 
 
Compounds 22a, termed ML161, was a promising compound in itself but to try and 
increase the potency, and most importantly to improve the mouse plasma stability, 
a series of SAR studies were completed. Compounds 22b was the only compound 
found to have equivalent potency, in the P-selectin assay (IC50 = 0.29 µM), but 
improved mouse plasma stability (65% remaining after 5 h). The compounds only 
differ by the addition of a methyl group β to the left-hand amide. More generally, 
the results from the SAR studies showed that, on the right-hand side of the 1,3-
disubstituted benzene ring, a secondary benzamide (with a small, electron-neutral, 
or electron withdrawing, ortho-substituent) was required. Whilst, on the left-hand 
side, a secondary amine or amide with a linear, or branched, aliphatic chain (no 
longer than four carbons) was required.120 The group hope to use the more stable 
analogue to evaluate whether allosteric inhibitors could be used to decrease the 
risk of haemorrhage related to the use of PAR-1 inhibitors. 
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Project Aims 
The Chambers group were the first to recognise the opportunity for using allosteric 
antagonists, such as Q94, as a starting point for the development of a selective 
PAR-1 inhibitor. Consequently, they wanted to advance their understanding of its 
mechanism of action. They had used up most of their batch of “Caden Biosciences 
Q94”, thus, in order to further their research, they purchased a new batch of Q94 
from ChemDiv. They tested the ChemDiv batch with the CCL2 detecting ELISA but 
found no activity. Worse still, the “ChemDiv Q94” appeared to precipitate when 
added to the biological medium. Precipitation had never been seen with “Caden 
Biosciences Q94”.121 
 
 
Compound 19: “ChemDiv Q94” 
 
Rachel Chambers started collaborating with us to provide chemistry expertise, 
before other allosteric antagonists such as Q89, Q109, JF5 and ML161 had been 
reported on. Accordingly, the initial aim of this project was to validate a suitable 
synthetic route to Q94 and use it to supply the Chambers group with a pure sample 
so they could continue with their research. From there, the aim was to synthesise a 
series of Q94 analogues which could be tested to establish an SAR profile for the 
benzimidazole series. It was intended that at least one of these analogues would 
show improved potency and thus potential as a selective PAR-1 inhibitor which 
could be used for the treatment of IPF. 
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Chapter 2: Q94 Synthesis and Testing 
Introduction 
The structure of “ChemDiv Q94” is not complex and so theoretically would be 
expected to be straightforward to synthesise. It is based around a benzimidazole 
motif which is frequently found in pharmaceutical agents. In the literature, 
benzimidazoles are formed by condensing o-phenylenediamine with a carboxylic 
acid in the presence of a strong acid.122,123 It has been shown that the 
benzimidazole core can then be N-alkylated with a benzylhalide, in the presence of 
a base, in a variety of solvents, including ionic liquids.124 This two step process 
should render the synthesis of Q94 and its analogues easy to develop. The 
synthetic route used by Asteriti et al., for their “in-house” synthesis of Q94, has not 
been disclosed at this time. 
 
Synthesis 
 
Scheme 2: The synthesis of “UCL Q94” (24) and its analogue (25). 
 
“UCL Q94” (24) was synthesised using the route outlined in Scheme 2. o-
Phenylenediamine (S2.1) was condensed with benzoic acid (S2.2) in the presence 
of concentrated hydrochloric acid to give 23 in moderate yield (40%). This was 
then N-alkylated with 4-chlorobenzyl bromide to give 24 in modest yield (55%). The 
dibenzyl analogue 25 was synthesised in a similar fashion but with a greater yield 
(70%).  
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Biological Results and Discussion 
The Chambers group had already shown that “Caden Biosciences Q94” had an 
IC50 of 916 nM, when in competition with a Gαq C-terminal mimic.117 In trying to 
replicate their results with “ChemDiv Q94” they found no activity and observed 
considerable precipitation into the biological medium. Equally, when testing the 
newly synthesised batch of “UCL Q94” (24) and its analogue (25), precipitation, 
and lack of activity, was again observed. After many attempts to regain the activity 
observed with “Caden Biosciences Q94” and stop the precipitation seen with 
“ChemDiv Q94” and “UCL Q94”, the Chambers group had to conclude that the 
structure of the original batch was probably not consistent with that described. 
However, this was before the Italian group published their results regarding Q89, 
Q94 and Q109. The group in Italy claimed to have used both Q94 purchased from 
ChemDiv and some they had synthesised themselves to get positive results. They 
had also shown that a batch of Q94 could compete with a Gαq C-terminal mimic to 
give an IC50 of 923 nM. This is comparable to the IC50 obtained by the Chambers 
group with “Caden Biosciences Q94”. 
 
In light of the newly published results, “ChemDiv Q94” was tested again, along with 
a purchased batch of Q109. The compounds were tested at 3 µM in a Ca2+ flux 
FLIPR assay using human lung fibroblasts (HLF). The cells were stimulated with 0, 
0.3, 3 and 10 nM thrombin solutions. In a similar assay the Italian group had shown 
Q94 and Q109 to give IC50 of 10.3 and 19.2 nM, respectively.118 Unfortunately, as 
can be seen in Figure 4, our collaborators in the Chambers group saw very little 
effect.  
 
55 
 
 
Figure 4: The average (n = 3) relative fluorescence (RF) observed over time (sec) upon 
the addition of 10 nM thrombin to human lung fibroblasts in buffer pre-incubated with Fluo-
4 NW dye mix and 3 µM antagonist; 0.5% DMSO, ChemDiv Q94, Q109 and vorapaxar. 
 
Figure 4 shows the relative fluorescence (RF) observed over the time course of the 
Ca2+ flux experiment, at the highest thrombin concentration (10 nM). It is seen that 
there is no fluorescence observed with the positive control (vorapaxar). This 
supports the idea that the positive control provides full inhibition of PAR-1 because 
it suggests that no Ca2+ was released from the cell. On the other hand, with the 
negative control (0.5 % dimethylsulfoxide (DMSO) in medium) there is a huge 
increase in RF following the addition of thrombin. This implies that there was a 
huge efflux of Ca2+ which would have bound to the Fluo-4-NW dye, found in the 
biological medium, allowing it to fluoresce. Both, “ChemDiv Q94” and Q109, 
showed similar profiles to the negative control. This again suggests that there was 
a huge efflux of Ca2+ meaning that the effects of thrombin were not inhibited. 
Further, the percentage inhibition observed with “ChemDiv Q94” and Q109, at 
lower concentrations of thrombin, was very similar to the percentage inhibition 
seen with the negative control (Figure 5). In summary, the results obtained did not 
support the results found by the group in Italy. 
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Figure 5: The average (n = 3) percentage inhibition observed upon the addition of thrombin 
at varying concentrations (0, 0.3, 3 and 10 nM) to human lung fibroblasts in buffer pre-
incubated with Fluo-4 NW dye mix and 3 µM antagonist; 0.5% DMSO, ChemDiv Q94, 
Q109 and vorapaxar. 
 
Conclusions and Updated Aims 
There are two possible conclusions that could be made from this work. Either, 
“ChemDiv Q94” has a different structure to the one originally proposed, or, the 
published structure of Q94 is correct but perhaps existed as a salt to increase 
solubility. Nevertheless; it was concluded that, although what was thought to be 
Q94 had been successfully synthesised, we were not in a suitable position to use it 
as a starting point for the development of a novel PAR-1 inhibitor that could be 
used to treat IPF. As a consequence, the aim of the project was broadened. It was 
still the plan to design novel PAR-1 inhibitors to be used as potential IPF 
medicines; but, other sources were investigated to provide the initial inspiration. 
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Chapter 3: Vorapaxar Analogues 
Introduction 
The obvious candidates from which to develop novel PAR-1 inhibitors to provide 
new inspiration were atopaxar and vorapaxar. This is owing to the fact that at the 
time, the phase II trials assessing atopaxar were coming to an end and the 
haemorrhage complications seen in the phase III trials of vorapaxar were yet to be 
published. Both showed considerable promise that they could get to market and 
both had a wealth of patent literature behind them. Following an extensive 
literature search it was clear that the main pharmacophores for vorapaxar and 
atopaxar were the biaryl group and the substituted benzene, respectively. An initial 
idea was to combine the two groups to give a novel scaffold but it was thought that 
the resulting compounds would be too lipophilic and thus insoluble. A second idea 
was to look at cut-down versions of the compounds. Merck, and Lee et al., had 
shown that this was a successful strategy when applied to vorapaxar; whilst the 
benzimidazole series developed by Schering-Plough could be seen as atopaxar 
cut-downs. Therefore, it may be interesting to see how small one could go whilst 
still achieving potency. Finally, developing SAR around regions of the two 
molecules which have yet to be explored could be another way of achieving novel, 
potent PAR-1 inhibitors. The synthesis of atopaxar and vorapaxar were 
investigated to help direct which would be the best path to novelty to follow. 
 
Atopaxar Synthesis 
The synthesis of atopaxar was based around the coupling of the iminoisoindole 
fragment (S3.4) with the 3-tert-butyl-4-methoxy-5-morpholinophenyl group (S3.8) 
(Scheme 3).125 The iminoisoindole fragment (S3.4) was synthesised from 
commercially available 1,2-diethoxy-3-fluorobenzene (S3.1) via an 8 step 
sequence. The fluorobenzene was first selectively brominated adjacent to the 
fluorine using N-bromosuccinimide (NBS). The bromine was subsequently 
substituted with a cyanide group to afford the aryl cyanide (S3.2). This was then 
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formylated at the C-5 position to give S3.3. The aldehyde was reduced and 
mesylated allowing cyclisation to occur providing the key iminoisoindole fragment; 
S3.4. 
  
 
Scheme 3: Eisai’s Synthesis of Atopaxar (6) 
 
The 3-tert-butyl-4-methoxy-5-morpholinophenyl fragment (S3.8) was synthesised 
from 2-tert-butyl-phenol (S3.5) in 7 steps. First it was acylated, under Friedel-Crafts 
conditions, para to the hydroxyl group; next, bromination, ortho to the hydroxyl, 
was achieved to give S3.6. The added ketone was then ketal protected prior to 
methylation of the hydroxyl group giving S3.7. Next, palladium catalysed 
substitution of the C-5 bromine with morpholine was completed. Before the ketone 
was deprotected, terminal bromination of the ketal group was carried out. The final 
ketal deprotection gave 3-tert-butyl-4-methoxy-5-morpholinophenyl (S3.8) which 
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was coupled to the iminoisoindole fragment (S3.4) to give atopaxar (6) as a 
hydrogen bromide salt. The convergent synthetic approach would allow focused 
compound libraries to be synthesised relatively easily. Reflecting this, the patent 
literature surrounding atopaxar gave thousands of example compounds. This 
suggests that many compounds were tested and that the SAR at most positions 
would have already been explored. 
 
Vorapaxar Synthesis 
Himbacine is an interesting natural product both pharmaceutically and 
synthetically; consequently, there are a number of published synthetic routes used 
to make it. The majority of these revolve around building the tricycle with an 
intramolecular Diels-Alder (IMDA) reaction.126 Vorapaxar was synthesised using a 
similar IMDA reaction approach (Scheme 4).87,89 The synthesis was initiated with a 
Heck reaction to attach methyl acrylate to the commercially available ketal-
protected bromocyclohexenone (S4.1). The ester was then hydrolysed to give the 
dienoic acid (S4.2) which was coupled, using N,N'-dicyclohexylcarbodiimide 
(DCC), with (R,Z)-benzyl 4-hydroxypent-2-enoate (S5.3) to give the IMDA 
precursor; S4.3. The hydroxypentenoate (S5.3) was itself made according to 
Scheme 5.  
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Scheme 4: Schering Plough’s Synthesis of Vorapaxar (7) 
 
The IMDA precursor (S4.3) was cyclised in xylenes at high temperature giving 
S4.4. During this reaction the stereocentres were set by the absolute chirality of the 
C-3 methyl-substituent. It was thought that the methyl group caused a facial 
selectivity created by an allylic strain on the dienophile during one of the IMDA 
transition states. This differentiation was enough to set the stereochemistry at C-3a 
which in turn set the stereocentres for the rest of the tricycle. The relative 
stereochemistry between C-3a and C-4 was conveyed due to the cis-geometry of 
the dienophile whilst the exoselective transition state gave the trans-configuration 
61 
 
between C-3a and C-9a. Consequently, epimerisation at C-9a was promoted by 
the addition of DBU to give the desired cis-fused lactone (S4.5).  
 
 
Scheme 5: Schering Plough’s Synthesis of (R,Z)-benzyl 4-hydroxypent-2-enoate 
 
Once the tricycle had been assembled palladium-catalysed hydrogenation 
removed the benzyl (Bn) group whilst the platinum-catalysed diastereoselective 
hydrogenation was done to reduce the internal double bond giving S4.6. The 
resulting carboxylic acid (S4.6) was converted into an acid chloride before 
reduction using tributyltin hydride and tetrakis(triphenylphosphine)palladium(0) to 
give S4.7. The resulting aldehyde (S4.7) was coupled with a phosphonate ester of 
the biaryl group (S6.4) (made following Scheme 6) in a Horner-Emmons reaction to 
give S4.8. The final steps involved de-protecting the ketal at the C-7 position to 
give a ketone which in turn was reductively aminated to give a primary amine. 
Coupling with ethyl chloroformate finally gave vorapaxar (7). 
 
 
Scheme 6: Schering-Plough’s Synthesis of Biaryl Phosphonate Ester 
 
On the face of it, it looks like the synthesis of atopaxar is shorter and simpler than 
the synthesis of vorapaxar. However, if novel vorapaxar analogues were made with 
a methylene at C-7 the synthesis would be significantly simplified. Since the C-7 
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carbamate was installed primarily to block metabolism, analogues without the 
carbamate tend not to have diminished potency. Consequently, it would not be 
unreasonable to omit the carbamate if a series of novel vorapaxar analogues were 
to be investigated. 
 
Novel Synthesis of Himbacine 
A recent publication, from Casey et al., described a novel method towards 
synthesising the himbacine tricycle.127 It used a double Michael-Initiated Ring 
Closure (MIRC) reaction (Scheme 7) rather than the typical intramolecular Diels-
Alder seen in most other himbacine syntheses. The first few steps of the synthesis 
were already established in the literature. It commenced with acid catalysed ring-
opening of the commercially available dihydropyran (S7.1). In the same pot, the 
product was subjected to Horner-Emmons reaction conditions to give an α,β-
unsaturated ester with a terminal alcohol.128 The alcohol was converted into an 
iodo species (S7.2)129 before the first of two MIRC reactions was performed.130 The 
resulting racemic cyclodiester (S7.3) was then reacted with a stereoisomeric 
lactone (S7.4; itself made in two steps131) in a second MIRC reaction to give the 
himbacine tricycle with a ketone at the C-9 position (S7.5). It was their intention to 
continue with this approach to eventually provide a novel, short, enantioselective 
route to himbacine. However, to the best of our knowledge, there are no examples 
in the vorapaxar literature with substitutions at C-9. Consequently, this new 
synthetic route could be used to provide originality. The synthetic route could be 
adapted to give the ent-himbacine tricycle. The C-9 ketone could then be used as a 
synthetic handle to access novel analogues of vorapaxar and allow the exploration 
of SAR from ring II. 
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Scheme 7: Casey et al’s Developments Towards a Novel Himbacine Synthesis 
 
Vorapaxar SAR 
The potential for using the new synthetic route towards himbacine as a starting 
point for making novel vorapaxar analogues meant that it was important to fully 
appreciate the existing SAR knowledge surrounding vorapaxar and its analogues. 
The SAR studies completed during the development of vorapaxar highlighted 
several regions which appeared vital for effective PAR-1 binding and selectivity. On 
the other hand, some of the structural features were shown to merely aid 
pharmacokinetics or synthesis (Figure 6). It was found that the stereochemistry of 
the tricycle head group was vital. Having the ent-himbacine scaffold hugely 
increased potency. Conversely, the C-3 methyl group was not required to maintain 
potency. However, it was kept throughout the vorapaxar development process as it 
acted as a useful stereocentre to aid the stereospecific synthesis. As previously 
discussed, the C-7 carbamate must be present for successful oral dosing of 
vorapaxar as it blocks the metabolic site targeted by liver enzymes during first-pass 
metabolism. 
 
The SAR studies showed that variation was tolerated on both rings I and III, 
provided a hydrogen bond acceptor existed at the C-1 position. On the flip side, the 
trans-alkene linker at C-4 appeared essential for potency as it was thought to help 
orientate the pyridine nitrogen into a beneficial position. The basicity and 
orientation of the pyridine nitrogen was thought to be important. Thus, attachment 
at pyridine C-2 was seen to improve potency as it was thought to manipulate the 
nitrogen into a favourable position. Finally, substitution around the pyridine ring 
hugely influenced potency.86 It was seen that the pyridine C-5 tolerated small alkyl 
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substitution whilst the C-6 position required aryl substitution. Extension from the 
pyridine C-3 and C-4 seemed to greatly reduce potency. 
 
Figure 6: Summary of the Vorapaxar (7) SAR Studies 
 
New Project Aims 
Taking inspiration from the newly published synthetic route towards himbacine, it 
was concluded that novel vorapaxar analogues would be investigated. The first 
step would be to adapt the synthesis to give the ent-himbacine scaffold. It would 
then be necessary to complete the route to allow the attachment of the biaryl motif. 
Once full C-9 keto-analogues had been produced biological testing would be 
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required to provide a proof of concept. It would be necessary to show that growth 
from the C-9 region would be tolerated. Finally, an SAR profile of different 
functional groups at this position would be ideal. Alongside this study, it was also 
hoped that some analogues of vorapaxar with smaller head groups could be 
profiled. 
 
Results and Discussion 
Vorapaxar Analogues with Smaller Head Groups 
Synthesis 
Synthesising vorapaxar analogues with smaller head groups could easily be 
achieved by coupling a biaryl phosphonate ester with a range of commercially 
available aldehydes using Horner-Emmons conditions. First the phosphonate ester 
needed to be synthesised. This was achieved using a similar sequence to that 
used by Schering-Plough. Initially, commercially available hydroxy-2-
methylpyridine (S8.1) was converted to the trifluoromethanesulfonate ester using 
N,N-bis(trifluoromethylsulfonyl)aniline and potassium carbonate (K2CO3) in DMF to 
give 26 in good yields (89%). N,N-Bis(trifluoromethylsulfonyl)aniline was used 
instead of triflic anhydride as it is a safer triflating agent. It may not have been used 
in the original synthesis as it is not so atom efficient and the by-product can be 
difficult to remove. The next step involved the Suzuki coupling of the triflated 
starting material with 3-trifluoromethyl phenyl boronic acid. The conditions used for 
the synthesis of vorapaxar gave little or no yield. However, changing the solvents, 
from a mixture of toluene, ethanol and water, to dimethoxyethane (DME) and water 
gave 78% yield in the synthesis of the methyl substituted biaryl 27. Finally, the 
methyl group was deprotonated with lithium diisopropylamide (LDA) (prepared in 
situ) and reacted with diethyl chlorophosphate to give the phosphonate ester 28 in 
reasonable yields (66%). 
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Scheme 8: Synthesis of Vorapaxar Analogues with Smaller Head Groups (29-40) 
 
The biaryl phosphonate ester (28) was next deprotonated with tert-butyl lithium (t-
BuLi) and coupled with a range of aldehydes (Scheme 8). Coupling with 
cyclohexanecarboxaldehyde gave the simplest of the analogues. In this reaction 
the (E)-product (29) was afforded in excellent yield (89%) whilst a minimal amount 
of the (Z)-product (30) was also produced (4%). In order to assess the effects of 
aryl head groups, para-methoxybenzaldehyde was coupled to the deprotonated 
phosphonate ester. Unfortunately, although the yields were reasonable (54-67%), it 
appeared that the product (31) dimerised about the alkene linker to give the dimer 
32 (Scheme 9). This suggested that the compounds could be photosensitive so the 
subsequent compounds were made in dark conditions. 
 
 
Scheme 9: Dimerisation of Analogue 31 Giving Compound 32 
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meta-Methoxybenzaldehyde was coupled to the biaryl functionality in excellent 
yield (92%) to give 33. It was hoped that having the methoxy in the meta-position 
would reduce dimerisation because the added electron density in the aryl group 
would not conjugate onto the alkene. This would make the alkene less electron rich 
and thus less reactive. The meta-methoxy group was also hoped to fulfil the 
requirement of having a hydrogen bond acceptor at the vorapaxar C-1 position. 
Consequently, meta-dimethoxybenzaldehyde was also coupled giving compound 
34 in an 82% yield. In a similar vain, meta-carbomethoxybenzaldehyde was 
coupled because it would also offer a hydrogen bond acceptor. This reaction gave 
compound 35 in an 84% yield. A portion of 35 underwent base hydrolysis to give 
the acid product 36 in a 41% yield. A second portion was reduced using lithium 
aluminium hydride to give the hydroxyl product 37 in 61% yield. With the continuing 
aim of displaying a hydrogen bond acceptor in place of the vorapaxar C-1 carbonyl, 
ethyl-2-formyl-1-cyclopropanecarboxylate was coupled to give compound 38 in 
83% yield. Again, the hydroxyl product 39 was obtained in 52% yield by reducing a 
portion of 38 using lithium aluminium hydride. Finally, nicotinaldehyde was coupled 
giving compound 40 in an 83% yield providing a second pyridine in the compound 
(Table 1). 
 
Table 1: Vorapaxar Analogues with Smaller Head Groups 
Compound Head Group Yield Percentage 
Inhibition (3 µM) 
Percentage 
Inhibition (300 µM) 
28 
 
66% -29 20 
29 
 
89% -21 41 
31 
 
62% -25 13 
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33 
 
92% Not Tested Not Tested 
34 
 
82% -30 74 
35 
 
84% Not Tested Not Tested 
36 
 
 
41% Not Tested Not Tested 
37 
 
61% Not Tested Not Tested 
38 
 
83% Not Tested Not Tested 
39  
 
52% Not Tested Not Tested 
40 
 
83% Insoluble Insoluble 
 
Biological Results and Discussion 
A number of the compounds were tested, in the Ca2+ flux FLIPR assay, by our 
collaborators in the Chambers group. They were tested at concentrations of 3 and 
300 µM against varying thrombin concentrations (0, 0.3, 3 and 10 µM). The 
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compounds were first dissolved in DMSO before they were diluted with biological 
medium containing the Fluo-4-NW dye which would fluoresce upon binding Ca2+. 
Compound 40 was found to be insoluble in DMSO so it could not be tested. The 
insolubility may have been indicative of dimerisation. 
 
The results are given as percentage inhibitions, calculated relative to the positive 
control (vorapaxar) and the negative control (medium + 0.5% DMSO). The 
compounds did not give significant inhibition when dosed at 3 µM (Figure 7). In the 
no thrombin condition, all of the tested compounds (apart from compound 34) 
showed a relative inhibition around 100%. This shows that the compounds in 
themselves did not activate the PAR-1 as there was no activity without thrombin. 
Compound 34 gave an average relative percentage inhibition of 88%; however, if 
one looks at the three distinct trial values (99%, 97% and 69%) it could be 
assumed that the average was skewed by the one outlying data point of 69%. At 
0.3 and 3 µM doses of thrombin, the compounds tended to give relative percentage 
inhibitions which clustered around that of the negative control. At the highest 
concentration of thrombin, the compounds gave negative relative percentage 
inhibitions, which in the case of compound 34 reached as low as -30%. This could 
suggest that the compounds were acting agonistically and adding to the effect of 
thrombin, although, if this were the case an effect should have been observed at 0 
µM thrombin. 
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Figure 7 The average (n = 3) relative percentage inhibition observed upon the addition of 
thrombin at varying concentrations (0, 0.3, 3 and 10 nM) to human lung fibroblasts in 
buffer pre-incubated with Fluo-4 NW dye mix and 3 µM antagonist; 0.5% DMSO, 
Compounds 28, 29, 31, 34, dimer 32 and vorapaxar. 
 
Testing the compounds at 300 µM showed slightly more promising results (Figure 
8); compound 29 gave a relative percentage inhibition of 41% and better still 
compound 34 showed a 74% inhibition. Unfortunately, at this concentration, 
compounds 29, 31 and 34 precipitated in the biological medium. This would have 
affected the passage of light through the wells and thus affected the results. This 
may have been the cause of the 26% relative inhibition seen with compound 34 at 
0 µM thrombin. As a consequence, the results were inconclusive. In addition, 
because it was very difficult to tell whether the compounds had dimerised prior to 
or during the biological testing the rest of the analogues were not assessed. 
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Figure 8: The average (n = 3) relative percentage inhibition observed upon the addition of 
thrombin at varying concentrations (0, 0.3, 3 and 10 nM) to human lung fibroblasts in 
buffer pre-incubated with Fluo-4 NW dye mix and 300 µM antagonist; 0.5% DMSO, 
Compounds 28, 29, 31, 34 and vorapaxar. 
 
In conclusion, although the vorapaxar analogues with smaller head groups were 
easy to synthesise and were given in good to excellent yields they suffered from 
dimerisation, poor solubility and lacked potency in the Ca2+ flux FLIPR assay. 
Consequently, this avenue of investigation was discontinued and all hope was 
pinned on the C-9 carbonyl derivatives of vorapaxar. 
 
C-9 Substituted Vorapaxar Analogues 
Synthesis 
The first step towards the substituted C-9 vorapaxar analogues was to adapt the 
new himbacine synthesis, published by Casey et al.,127 to give the ent-himbacine 
scaffold. It was decided that the C-7 carbamate found on vorapaxar would not be 
necessary. In the short term, the missing carbamate should make little difference to 
the potency of the compounds. In the long run omitting the carbamate would 
facilitate the topical administration of the compounds. They could be inhaled 
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straight into the lungs and to the site of the IPF lesions and then be quickly 
metabolised upon reaching the blood. This would avoid off-target effects as the 
drug would not be able to affect PAR-1s found at other sites. 
 
The initial stage of the synthesis followed the steps used by Casey et al. to give the 
racemic cyclodiester (43) (Scheme 10). Commercially available 3,4-dihyrdo-2H-
pyran (S10.1) was hydrolysed in H2O, catalysed by HCl. The resultant 
tetrahydropyranol was then treated with K2CO3 and DMSO in the same pot to give 
an aldehyde which could undergo a Horner-Emmons reaction with trimethyl 
phosphonoacetate. Methyl 7-hydroxyhept-2-enoate (41) was obtained in a 
reasonable yield (63% over the two steps). The terminal hydroxyl group was 
displaced using imidazole, triphenylphosphine and iodine (I2) to give compound 42 
as the major product in low to moderate yields (32-44%). 
 
Scheme 10: Racemic Diester (43) Synthesis 
 
The next step was to react 42 in a MIRC. LDA (made in situ) was used to 
deprotonate tert-butyl acetate. This then underwent Michael addition to 42 as it 
was added to the solution. Casey et al. suggested that the subsequent addition of 
potassium tert-butoxide (KOt-Bu) acted to destabilise the resulting lithium enolate 
allowing the final cyclisation. However, it was found that the addition of KOt-Bu, 
before or after the Michael addition, made very little difference to the yields of the 
reaction. In all cases the yields of 43 were typically low. This was partly because 
purification was particularly problematic. Purification by distillation was shown to be 
ineffective as the by-products appeared to distill at a similar temperature. 
Consequently, purification by flash column chromatography had to be relied upon. 
Unfortunately, monitoring the progression of the purification was very difficult 
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because 43 was optically inactive but co-eluted on thin layer chromatography 
(TLC) with both optically active and optically inactive by-products. The best method 
for identifying 43 was found to be by TLC stained with potassium permanganate. 
However, the major differential between 43 and the by-products was only the rate 
at which they stained. This made it quite difficult to tell which column fractions 
contained product and which contained impurity. In the end the best purification 
method was found to be reverse-phase column chromatography which still gave 
very close running impurities. 
 
Despite the difficult purifications 43 was eventually isolated in 20-30% yield. With 
the diester in hand the tricycle synthesis could be completed. Initially the reaction 
was trialled with commercially available 2(5H)-furanone. 43 was deprotonated with 
lithium tetramethylpiperidine (LTMP) (made in situ). For the best results, it was 
found that the LTMP should be made with freshly distilled 2,2,6,6-
tetramethylpiperidine (TMP), using flame-dried glassware and with the lithiation 
occurring at 0 °C (after the addition of n-butyl lithium (n-BuLi) at -78 °C). Following 
the deprotonation of 43, back at -78 °C, furanone was added promoting the 
Michael addition. Casey et al. next added KOt-Bu before warming the reaction to -
30 °C to allow the final intramolecular Claisen condensation. It was initially thought 
that the KOt-Bu was essential for the reaction to progress however it was later 
found that, in our hands, the reaction proceeded more efficiently without it. 
 
Scheme 11: Racemic Tricycle Synthesis giving Compounds 47, 48 and 49 
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In the early trials of this reaction, excess furanone was used which resulted in 
double addition side products both on the cyclised and uncyclised scaffolds 
(Compounds 48 and 49). This resulted in poor yields for the desired tricycle 
products. The major product was compound 47 which was obtained in 20% yield 
(Scheme 11). This unfortunately had the undesired stereochemistry at C-4. 
Nevertheless, with some working conditions for the reaction in hand it was 
important to trial the reaction with enantiocontrol. 
 
It was believed that the ent-himbacine tricycle scaffold could be made by using a 
enantiomerically pure furanone in the tricycle synthesis. It was hoped that an R-
methyl group at the furanone C-5 would set the stereochemistry of the tricycle in a 
similar vain to that seen by Casey et al.. The enantiomericaly pure furanone was 
made from pent-3-enoic acid (S12.1) which was first esterified using sulfuric acid 
(H2SO4) in methanol (MeOH) to give methyl pent-3-enoate (50) in good yield 
(89%). Next, a Sharpless asymmetric dihydroxylation, using AD-mix-β in a 50:50 
mixture of tert-butanol (t-BuOH) and H2O, gave the dihydroxylated product which 
spontaneously cyclised to give the dihydrofuranone 51 in a moderate yield (44%). 
Finally, treatment with triethylamine (NEt3) and methanesulfonyl chloride 
(MeSO2Cl) in dichloromethane (CH2Cl2) gave the dehydration product 52; again, in 
moderate yields (49%) (Scheme 12). It was found that the products were relatively 
volatile so in later syntheses 51 was extracted into CH2Cl2 which was only partially 
evaporated away before the dehydration step. Unfortunately, the yield was still not 
significantly improved with a 27% yield across the two steps. 
 
 
Scheme 12: Stereospecific Furanone (52) Synthesis 
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The tricycle synthesis was completed using 52. Casey et al. used 0.5 equivalents 
of the methylfuranone to achieve a degree of kinetic resolution on the racemic 
diester. They showed a threefold selectivity for the desired diester enantiomer. In 
the 2-furanone investigations it had been found that using 0.5 or 1 equivalents 
made little difference to the stereoselectivity but using 4 equivalents led to further 
addition of the furanone to C-9a. As a consequence, the stereoselective tricycle 
synthesis was carried out with 0.5-0.7 equivalents of 52. Using the conditions 
acquired on request from Casey et al. tricycle 55 was obtained in a 12% yield 
whilst the desired tricycle, 56, was only given in a 5% yield (Scheme 13). There 
was again about 25% of starting material returned and small amounts of other 
isomers made. This made it difficult to purify, which impacted further on the yields.  
 
 
Scheme 13: Synthesis of Chiral Tricycles Giving Compounds 55 and 56 
 
Casey et al. did not develop the synthesis past the tert-butyl tricycle so with the 
desired enantiomerically pure tricycle in hand it was next necessary to convert the 
C-4 tert-butyl ester into an aldehyde so the vorapaxar biaryl motif could be 
attached. One option would have been to follow the protocol used in the vorapaxar 
synthesis. However, this used tributyltin hydride which is very toxic. Instead, the 
first step was to de-protect the tert-butyl group using trifluoroacetic acid (TFA) and 
CH2Cl2. This was done with 100% conversion to give the carboxylic acid 57. This 
was then coupled with ethanethiol, using DCC and catalytic 4-
dimethylaminopyridine (DMAP) as the coupling reagents, to give the thioester 58 in 
around 70% yield. The resulting thioester was then reduced using triethylsilane and 
catalytic palladium on carbon to give the aldehyde 59 in moderate yields (50%). 
These were mild reducing conditions132 which did not appear to attack the lactone 
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ring. Further, upon silica gel column chromatography purification, the aldehyde 
partially epimerised at the C-4 position (Scheme 14). This meant that the more 
readily available but undesired C-4 epimer could be used to form a portion of the 
desired epimer via this pathway. 
 
 
Scheme 14: Vorapaxar Analogue Synthesis Giving Compounds 61, 62, 64 and 65  
 
The final step was to couple 28 with 59. 28 was deprotonated with n-BuLi before 
59 was added to allow the Horner-Emmons reaction to proceed in a reasonable 
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yield. Since the aldehyde epimerised to give inseparable isomers of 59 the Horner-
Emmons reaction gave compound 61 in a 41% yield and compound 62 in a 15% 
yield. Compounds 61 and 62 were readily separable. Further, analytical chiral high-
performance liquid chromatography (HPLC) of 61 gave two peaks of 95% and 5%. 
This suggests that the asymmetric synthesis gave an enantiomeric excess (ee) of 
90%. 
 
Since more of 61 had been synthesised, a portion of it was reduced with sodium 
borohydride to convert the C-9 ketone into a C-9 hydroxyl giving (9R)-hydroxy-
compound 64 and and the (9S)-hydroxy-compound 65 in 38% and 29% yield, 
respectively. It was thought that the hydroxyl products would be important for SAR 
purposes as the sp2 carbon on the ketone would give a different tricycle ring 
configuration in comparison to the sp3 carbon observed with the hydroxyl-
analogues. 
 
Proof of Concept 
The completed stereospecific C-9-substituted vorapaxar analogues were tested in 
the Ca2+ flux FLIPR assay in order to prove that they could actually be used to 
inhibit the PAR-1. The compounds were tested using HLF and 10 nM thrombin as 
the agonist. The positive control was a sample of RWJ-58259 (synthesised by a 
colleague within the group) whilst the negative control was DMSO in biological 
medium. Each compound was tested 6 times across two different days. In the first 
instance all of the compounds were tested across a concentration range of 0.0003-
30 µM. If the compound did not show full antagonism by 30 µM on the second 
round of testing it was tested at concentrations ranging from 0.003 µM to 300 µM. 
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Figure 9: The average (n = 6) percentage inhibition observed upon the addition of thrombin 
(10 nM) to human lung fibroblasts in buffer pre-incubated with Fluo-4 NW dye mix and 
0.0003 - 30 µM antagonist; Compounds 61, 62, 64, 65 and RWJ-58259 
 
The results from the Ca2+ flux FLIPR assay suggested that the C-9-substituted 
vorapaxar analogues were tolerated in PAR-1 and gave dose-dependent inhibition. 
Unfortunately, none of the compounds were as potent as the RWJ-58259 sample 
(IC50 = 0.19 µM) which in turn would make them much less potent than vorapaxar. 
Interestingly, the hydroxyl-analogues were less potent (IC50: 64 = 80 µM and 65 = 
150 µM) than the keto-analogues (IC50: 62 = 0.5 µM and 61 = 10 µM). This 
suggests that the ring configuration promoted by the sp2 C-9 was preferred. 
However, the hydroxyl compounds were only made from 61, the least potent of the 
two keto-analogues. This was because, with only 14 mg of compound 62, there 
was insufficient material to give useful quantities of the hydroxy-compounds. 
Therefore, one of the questions that needed to be addressed going forward was 
whether the hydroxyl-analogues derived from 62 were in fact more potent than 
those derived from 61. All the same, this study gave proof of concept and opened 
the avenue for the development of more novel vorapaxar analogues that would 
hopefully give greater potency. 
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Computational Modelling 
The strength of binding of vorapaxar to PAR-1 was clearly of interest to other 
people in the scientific community. Shortly after our proof of concept study had 
been completed a paper was published with the crystal structure of vorapaxar 
bound to PAR-1.133 This highlighted some interesting details with regards to the 
mode of binding. It was shown that vorapaxar bound very close to the extracellular 
surface in a tunnel made up of residues from the transmembrane segments. The 
binding site appeared to only have a small opening to the extracellular surface so it 
was hypothesised, in the paper, that vorapaxar got into the binding site by diffusing 
across the lipid bilayer. 
 
 
Figure 10: Computational Model of Vorapaxar (7) Binding PAR-1 Based on Published 
Crystal Structure133 
 
The published crystal structure allowed the established SAR of vorapaxar and the 
results from our proof of concept study to be rationalised using computational 
modelling. Vorapaxar was docked, by our collaborators at GSK, into a 
computational model of the vorapaxar binding site on PAR-1 (Figure 10). The key 
hydrogen bonds (H-bond) seen support the SAR profile of vorapaxar. The basic 
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nitrogen on the pyridine appeared to form a strong H-bond to the tyrosine-OH 
whilst the C-1 carbonyl was calculated to form an H-bond with the leucine-NH. This 
helped to explain the observed importance of the pyridine and C-1 carbonyl 
groups. The third H-bond appeared to be between the NH on the carbamate and 
the carbonyl on a PAR-1 alanine. This was interesting because the SAR profile 
suggested that the carbamate was not important for the potency of vorapaxar. If 
the H-bond shown in the computational model was a true H-bond then it would be 
expected to influence the potency. Typically each additional H-bond a ligand can 
form with the receptor will lead to an increase in the potency. Despite this one 
unexpected H-bond, the computational modelling appeared to be a useful tool. 
 
 
Figure 11: Computational Model of 62 Binding PAR-1 Based on Published Crystal 
Structure 
 
The stereospecific C-9-substituted vorapaxar analogues, which had already been 
tested in the proof of concept study, were docked into the same computational 
model. The closed, tunnel-shaped binding pocket should have meant that there 
was very little room to expand from the C-9 position. This may have explained the 
reduction in potency observed with the C-9-substituted analogues in comparison to 
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vorapaxar. In theory, the additional bulk of the carbonyl could have pushed the 
analogues deeper into the pocket disrupting the H-bond network. However, it can 
be seen from the model that 62, the most potent of the tested compounds, docked 
in a very similar fashion to vorapaxar (Figure 11). Again, the pyridine nitrogen was 
shown to form an H-bond with the tyrosine-OH and the C-1 carbonyl was seen to 
be H-bonding with the leucine-NH. The additional C-9 carbonyl did not appear to 
be affecting the mode of binding at all making it difficult to rationalise the 
considerable difference in potency between 62 and vorapaxar. 
 
 
Figure 12: Computational Model of 61 Binding PAR-1 Based on Published Crystal 
Structure 
 
The computational modelling was much more powerful in helping to explain the 
differences in potencies across the tested compounds. Whilst 62 docked in a very 
similar fashion to vorapaxar, 61, the 4R-epimer of 62, seemed to bind with the 
tricycle rotated by 180°. This meant that the C-1 carbonyl was no longer able to 
form the favourable H-bond, instead the C-9 carbonyl now appeared to be forming 
a weak, bifurcated H-bond with the leucine and valine-NH (Figure 12). The loss of 
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one of the key interactions would be sufficient to explain the 10 fold decrease in 
potency observed between 61 and 62. 
 
 
Figure 13: Computational Model Comparing the Docking of 61 and 64 to PAR-1 
 
The fact that the C-9-hydroxyl compounds had only been made from the less 
potent 61 meant that they also docked with the tricycle rotated by 180°. However, 
comparing the docking pose of 61 to its hydroxyl derivative, 64, (Figure 13) gave 
an indication as to why the hydroxyl compounds were less potent. Reducing the 
carbonyl group removed the easily accessible H-bond acceptor which was forming 
the bifurcated H-bond. Instead, a third H-bond donor was created causing potential 
clash between the C-9-hydroxyl and the PAR-1 leucine and valine-NH. 
Nevertheless, there was still possibility for an H-bond to form between the leucine 
and valine NH and the oxygen on the hydroxyl group. This could then explain the 
difference in potencies between the two hydroxyl compounds. It can be seen from 
Figure 14 that the hydroxyl group on compound 64 is closer to the H-bond donors 
on the leucine and valine. As a consequence, it could be proposed that 64 would 
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make stronger H-bond interactions than compound 65. This would reflect in the 
relative potencies observed with the two compounds. 
 
 
Figure 14: Computational Model Comparing the Docking of 64 and 65 to PAR-1 
 
In addition to using the computational modelling for rationalising observed results it 
was hoped that it would be possible to use it as a predictive tool. Looking at other 
residues in the binding pocket would highlight regions on the molecule that could 
be altered to make the C-9-substituted compounds more potent. Figure 15 shows 
that in the region of the pyridine there are two other tyrosines close enough to form 
H-bonds. In theory, having a pyrimidine instead of a pyridine could lead to a 
second H-bond to the biaryl portion of the compounds and thus an increase in 
potency. Testing this experimentally would help to justify the strength of the 
predictability of the computational model. 
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Figure 15: Using Computational Modelling as a Predictive Tool 
 
Optimisation 
The synthesis of the stereospecific C-9-substituted vorapaxar analogues 
highlighted several issues with the chosen route. In fact the synthesis was much 
more troublesome than would have been predicted from the paper published by 
Casey et al.. As a consequence, several different approaches were investigated to 
try and achieve greater overall yields of the desired keto-vorapaxar analogues. It 
was hoped that enough could be made to provide a stock batch which could be 
diversified ready for SAR profiling. 
 
The starting materials being used to make the tricycle were needed in large 
quantities so it seemed appropriate to try and optimise these steps. Of the early 
steps, the iodination was the lowest yielding transformation. The Appel-like 
reaction was very effective in converting the terminal hydroxy-group into a terminal 
iodine. However, the reaction created large amounts of triphenylphosphine oxide 
which co-eluted with the desired product. This necessitated multiple purifications 
by silica gel column chromatography which greatly reduced product recovery. 
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Consequently, the reaction was trialled in a different solvent; tert-butylmethylether 
(t-BME). The reaction appeared to progress just as efficiently but the 
triphenylphosphine oxide crashed out into the t-BME allowing the majority of it to 
be filtered off. This meant that only one round of column chromatography was 
required and a larger proportion of the product was recovered. 
 
The improvements made to the iodination were useful but there were definitely 
more significant issues that needed to be addressed. One of these issues was the 
poor yields and purification complications seen during the diester synthesis. It was 
thought that changing the ester protection group could provide a UV active product 
which would be easier to identify during purification and thus improve the yields. 
para-Methoxybenzyl acetate was trialled in the diester synthesis. The p-
methoxybenzyl group was successful in giving traceable products but it also gave a 
large number of impurities which made purification difficult. The major product from 
this reaction was the uncyclised diester 68. Despite being the major product, 68 
was still only obtained in a low 21% yield. Fortunately, simply treating 68 with LDA 
gave cyclisation to 69 in excellent (91%) yield (Scheme 15). 
 
 
Scheme 15: p-Methoxybenzyl Protected Tricycle Synthesis Giving Compounds 73 and 74 
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The p-methoxybenzyl group still gave lots of impurities and required two steps to 
get to the diester. Clearly, it was not the best choice of protection group. As a 
consequence, it was hoped that the tris(triethylsilyl)silyl (“supersilyl”) group could 
be used as an alternative to make a suitable acetate for the diester synthesis. The 
“supersilyl” group had been shown to be a suitable carboxylic acid protecting group 
which was UV-active, stable and suitable for providing selectivity in aldol 
reactions.134 Regrettably, despite several conditions being trialled, the “supersilyl” 
acetate was not successfully synthesised. On the other hand, an Evan’s auxiliary 
was easily acetylated using acetyl chloride and n-BuLi in 2-methyltetrahydrofuran 
(2-MeTHF) to give (S)-3-acetyl-4-isopropyloxazolidin-2-one (70) in 89% yield. The 
diester synthesis was trialled with 70 with the hope that it could direct the transition 
state to get an enantioenriched diester. In turn, it was hoped that this would direct 
the subsequent tricycle synthesis and improve the yield of the desired tricycle 
scaffold. Unfortunately, the diester formation reaction did not work when 70 was 
used. Equally, the diester synthesis did not work when trialled with pyridin-2-yl 
acetate (71) which had been made in a 33% yield by reacting pyridin-2-one with 
acetyl chloride in the presence of pyridine. It was unfortunate that the pyridine 
protected diester could not be synthesised because it had been shown that 
pyridinyl esters can be reduced directly into aldehydes in a similar fashion to the 
sulfonate ester reduction.135 This would have decreased the number of synthetic 
steps required following the synthesis of the tricycle and thus increased the overall 
yield. 
 
 
Compounds 70 and 71: Acetates Trialled in Diester Synthesis 
 
Since most of the protected acetates had not been successfully turned into the 
relevant diester only the p-methoxybenzyl protected diester could be taken forward 
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for the tricycle synthesis. Compound 69 was reacted using the established tricycle 
synthesis conditions but gave very poor yields. The two tricycles 73 and 74 were 
obtained in only 2% yield each (Scheme 15). Additionally, they were derived from 
the (1S,2R)-diester. This meant that not only was a very small amount of material 
isolated it was of the wrong relative stereochemistry. It was concluded that it would 
be best to resort back to the t-butyl protecting group despite the issues associated 
with its use. 
 
In addition to continuing with the t-butyl protection group, the use of the 
commercially available 2-(5H)-furanone was returned to in an attempt to simplify 
the tricycle synthesis. Using 2-(5H)-furanone avoided the three extra, low yielding, 
steps required to make the stereospecific furanone. Obviously, using the 
commercial furanone would lead to the synthesis of racemic compounds. This is 
because the double bond could easily be approached from both sides without the 
added steric bulk of the methyl group creating a bias. The racemic products would 
need to be separated so it was hoped that this could be completed using chiral 
column chromatography.  
 
LTMP is one of the strongest bases available and since it was required for the 
initial deprotonation other choices of base were not explored as they simply would 
not have been strong enough. However, a few adaptations were made to the 
original synthetic route proposed by Casey et al.. The use of KOt-Bu following 
deprotonation with LTMP was found to be unnecessary. The reaction solvent was 
switched from tetrahydrofuran (THF) to 2-MeTHF. This was only done to allow the 
reaction solvent to be used directly for extraction following work-up. Finally, during 
the initial lithiation of TMP, the reaction mixture was warmed to 0 °C to aid the 
formation of LTMP. Otherwise, the reaction conditions were fairly close to those 
provided by Casey et al.. 
 
These optimisations led to minor improvements in the yields. In the most 
successful attempt of the racemic tricycle synthesis both enantiomers of the diester 
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reacted efficiently. In this case the major products were 45 and 47 which were 
made in 26% and 25% yields respectively (Scheme 16). Evidently, the furanone 
seemed to add preferentially to give the relative R-stereochemistry at C-4 no 
matter which enantiomer of 43 reacted. Either way, the combined yield was only 
51% which was disappointing considering Casey et al. obtained a 53% yield of 47 
alone. The still comparatively poor yields could be accounted for by the 
considerable amount of returned starting material along with the presence of some 
uncyclised product and a small amount of the S-C-4 product (compound 75 in the 
experimental section). 
 
 
Scheme 16: Optimised Racemic Tricycle Synthesis Giving Compounds 45 and 47 
 
Since the tricycle synthesis was still low yielding and problematic, despite 
optimisation, the idea of using a different coupling method to attach the biaryl motif 
was investigated. It was hoped that a coupling method which required fewer 
synthetic steps on the tricycle portion could be used. One way of achieving this 
would be to functionalise the biaryl motif to give an allyl boronic ester or acid whilst 
converting the t-butyl ester on the tricycle into a halogen allowing the final coupling 
to be done with a Suzuki reaction. There was literature evidence to suggest that an 
ester could be directly replaced by an iodine in a one pot, two step, reaction.136 
Consequently, it was thought that the biggest challenge would be to furnish the 
biaryl portion with an allyl boronic ester or acid. 
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Scheme 17: Retro-Synthetic Analysis of Suzuki Coupled Analogues 
 
Alkynes can be borylated to give trans-allyl boronic acids,137 thus it was hoped that 
a Sonogashira reaction could be used to install an alkyne onto the biaryl motif. 
There was literature precedent which suggested that using trimethylsilyl acetylene 
for the Sonogashira followed by a basic work-up could give the required terminal 
alkyne.138 Since the biaryl portion was originally constructed using a Suzuki 
reaction it would be necessary to consider the order of the reactions to selectively 
install the alkyne onto the pyridine at the 2-position and the second aryl group at 
the 5-position. Therefore it was hoped that the Sonogashira could be carried out on 
a triflate group which could be installed after the addition of the aryl group with a 
Suzuki reaction (Scheme 17). 
 
The investigations for the Suzuki coupled analogue route were carried out using a 
pyrimidine rather than the pyridine found on the vorapaxar biaryl portion. It was 
thought that using a pyrimidine had the potential to increase potency whilst 
introducing another degree of novelty to the vorapaxar analogues. This was based 
on the predictions from the computational modelling which suggested that there 
was the potential to form a second H-bond to the biaryl portion.  
 
The initial Suzuki reaction for the trial route was found to be successful using 5-
bromopyrimidin-2-ol, (3-(trifluoromethyl)phenyl)boronic acid, [1,1'-bis 
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diphenylphosphino)ferrocene]dichloropalladium (PdCl2(dppf)) and K2CO3 in a 4:1 
mix of isopropanol (i-PrOH) and H2O at 120 °C in a microwave. It gave compound 
76 in a 49% yield. The triflation was subsequently attempted using both N,N-
bis(trifluoromethylsulfonyl)aniline and triflic anhydride as the triflating reagents. The 
former gave 7% of the desired biaryl-triflate 77, whilst the latter gave nothing upon 
purification. It was presumed that the product was very unstable. However, the 
small amount of product retrieved was trialled in the Sonogashira reaction 
(Scheme 18). 
 
 
Scheme 18: Towards a Biaryl Boronate Ester 
 
Compound 77 was heated to 100 °C in a microwave for 10 min with 
ethynyltrimethylsilane, bis(triphenylphosphine)palladium(II) chloride (PdCl2(PPh3)2), 
copper(I) iodide and NEt3 in DMSO to give the desired Sonogashira product 78 (in 
experimental section), based on LCMS analysis. The trimethylsilyl group was then 
removed using methanolic sodium hydroxide. Unfortunately, the desired alkyne 
product 79 was only assumed to have been produced based on an LCMS analysis 
as it was lost upon isolation. This route was proving very problematic so another 
approach was trialled.  
 
Instead of carrying out a Sonogashira reaction on a potentially unstable triflate it 
was hoped that a halogen could be introduced following the initial Suzuki reaction. 
Consequently, pyrimidine 80 was synthesised in 97% yield using similar Suzuki 
conditions as before. The yield was greatly increased as there was no longer a 
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hydroxyl-group present which made work-up and purification much easier. In the 
literature it had been shown that LTMP could be used to deprotonate at the 2-
position of a pyridine ready for the addition of an iodine.139 This was trialled; 
unfortunately, the 2-iodobiaryl was not afforded. Instead, the 4,4-dimer 81 was 
produced (Scheme 19). This general approach to the novel vorapaxar analogues 
seemed to be producing more problems than it was resolving so, in the interests of 
time, these investigations were discontinued. 
 
 
Scheme 19: Towards a Biaryl Boronate Ester - Undesired Dimerisation Giving 81 
 
Resorting back to the reaction scheme established with the enantiomerically pure 
tricycles, the bulk of the racemic tricycles were taken through to the final 
compound. This gave 86, 87 and 94. The 4S derivative of 94 was not isolated 
because aldehyde 93 did not epimerise to the same extent as aldehyde 84. The 
racemic compounds were supplied to our collaborators at GSK who found that the 
enantiomers could be very easily separated using chiral purification techniques. 
10-14 mg of each enantiomer was isolated. 
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Compounds 86, 87 and 94 
 
Both compounds 45 and 47 were taken through to the fully furnished tricycle 
because it was thought that 94 would take up a similar configuration to the desired 
vorapaxar like tricycle.  If this were to be the case then 94 would be more potent 
than the compounds derived from 47 whilst being an unexplored tricycle scaffold. 
Consequently, in order to test this hypothesis, the next stage was to trial the 
racemic and enantiomerically pure compounds in the Ca2+ flux FLIPR assay. 
 
Biological Testing 
The synthesis of 62; the novel keto-analogue of vorapaxar which had shown the 
greatest potency of all the compounds tested in the proof of concept studies, was 
never achieved on large scale. Equally, the racemic version (87), which should 
have been easier to make, was also not obtainable in large quantities. Starting the 
synthetic route on a 40 g scale led to no more than 100 mg of each of the final 
racemic products. This meant that it was not a viable option to explore the potential 
of the additional ketone as a synthetic handle. It had been hoped that an array of 
analogues could be made to establish SAR at the C-9 position. Poor yields in a 
difficult synthesis meant that this was not possible. However, whilst trying to 
optimise the route, a new tricycle scaffold was developed (94). Based on modelling 
it was hypothesised that 94 would be at least as potent as 62, if not more so. 
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Compounds 61, 62, 64 and 65: Enantiomerically Pure Compounds Tested in the Proof of 
Concept Study 
 
The biological testing in the proof of concept study allowed the comparison of the 
potencies when the C-4 biaryl portion was positioned in the R or S configurations. 
In addition, the R and S C-9 hydroxy-analogues of 61; 64 and 65 respectively, 
were compared. These initial studies confirmed that having the biaryl group in the 
4S orientation gave a more potent compound. Furthermore, having the C-9 ketone 
was shown to be more potent than when it had been reduced to give a hydroxyl 
group at the C-9 position. The second round of testing allowed the analysis of the 
racemic analogues along with their chirally purified derivatives and showed the first 
assessment of 94, the analogue with the novel tricycle scaffold. 
 
The first question to answer was whether the racemic compounds actually caused 
a significant drop in potency. Using the same FLIPR assay as that used in the 
proof of concept study racemic compounds, 86 and 87, were shown to have IC50 
values of 2.6 and 1.3 µM, respectively. This made them more potent than all but 
one of the enantiomerically pure compounds used in the proof of concept study. 
Only compound 62 was more potent (IC50 = 0.5 µM) than the racemic compounds. 
This is interesting because the belief throughout the development of vorapaxar was 
that having a specific enantiomer was essential for activity. Further, having the 
biaryl portion extending from C-4 with S-stereochemistry was also seen as crucial. 
However, in the racemic examples there was negligible difference between the 
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potencies even though one had a relative S-C-4 and the other a relative R-C-4. 
This would suggest that the enantiomeric pairings contributed to balance the 
disfavoured orientation. A final conclusion that can be made from these results is 
that the C-3 methyl group does not appear to be essential. With all this said, the 
dose-response curves given by 86 and 87 (Figure 16) are not clean sigmoidal 
curves which reach 100% inhibition so any IC50 values taken from them may be 
inaccurate. 
 
 
Figure 16: The average (n = 5) percentage inhibition observed upon the addition of 
thrombin (10 nM) to human lung fibroblasts in buffer pre-incubated with Fluo-4 NW dye 
mix and 0.0003-30 µM antagonist; Compounds 86, 87 and RWJ-58259 
 
Separating out the enantiomeric pairs allowed a clearer picture of how each 
enantiomer affected the potency of the racemic mixtures. As can be seen from 
Figure 17, racemic-86 and the positive enantiomer derived from it had very similar 
dose-response profiles, thus giving similar IC50 values (ca. 2.5 µM). However, the 
negative enantiomer showed a noticeable decrease in potency (IC50 ≈ 15 µM). 
Although it was expected that one of the enantiomers would show decreased 
potency it is odd that the dose-response curve for the racemic compound did not 
lie between the curves of the two resulting compounds. This may be a result of 
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experimental variation in the assay. Nevertheless, in all cases the potency is much 
lower than the tool compound RWJ-58259 which in turn makes them significantly 
less potent than vorapaxar. Consequently, the slightly unexpected results were not 
investigated. 
 
 
Compounds 86, (-)-86 and (+)-86 
 
 
Figure 17: The average (n = 5 or 6) percentage inhibition observed upon the addition of 
thrombin (10 nM) to human lung fibroblasts in buffer pre-incubated with Fluo-4 NW dye 
mix and 0.0003-30 µM antagonist; Compounds rac-86, (+)-86, (-)-86 and RWJ-58259 
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Figure 18 shows the equivalent results for 87 and its enantiomeric derivatives. 
These results are more in line with what would be expected. The dose-response 
curve for the racemic compound falls between that of the positive and negative 
enantiomers. In all cases the curves are still relatively shallow and do not reach 
100% inhibition. It is hard to say whether this is a real indication of how the 
compound is interacting within the receptor or if it is a consequence of giving a 
percentage inhibition relative to the positive control; RWJ-58259. This means that 
despite (-)-87 being twice as potent (IC50 = 0.10 µM) as RWJ-58259 (IC50 = 0.19 
µM) it might be inadvisable to draw firm conclusions. 
 
 
Compounds 87, (-)-87 and (+)-87 
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Figure 18: The average (n = 5 or 6) percentage inhibition observed upon the addition of 
thrombin (10 nM) to human lung fibroblasts in buffer pre-incubated with Fluo-4 NW dye 
mix and 0.0003-30 µM antagonist; Compounds rac-87, (+)-87, (-)-87 and RWJ-58259 
 
The results so far have helped us to answer the question of whether racemic 
compounds are less potent than enantiopure ones. The evidence suggests that 
compounds with S-stereochemistry at C-4 show a significant difference in the 
potencies of racemic and enantiopure compounds. On the other hand, having R-
stereochemistry at C-4 appears to impact on the potency itself so greatly that 
enantiopure compounds tend to be no more active than the racemic ones. With this 
in mind, the next question that needed to be answered was whether the novel 
tricycle scaffold, given in compound 94, actually led to greater potency than the 
established scaffolds of 62 and 87. 
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Compounds 94, (+)-94 and (-)-94 
 
 
Figure 19: The average (n = 6) percentage inhibition observed upon the addition of 
thrombin (10 nM) to human lung fibroblasts in buffer pre-incubated with Fluo-4 NW dye 
mix and 0.0003-30 µM antagonist; Compounds (+)-94, (-)-94 and RWJ-58259 
 
Figure 19 shows the percentage inhibitions of (+)-94, (-)-94 and RWJ-58259. In this 
case there is a huge difference in the potencies of the enantiomeric pair derived 
from racemic-94. More significantly, the dose-response curve for compound (-)-94 
is considerably left-shifted indicating a high potency. Compound (-)-94 gave an IC50 
of 0.027 µM. This is the best potency of all of the compounds developed so far. It is 
0
10
20
30
40
50
60
70
80
90
100
0.0003 0.003 0.03 0.3 3 30
Percentage 
Inhibition
Concentration (µM)
Percentage Inhibition of PAR-1 
(+)-94
(-)-94
RWJ58259
99 
 
10 times that of RWJ-58259 and approaching the level of potency described for 
vorapaxar. This means that, as predicted, the novel tricycle scaffold was in fact 
more potent than the established scaffold more analogous to that used in 
vorapaxar. Conversely, its enantiomeric pair gave an IC50 of 13 µM. This is one of 
the worst potencies of all of the C-9 ketone compounds. In this case having the 
enantiopure compound was definitely important. 
 
 
Figure 20: The average (n = 5 or 6) percentage inhibition observed upon the addition of 
thrombin (10 nM) to human lung fibroblasts in buffer pre-incubated with Fluo-4 NW dye 
mix and 0.0001-10 µM antagonist; Compounds (-)-94, vorapaxar and RWJ-58259 
 
Considering compound (-)-94 appeared to be approaching similar potencies to 
vorapaxar it seemed prudent to directly compare the two in the same assay. Figure 
20 shows the results of these investigations. Clearly, vorapaxar is still more potent 
with an IC50 of 0.013 µM (in this assay). However, it is clear that the sigmoidal 
curve of (-)-94, in comparison to that of vorapaxar, is still relatively shallow. This 
suggests that the shallow dose-response curve is a property of this class of 
compounds. If it was a direct result of using RWJ-58259 as the comparison when 
calculating the relative percentage inhibitions then vorapaxar would also have a 
shallow curve, but it does not. 
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In order to confirm that using the positive control as the comparator when 
calculating the relative percentage inhibition made little difference to the results a 
compound baseline was determined. This was done using compound 62 because 
in the proof of concept study it had been shown to have moderate potency whilst 
giving a good sigmoidal dose-response curve. Further, as the most potent 
compound of the series, (-)-94 was used to obtain a compound baseline. In order 
to give the baseline, the assay was completed using the same method as before 
but without the addition of the agonist; thrombin. This gave a clearer idea of what 
the compound was doing to the cells in the absence of thrombin.  
 
 
Figure 21: The average (n = 8) percentage inhibition observed upon the addition of 
thrombin (10 nM) to human lung fibroblasts in buffer pre-incubated with Fluo-4 NW dye 
mix and 0.0003-30 µM antagonist; Compounds 62 and RWJ-58259, against a compound 
baseline or simply against the positive control (RWJ-58259). 
 
Figure 21 and Figure 22 show that using the baseline to calculate the relative 
percentage inhibition gives very similar results as when the strongest inhibition 
elicited by the positive control is used for the calculations. This would suggest that 
the shallow dose-response curve, seen with this series of compounds, is a result of 
how they interact with PAR-1. In some of the cases, such as with rac-87, (+)-87 
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and (-)-87, the fact that 100% inhibition was not reached could suggest that they 
were acting as partial agonists. On the other hand, some of the compounds, 
namely 62 and (-)-94, did reach 100% inhibition so the partial agonist argument 
cannot be used. However, a recent paper by Fallahi-Sichani et al. suggests that 
variation in dose-response curve shape can be indicative of cell-to-cell variability. 
They based their study on drugs targeting the Akt/PI3K/mTOR pathway which 
tended to give shallower dose-response curves.140 Since PAR-1 is upstream of the 
Akt/PI3K/mTOR pathway a similar effect may be occurring with these compounds. 
 
 
Figure 22: The average (n = 12) percentage inhibition observed upon the addition of 
thrombin (10 nM) to human lung fibroblasts in buffer pre-incubated with Fluo-4 NW dye 
mix and 0.0003-30 µM antagonist; Compounds (-)-94 and RWJ-58259, against a 
compound baseline or simply against the positive control (RWJ-58259). 
 
In summary, despite not being able to fulfil the early aim of testing a wide array of 
analogues, with different functional groups attached to C-9, several significant 
conclusions were made. The proof of concept study had already told us that the C-
9 ketone was tolerated. However, the further investigations confirmed that losing 
the methyl group at C-3 was not an issue and that enantiomerically pure 
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compounds were only beneficial if the compound tricycle was suitable. This led to 
the identification of a new, more potent tricycle; the tricycle used in compound 94. 
 
Investigations Towards an Alternative Route 
Even though a suitable synthesis for the novel C-9-keto-tricycle had been 
established it was still low yielding. It was still a desirable aim to obtain sufficient 
material to make a series of analogues with variation at the C-9 position. 
Consequently some investigations were made into an alternative, potentially higher 
yielding route. A variation on the IMDA reaction used for the synthesis of vorapaxar 
was investigated. It was thought that if the IMDA could be done on an α,β-
ketoester the desired C-9-ketone would already be installed (Scheme 20). The 
dieneophile could be constructed using the same methodology developed for the 
synthesis of vorapaxar to give the enantiopure hydroxy-pentynoate species.141 This 
could either undergo stereospecific hydrogenation prior to being coupled to the 
α,β-ketoester or after the coupling had occurred. The α,β-ketoester could be made 
via a Claisen condensation between an alkyl acetate and a 
cyclohexenecarboxylate. 
 
 
Scheme 20: Retro-Synthetic Analysis of α,β-Ketoester IMDA 
 
The Claisen condensation was first trialled to give ethyl 3-cyclohexenyl-3-
oxopropanoate (95) but the yields were poor (0-28%). The best conditions found 
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involved condensing 1-(cyclohex-1-en-1-yl)ethanone (S21.1) and diethyl carbonate 
using KOt-Bu as the base (Scheme 21). On the other hand, condensing tert-butyl 
acetate deprotonated with LDA with methyl cyclohex-1-enecarboxylate (S21.2) 
gave tert-butyl 3-cyclohexenyl-3-oxopropanoate (96) with yields as high as 95% 
(Scheme 21). The difference in yields is likely to be a reflection of the difference of 
stabilities. Nevertheless, the two different α,β-ketoesters were taken forward. The 
α,β-ketoesters needed to be coupled to an enantiopure hydroxy-pentynoate. 
Therefore, (R)-benzyl 4-hydroxypent-2-ynoate (98) was obtained in a moderate 
yield (55%) using a similar protocol as that used in the vorapaxar synthesis 
(Scheme 22). 
 
 
Scheme 21: Synthesis of the α,β-Ketoesters 95, 96 and 97 
 
With 98 in hand, a portion of 96 was deprotected using a 1:1 TFA/CH2Cl2 mix to 
give 3-cyclohexenyl-3-oxopropanoic acid (97) in an 83% yield (Scheme 21). 97 
was then coupled to 98 using 1-[bis(dimethylamino)methylene]-1H-1,2,3-
triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (HATU) and 
diisopropylethylamine (DIPEA) in dimethylformamide (DMF). The coupling was 
very low yielding giving the coupled product 99 in only a 6% yield. An alternative 
coupling was trialled; 95 was reacted with 98 in an NBS catalysed 
transesterification reaction. This gave 99 in a slightly improved but still 
disappointing 14% yield (Scheme 23). The low yields of the coupling could be 
explained by the instability of 95 and 97. The transesterification reaction was 
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trialled with NEt3 as the coupling reagent but it gave benzyl 3-cyclohexenyl-3-
oxopropanoate (101) as opposed to the desired product. 
 
 
Scheme 22: Synthesis of (R)-Benzyl 4-hydroxypent-2-ynoate (98) and Undesired 100 
 
Nevertheless, the successfully coupled material was taken forward. Combined 
batches of 99 were subjected to Lindlar catalyst conditions to promote 
stereospecific hydrogenation. Unfortunately, this was unsuccessful (Scheme 23). 
The failed hydrogenation was probably due to the very small scale on which it was 
trialled. This in turn was due to the insufficient material made in the coupling trials. 
In order to avoid the coupling step the Diels-Alder (DA) reaction was trialled 
intermolecularly instead. The idea would be to deprotect the ester and couple it to 
give the lactone following the DA. It had been shown that caesium carbonate 
(Cs2CO3) could be used to initiate similar DA reactions with α,β-ketoesters142 so 
this was trialled. The hydroxyalkyne, 98, was used because attempts at mild 
reduction to the alkene had resulted in full reduction to 100. Consequently, it was 
hoped that the double bond that would remain following the DA could be more 
easily reduced on the cyclised product. 
 
Scheme 23: Synthesis of IMDA Pre-curser 99 
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Reacting a couple of different α,β-ketoesters with the hydroxyalkyne in the 
presence of Cs2CO3 gave some interesting results. Sadly, the desired DA reaction 
did not occur. Instead, an interesting transformation which appeared to require the 
migration of an acetate group to give a tri-substituted alkene took place (Scheme 
24). Using 101 gave compound 102 as a single symmetrical product. On the other 
hand, reacting 95 under the same conditions gave two major products; 103 and 
104, which were only separable using chiral column chromatography. It was 
believed that the reaction was initiated by the hydroxy group attacking the β-
ketone. Consequently, a series of trial reactions, excluding a free hydroxyl group, 
were completed to see if the DA could be promoted. 
 
 
Scheme 24: Mechanism of Hydroxyalkyne Reacting with α,β-Ketoesters. 
 
Compound 96 was reacted with diethyl fumarate, diethyl maleate, maleic acid 
monoethyl ester and maleic acid using Cs2CO3 in ethyl acetate (EtOAc) at RT. The 
maleic acid reaction did not work at all whilst the other three substrates reacted to 
give the same addition product, 106. The reaction also gave a minimal amount of 
the fully cyclised DA product, 107, in a 2% yield (Scheme 25). This suggested that 
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although the DA reaction was feasible it was not the predominant reaction 
pathway. Compound 106 was treated with a selection of strong bases (LiHMDS, 
LDA and LTMP) to try and drive the cyclisation but this was unsuccessful. Once 
again this route appeared to be causing more issues than it was solving so due to 
time constraints no further investigations were completed. 
 
Scheme 25: Trial Diels-Alder Reactions 
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Chapter 4: Conclusions and Future Work 
The overall aim of this project was to design and synthesise novel PAR-1 inhibitors 
in order to develop a novel treatment for IPF. Originally the commercially available, 
allosteric PAR-1 inhibitor, “Q94” was going to act as a starting point for 
development. Unfortunately, after failing to replicate literature results and finding 
“Q94” inactive and insoluble, new inspiration was required. Examining the literature 
identified atopaxar and vorapaxar as potent PAR-1 inhibitors which were, at the 
time, being tested in clinical trials. Vorapaxar had been developed from the natural 
product, tricyclic, himbacine. From the literature search a novel synthesis towards 
himbacine had also been found. The route was incomplete and left a ketone on the 
central ring of the tricycle. It was hypothesised that the novel synthetic route could 
be adapted to make novel analogues of vorapaxar. Further, the novel analogues 
could be used to examine the SAR from the central ring of the tricycle; a previously 
unexplored region of the molecule. 
 
The published novel synthetic route towards himbacine was successfully adapted 
to give the desired C-9-keto-ent-himbacine tricycle. This was not achieved without 
difficulty. Nevertheless, some of the earlier synthetic steps were improved upon 
and several lessons were learnt along the way about the tricycle synthesis. It was 
found that obtaining pure starting material for the tricycle synthetic step was 
obviously essential but unexpectedly problematic; purification at this step led to a 
marked drop in the overall yield. Further, the tricycle synthesis itself was never 
completed to meet the published yields giving another reduction to the overall yield 
of the route. Nonetheless, having synthesised the tricycle, the route had to be 
completed to be able to furnish the tricycle with the characteristic biaryl group 
found on vorapaxar. This was done with much greater success. In four steps the C-
4 ester was replaced with the biaryl group to give the desired vorapaxar analogue; 
each step typically achieved around 90% yield.  
 
Alongside the initial investigations, into the novel tricycle synthesis, the biaryl group 
was attached to a series of smaller, monocyclic or aromatic groups. Some of these 
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compounds were tested against PAR-1 in a biological assay and were found to be 
inactive and in some cases insoluble. Fortunately, the novel vorapaxar analogues 
with the full tricycle were tested and were shown to have some potency against 
PAR-1. The hypothesis that vorapaxar analogues with a C-9-keto-group could be 
used as a starting point for developing novel PAR-1 inhibitors was proven correct. 
 
The next step was to synthesise more of the keto-compound in order to be able to 
use it to make a series of compounds with extension from C-9 to enable the 
exploration of the SAR from this point. However, due to continued problems with 
the low yielding synthetic route time was taken to try and establish a better, higher 
yielding route. This did not prove successful but it did identify a new, more potent 
tricycle scaffold. Compound (-)-94 was shown to be the most potent of the series of 
compounds tested, achieving an IC50 of 27 nM. In the same assay vorapaxar gave 
an IC50 of 13 nM. 
 
If future work were to be done, apart from further investigations into improving or 
changing the synthetic route, compound (-)-94 should be fully assessed. It has 
been shown to have great potency in one biological assay but to test it in other 
assays would be ideal to see if the potency holds up. Further, obtaining DMPK 
data and assessing receptor selectivity would be essential to determine if it would 
be a suitable drug candidate. In addition, synthesising enough of compound (-)-94 
to allow exploration of SAR from the C-9 position would be desirable. Investigating 
the extent to which you can grow upwards using reactions such as reductive 
amination, acetylation and the addition of organometallic compounds. Equally, 
replacing the ketone with a thioketone or fluorinating at the C-9 position would be 
interesting (Figure 23). 
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Figure 23: Scope of Transformations to Allow Exploration of SAR from C-9 
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Experimental 
Chapter 2 
General Experimental 
All solvents employed in this study were reagent grade. All reagents were 
purchased from Sigma-Aldrich, UK and Alfa Aesar, UK and used as received 
unless otherwise stated. All reactions were magnetically stirred and monitored by 
thin layer chromatography (TLC) on pre-coated silica gel plates (254 μm). Silica 
plates were initially examined under UV light and then developed using aqueous 
basic potassium permanganate stain. Flash chromatography was carried out with 
silica gel (33-70 μm) supplied by Merck Co.. Quoted yields refer to 
chromatographically and spectroscopically pure compounds unless otherwise 
stated. 1H NMR spectra were recorded at either 500 MHz with a DRX500 or at 600 
MHz with a Bruker AMX600. 13C NMR spectra were recorded at 150 MHz.  
Chemical shifts (δ values) are reported in parts per million (ppm) whilst coupling 
constants are reported in Hertz (Hz). 
 
2-Benzyl-1H-benzimidazole123 (23) 
 
Benzoic acid (0.63 g, 4.60 mmol) was added to a solution of 1,2-phenylenediamine 
(0.50 g, 4.60 mmol) in conc. HCl (37%) (5 mL) and H2O (5 mL). The reaction 
mixture was refluxed for 16 h. Once cool the solution was basified with solid NaOH 
(pH ~ 9) to form a precipitate. This was filtered under vacuum, washed with H2O 
and dissolved in CH2Cl2 (10 mL). The filtrate was extracted with CH2Cl2 (3 x 20 
mL). The combined organic layers were dried (MgSO4), filtered and concentrated 
in vacuo. Purification by flash column chromatography (0-25% EtOAc/CH2Cl2) and 
recrystallisation (EtOAc) gave 2-benzyl-1H-benzimidazole (23) (363 mg, 1.74 
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mmol, 38%) as pearlescent needles; Rf. 0.45 (30% EtOAc in CH2Cl2);  m.p. 182-
183 °C (lit. 182 °C143); 1H NMR (600 MHz, MeOH-d4)  7.48 (2H, bs, 2 x CHCN), 
7.31-7.28 (4H, m, 2 x CHCCH2 & 2 x CHCHCCH2), 7.24-7.20 (1H, m, 
CHCHCHCCH2), 7.20-7.16 (2H, m, 2 x CHCHCN), 4.21 (2H, s, CH2); 13C NMR 
(150 MHz, MeOH-d4)  155.2 (NCCH2), 138.3 (CH2CCH), 129.8 (2 x CHCCH2), 
129.8 (2 x CHCHCCH2), 128.0 (CHCHCHCCH2), 123.3 (2 x ArCH), 36.1 (CH2Ph), 
Note: Four of the benzimidazole C are not observed due to peak broadening 
caused by tautomerisation. In CDCl3 two more benzimidazole-CH are seen as a 
broad peak at 115.0 ppm; IR (thin film) 3048 (br) (ArC-H), 1536 (ArC-C), 1494 
(ArC-C), 1455 (ArC-C), 1435 (ArC-C), 1272 (C-N), 1024 (C-N), 767, 744, 721, 694 
cm-1; m/z (ES+) 209 (100%, [M+H]+); HRMS (ES+) calcd for C14H13N2 [M+H]+ 
209.1079, observed 209.1077. Data agrees with that reported by Algul et al.123 and 
Matsushita et al..144  
 
2-Benzyl-1-(4-chlorobenzyl)-1H-benzimidazole117 (24) 
 
Solid KOH (26.9 mg, 0.48 mmol) and 1-(bromomethyl)-4-chlorobenzene (98.6 mg, 
0.48 mmol) were added to a solution of 2-benzylbenzimidazole (23) (100 mg, 0.48 
mmol) in acetone (4 mL). The reaction mixture was stirred at 20 °C for 16 h before 
the solvents were removed in vacuo. The residue was dissolved in CH2Cl2 (10 mL) 
and sat. aq. Na2CO3 (10 mL). The aqueous layer was extracted with CH2Cl2 (2 x 
20 mL). The combined organic layers were dried (MgSO4), filtered and 
concentrated in vacuo. Purification by flash column chromatography (0-20% 
EtOAc/CH2Cl2); then (0-20% Et2O/Pet. Ether) and recrystallisation (20% Et2O/Pet. 
Ether) gave 2-benzyl-1-(4-chlorobenzyl)-1H-benzimidazole (24) (88 mg, 0.26 
mmol, 55%) as colourless solid; Rf. 0.41 (30% EtOAc/CHCl3); m.p. 108-109 °C; 1H 
NMR (600 MHz, CDCl3)  7.81 (1H, d, J = 7.9, CHCN), 7.28 (1H, dt, J = 7.5, 1.1, 
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CHCN), 7.25 (2H, d, J = 7.5, 2 x CHCCH2C), 7.23-7.17 (6H, m, CHCHCN, 2 x 
CHCCl, 2 x CHCHCCH2C and CHCHCHCCH2C), 7.14 (1H, d, J = 7.9, CHCHCN), 
6.81 (2H, d, J = 8.7 Hz, 2 x CHCHCCl), 5.15 (2H, s, CH2N), 4.25 (s, 2 H, CH2Ar); 
13C NMR (150 MHz, CDCl3)  153.4 (NCCH2), 142.8 (ArC), 136.0 (CCH2CCH), 
135.7 (ArC), 134.3 (NCH2C), 133.8 (CCl), 129.2 (2 x CHCCl), 129.0 (2 x 
CHCCH2C), 128.6 (2 x CHCHCCH2C), 127.6 (2 x CHCHCCl), 127.2 (p-Bn-
CHCHCHCCH2), 122.9 (ArCH), 122.4 (ArCH), 119.9 (ArCH), 109.6 (ArCH), 46.7 
(CH2N), 34.7 (CH2Ph); IR (thin film) 3061 (ArC-H), 2925 (ArC-H), 1651 (ArC-C), 
1605 (ArC-C), 1492 (ArC-C), 1460 (C-H), 1403 (C-H), 1332 (C-N), 1286 (C-N), 
1249 (C-N), 1161 (C-H), 1091, 1014, 804, 742 (C-Cl), 722, 696 cm-1; m/z (ES+) 
333 (100%, [M+H]+); HRMS (ES+) calcd for C21H18N235Cl [M+H]+ 333.1159, 
observed 333.1135. Mass spec data agrees with that obtained from the vendor for 
the commercial compound. 
 
1,2-Dibenzyl-1H-benzimidazole145 (25)  
 
Solid KOH (32.5 mg, 0.58 mmol) and benzylbromide (69.0 μL, 0.58 mmol) were 
added to a solution of 2-benzylbenzimidazole (23) (121 mg, 0.58 mmol) in acetone 
(4 mL). The reaction mixture was stirred at 20 °C for 3 h before the solvents were 
removed in vacuo. The residue was dissolved in CH2Cl2 (10 mL) and sat. aq. 
Na2CO3 (10 mL). The aqueous layer was extracted with CH2Cl2 (2 x 20 mL). The 
combined organic layers were dried (MgSO4), filtered and concentrated in vacuo. 
Purification by flash column chromatography (0-20% EtOAc/CH2Cl2) and 
recrystallisation (CH2Cl2) gave 1,2-dibenzyl-1H-benzimidazole (25) (121 mg, 0.41 
mmol, 70%) as colourless crystals; m.p. 126-127 °C; 1H NMR (600 MHz, CDCl3)  
7.81 (1H, d, J = 7.9 Hz, CHCN), 7.29-7.24 (6H, m, CHCN, 2 x CHCCH2N, 2 x 
CHCHCCH2 and CHCHCHCCH2N), 7.23-7.18 (5H, m, 2 x CHCHN, 2 x CHCCH2 
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and CHCHCHCCH2), 6.94-6.91 (2H, m, 2 x CHCHCCH2N), 5.19 (2H, s, CH2N), 
4.26 (s, 2 H, CH2); 13C NMR (150 MHz, CDCl3)  153.5 (NCCH2), 142.8 (C-N), 
136.2 (CH2C), 135.9 (NCH2C), 135.9 (C-N), 129.0 (2 x CHCHC), 129.0 (2 x 
CHCCH2N), 128.6 (2 x CHC), 128.0 (CHCHCHCCH2N), 127.1 (CHCHCHC), 126.3 
(2 x CHCHCCH2N), 122.7 (CHCHCN), 122.3 (CHCHCN), 119.7 (CHCN), 109.8 
(CHCN), 47.2 (NCH2), 34.7 (CH2); IR (thin film) 3061 (ArC-H), 3030 (ArC-H), 2930 
(C-H), 1607 (ArC-C), 1508 (ArC-C), 1494 (ArC-C), 1454 (C-H), 1406 (ArC-C), 1356 
(C-H), 1331 (C-N), 1285 (C-N), 1249 (C-N), 1159 (C-H), 1030, 912, 857, 742, 721, 
694 cm-1. Data agrees with that reported by Cetinkaya et al..145  
 
Chapter 3 
General Experimental 
All solvents employed in this study were reagent grade. All reagents were 
purchased from Sigma-Aldrich, UK and Alfa Aesar, UK and used as received 
unless otherwise stated. All reactions were magnetically stirred and monitored by 
thin layer chromatography (TLC) on pre-coated silica gel plates (254 μm) and/or by 
LCMS. Silica plates were initially examined under UV light and then developed 
using aqueous basic potassium permanganate stain. LCMS analysis was 
conducted on either System A, an Acquity UPLC BEH C18 column (2.1 mm × 50 
mm ID, 1.7 μm packing diameter) eluting with 0.1% formic acid in H2O (solvent A) 
and 0.1% formic acid in acetonitrile (MeCN) (solvent B), using the following elution 
gradient 0.0−1.5 min 3−100% B, 1.5−1.9 min 100% B, 1.9−2.0 min 3% B, at a flow 
rate of 1 mL min−1 at 40 °C. The UV detection was an averaged signal from 
wavelength of 210 to 350 nm, and mass spectra were recorded on a mass 
spectrometer using alternate-scan electrospray positive and negative mode 
ionization (ES +ve and ES −ve); or System B, an Acquity UPLC BEH C18 column 
(50 mm × 2.1 mm ID, 1.7 μm packing diameter) eluting with 10 mM ammonium 
bicarbonate ((NH4)HCO3) in H2O adjusted to pH10 with ammonia solution (solvent 
A) and MeCN (solvent B) using the following elution gradient 0−1.5 min 1−97% B, 
1.5−1.9 min 97% B, 1.9−2.0 min 100% B at a flow rate of 1 mL min−1 at 40 °C. 
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Flash chromatography was carried out with silica gel (33-70 μm) supplied by Merck 
Co.. Automated column chromatography was performed using pre-packed silica 
gel columns on a Flashmaster II. The Flashmaster II is an automated multiuser 
flash chromatography system, available from Argonaut Technologies Ltd, which 
utilizes disposable, normal phase, SPE cartridges (2−100 g). Mass-directed auto-
preparative HPLC (MDAP) was conducted on  either System A, a Sunﬁre C18 
column (150 mm × 30 mm ID, 5 μm packing diameter) at ambient temperature 
eluting with 0.1% formic acid in H2O (solvent A) and 0.1% formic acid in MeCN 
(solvent B), using an appropriate elution gradient over 25 min at a ﬂow rate of 40 
mL min−1 and detecting at 210−350 nm at room temperature; or System B, an 
XBridge C18 column (100mm x 30mm i.d. 5µm packing diameter) at ambient 
temperature eluting with 10 mM Ammonium Bicarbonate in water adjusted to pH 
10 with Ammonia solution (solvent A) and MeCN (solvent B), using an appropriate 
elution gradient over 25 min at a ﬂow rate of 40 mL min−1 and detecting at 210−350 
nm at room temperature. Quoted yields refer to chromatographically and 
spectroscopically pure compounds unless otherwise stated. 1H NMR spectra were 
recorded at either 500 MHz with a DRX500 or at 600 MHz with a Bruker AMX600. 
13C NMR spectra were recorded at 101 MHz or 150 MHz. Chemical shifts (δ 
values) are reported in parts per million (ppm) whilst coupling constants are 
reported in Hertz (Hz). 
 
6-Methylpyridin-3-yl trifluoromethanesulfonate87 (26) 
 
Solid K2CO3 (3.80 g, 27.5 mmol) and N,N-bis(triflouromethylsulfonyl)analine (3.28 
g, 9.17 mmol) were added to a stirred solution of 5-hydroxy-2-methylpyridine (1.00 
g, 9.17 mmol) in DMF (20 mL). The reaction mixture was stirred at 25 °C for 2 h 
before being added to H2O (50 mL) and extracted into Et2O (1 x 100 mL). The 
organic layer was washed (brine), dried (Na2SO4), filtered and concentrated in 
vacuo to yield a crude pale yellow oil. Purification by flash column chromatography 
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(0-10% Et2O/CH2Cl2) yielded 6-methylpyridin-3-yl trifluoromethanesulfonate (26) 
(1.87 g, 7.71 mmol, 85%) as a colourless oil; Rf. 0.66 (10% Et2O/CH2Cl2); 1H NMR 
(600 MHz, CDCl3)  8.46 (1H, d, J = 2.6, CHN), 7.51 (1H, dd, J = 8.6, 2.6, 
CHCOTf), 7.26 (1H, d, J = 8.6, CHCMe), 2.60 (3H, s, CH3); 13C NMR (150 MHz, 
CDCl3)  159.1 (COTf), 145.1 (CMe), 142.0 (CHN), 129.3 (CHCOTf), 124.4 
(CHCMe), 118.8 (q, J = 319.5, CF3), 24.1 (CH3); IR (thin film) 1595 (ArC-C), 1481 
(ArC-C), 1425 (ArC-C), 1250 (ArC-N), 1207 (C-O), 1158 (C-O), 1137 (C-F), 1020 
(S=O), 879 (S-O), 833, 708 cm-1; m/z (ES+) 241 (100%, [M+H]+); HRMS (EI) calcd 
for C7H7NO3SF3 [M+H]+ 242.00987, observed 242.00960. Data agrees with that 
reported by Clasby et al..87  
 
2-Methyl-5-(3-(trifluoromethyl)phenyl)pyridine87 (27) 
 
Tetrakis(triphenylphosphine)palladium(0) (445 mg, 0.39 mmol) and 3-
trifluoromethylphenyl boronic acid (1.85 g, 9.74 mmol) were added to a stirred, 
degassed solution of 6-methylpyridin-3-yl trifluoromethanesulfonate (26) (1.86 g, 
7.70 mmol), aq. K2CO3 (2 M, 22 mL) and DME (30 mL) under Ar. The reaction 
mixture was stirred at 100 °C for 1 h before the DME was removed in vacuo. The 
residue was diluted with EtOAc, washed (brine), dried (Na2SO4), filtered and 
concentrated in vacuo to yield crude product. Purification by flash column 
chromatography (0-20% EtOAc/Pet. Ether) yielded 2-methyl-5-(3-
(trifluoromethyl)phenyl)pyridine (27) (1.58 g, 6.66 mmol, 86%) as a colourless, 
crystalline solid; Rf. 0.28 (40% EtOAc/Pet. Ether); 1H NMR (600 MHz, CDCl3)  
8.73 (1H, d, J = 2.3, CHN), 7.79 (1H, s, CHCCF3), 7.78 (1H, dd, J = 8.3, 2.3, 
CHCCHN), 7.74 (1H, d, J = 7.9, CHCCHCCF3), 7.64 (1H, d, J = 7.9, CHCCF3), 
7.59 (1H, t, J = 7.9, CHCHCCF3), 7.27 (1H, d, J = 7.9, CHCMe), 2.62 (3H, s, CH3); 
13C NMR (150 MHz, CDCl3)  158.2 (CMe), 147.5 (CHN), 138.9 (CCHCCF3), 135.0 
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(CHCCHN), 132.6 (CCHN), 131.6 (q, J = 32.2, CCF3), 130.4 (CHCCHCCF3), 129.7 
(CHCHCCF3), 124.6 (q, J = 3.6, CHCHCCF3), 123.9 (q, J = 3.6, CCHCCF3), 123.5 
(CHCMe), 124.2 (d, J = 271.8, CF3), 24.3 (CH3); IR (thin film) 2928 (C-H), 1602 
(ArC-C), 1582 (ArC-C), 1438 (ArC-C), 1335 (ArC-N), 1267 (ArC-N), 1166 (C-H), 
1125 (C-F), 1075, 801, 715, 700 cm-1; m/z (ES+) 238 (100%, [M+H]+); HRMS 
(ES+) calcd for C13H11NF3 [M+H]+ 238.0831, observed 238.0844. Data agrees with 
that reported by Clasby et al..87  
 
Diethyl (5-(3-(trifluoromethyl)phenyl)pyridin-2-yl)methylphosphonate87 
(28) 
 
t-BuLi (1.6 M in pentane) (10.4 mL, 16.7 mmol) was added dropwise to a stirred 
solution of 2-methyl-5-(3-(trifluoromethyl)phenyl)pyridine (27) (1.58 g, 6.66 mmol) 
and diisopropylamine (DIPA) (1.00 mL, 7.33 mmol) in anhydrous THF (30 mL) at -
78 °C, under Ar. The reaction mixture was stirred for 15 min at -78 °C before 
diethyl chlorophosphate (1.00 mL, 6.70 mmol) was added dropwise. The reaction 
mixture was stirred for a further 45 min and then quenched with sat. aq. NH4Cl (20 
mL). An extraction into EtOAc (2 x 40 mL) was done and the combined organic 
layers were dried (MgSO4), filtered and concentrated in vacuo to yield a crude 
brown oil. Purification by flash column chromatography (0-100% EtOAc/CH2Cl2) 
yielded diethyl (5-(3-(trifluoromethyl)phenyl)pyridin-2-yl)methylphosphonate (28) 
(1.88 g, 5.04 mmol, 75%) as an orange oil; Rf. 0.07 (50% EtOAc/CH2Cl2); 1H NMR 
(600 MHz, CDCl3)  8.75 (1H, d, J = 2.3, CHN), 7.85 (1H, dd, J = 8.2, 2.3, 
CHCCHN), 7.79 (1H, s, CCHCCF3), 7.74 (1H, d, J = 7.9, CHCCHCCF3), 7.64 (1H, 
d, J = 7.5, CHCHCCF3), 7.59 (1H, t, J = 7.5, CHCHCCF3), 7.48 (1H, dd, J = 8.2, 
2.3, CHCN), 4.11 (2H, q, J = 6.8, OCH2CH3), 4.10 (2H, q, J = 6.8, OCH2CH3), 3.46 
117 
 
(1H, d, J = 22.2, CH2P), 1.29 (6H, t, J = 6.8, 2 x OCH2CH3); 13C NMR (150 MHz, 
CDCl3)  152.5 (d, J = 8.3, CN), 147.9 (d, J = 2.4, CHN), 138.5 (d, J = 1.2, 
CCHCCF3), 135.2 (d, J = 3, CHCCHN), 133.7 (d, J = 3.6, CCHN), 131.6 (q, J = 
31.6, CCF3), 130.5 (CHCCHCCF3), 129.7 (CHCHCCF3), 124.9 (q, J = 3.6, 
CHCHCCF3), 124.5 (d, J = 4.8, CHCN), 123.9 (d, J = 4.2, CCHCCF3), 124.1 (d, J = 
272.4, CF3), 62.5 (d, J = 6.6, 2 x OCH2CH3), 36.4 (d, J = 135.3, CH2P), 16.5 (d, J = 
6.0, 2 x OCH2CH3); IR (thin film) 2984 (C-H), 2910 (C-H), 1598 (ArC-C), 1561 
(ArC-C), 1480 (ArC-C), 1440 (ArC-C), 1335 (C-N), 1261 (C-N), 1165 (P=O), 1123 
(C-F), 1025, 963 (P-O) cm-1; m/z (ES+) 374 (98%, [M+H]+); HRMS (ES+) calcd for 
C17H20NO3F3P [M+H]+ 374.1133, observed 374.1130. Data agrees with that 
reported by Clasby et al..87  
 
2-(2-Cyclohexylvinyl)-5-(3-(trifluoromethyl)phenyl)pyridine (29) 
 
t-BuLi (1.6 M in pentane) (175 µL, 0.28 mmol) was added dropwise to a stirred 
solution of diethyl (5-(3-(trifluoromethyl)phenyl)pyridin-2-yl)methylphosphonate (28) 
(100 mg, 0.27 mmol) in anhydrous THF (2 mL) at 0 °C, under Ar. The reaction 
mixture was stirred for 10 min at 0 °C before cyclohexanecarboxaldehyde (32.7 µL, 
0.27 mmol) in anhydrous THF (2 mL) was added. The reaction mixture was stirred 
for a further 3 h at 0 °C and then quenched with sat. aq. NH4Cl (5 mL). An 
extraction into EtOAc (2 x 10 mL) was completed and the combined organic layers 
were dried (MgSO4), filtered and concentrated in vacuo to yield a crude orange oil. 
Purification by flash column chromatography (0-10% Et2O/Pet. Ether) yielded (E)-
2-(2-cyclohexylvinyl)-5-(3-(trifluoromethyl)phenyl)pyridine (29) (79.4 mg, 0.24 
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mmol, 89%) as a white solid  and (Z)-2-(2-cyclohexylvinyl)-5-(3-
(trifluoromethyl)phenyl)pyridine (30) (3.7 mg, 0.01 mmol, 4%) as a pale yellow 
solid.  
 
Data for (E)-2-(2-cyclohexylvinyl)-5-(3-(trifluoromethyl)phenyl)pyridine (29): Rf. 
0.44 (30% Et2O/Pet. Ether); 1H NMR (600 MHz, CDCl3)  8.76 (1H, d, J = 1.9, 
CHN), 7.81 (1H, dd, J = 8.3, 2.3, CHCCHN), 7.80 (1H, s, CCHCCF3), 7.75 (1H, d, J 
= 7.5, CHCCHCCF3), 7.65-7.62 (1H, m, CHCHCCF3), 7.60-7.57 (1H, m, 
CHCHCCF3), 7.35 (1H, d, J = 8.3, CHCN), 6.77 (1H, dd, J = 15.8, 7.2, CHCH=CH), 
6.50 (1H, d, J = 15.8, CH=CHC), 2.22 (1H, dtd, J = 10.7, 7.2, 3.6, CHCH=CH), 
1.86 (2H, d, J = 11.7, 2 x CHCHeH), 1.79 (2H, td, J = 12.9, 3.3, 2 x CH2CHeH), 1.69 
(1H, td, J = 12.8, 3.4, CHeH), 1.34 (2H, tq, J = 12.4, 3.4, 2 x CHCHaH), 1.23 (2H, 
dq, J = 12.4, 3.0, 2 x CH2CHaH), 1.2 -1.17 (1H, m, CHaH); 13C NMR (150 MHz, 
CDCl3)  156.1 (CN), 147.9 (CHN), 142.4 (CHCH=CH), 138.8 (CCHCCF3), 134.9 
(CHCCHN), 133.0 (CCHN), 131.6 (q, J = 31.6, CCF3), 130.2 (CHCCHCCF3), 129.7 
(CHCHCCF3), 127.0 (CH=CHC), 124.6 (q, J = 3.0, CHCHCCF3), 123.7 (q, J = 3.0, 
CCHCCF3), 124.1 (d, J = 273.6, CF3), 121.2 (CHCN), 41.2 (CHCH=CH), 32.7 (2 x 
CHCH2), 26.2 (CH2), 26.1 (2 x CH2CH2); IR (thin film) 3007 (C-H), 2925 (C-H), 
2852 (C-H), 1650 (C=C), 1592 (ArC-C), 1555 (ArC-C), 1477 (ArC-C), 1442 (ArC-
C), 1334 (ArC-N), 1265 (ArC-N), 1165 (C-F), 1124, 1097, 1075, 1048, 970, 799, 
699 cm-1; m/z (ES+) 332 (100%, [M+H]+); HRMS (ES+) calcd for C20H21NF3 [M+H]+ 
332.1626, observed 332.1621. 
 
Data for (Z)-2-(2-cyclohexylvinyl)-5-(3-(trifluoromethyl)phenyl)pyridine (30): 
 
Rf. 0.53 (30% Et2O/Pet. Ether); 1H NMR (600 MHz, CDCl3)  8.85 (1H, d, J = 1.9, 
CHN), 7.85 (1H, dd, J = 8.3, 2.3, CHCCHN), 7.84 (1H, s, CCHCCF3), 7.78 (1H, d, J 
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= 7.9, CHCCHCCF3), 7.65 (1H, d, J = 7.5, CHCHCCF3), 7.60 (1H, t, J = 7.9, 
CHCHCCF3), 7.32 (1H, d, J = 8.3, CHCN), 6.40 (1H, d, J = 12.0, CH=CHC), 5.76 
(1H, dd, J = 11.7, 10.2, CHCH=CH), 3.11 (1H, bq, J = 10.9, CHCH=CH), 1.80 (2H, 
bd, J = 12.0, 2 x CHCHeH), 1.75 (2H, td, J = 13.2, 3.2, 2 x CH2CHeH), 1.69 (1H, bd, 
J = 12.8, CHeH), 1.34 (2H, tq, J = 12.8, 3.4, 2 x CH2CHaH), 1.24-1.14 (3H, m, 2 x 
CHCHaH, CHaH); 13C NMR (150 MHz, CDCl3)  156.6 (CN), 147.8 (CHN), 143.9 
(CHCH=CH), 138.8 (CCHCCF3), 134.5 (CHCCHN), 132.5 (CCHN), 131.7 (q, J = 
32.2, CCF3), 130.3 (CHCCHCCF3), 129.7 (CHCHCCF3), 126.1 (CH=CHC), 124.7 
(q, J = 3.6, CHCHCCF3), 123.8 (q, J = 3.6, CCHCCF3), 123.7 (CHCN), 124.1 (d, J 
= 272.4, CF3), 37.2 (CHCH=CH), 33.0 (2 x CHCH2), 26.2 (CH2), 25.8 (2 x 
CH2CH2); IR (thin film) 2924 (C-H), 2852 (C-H), 1644 (C=C), 1593 (ArC-C), 1479 
(ArC-C), 1444 (ArC-C), 1336 (ArC-N), 1267 (ArC-N), 1167 (C-F), 1128, 1098, 
1076, 1047, 803, 700 cm-1; m/z (ES+) 332 (100%, [M+H]+); HRMS (ES+) calcd for 
C20H21NF3 [M+H]+ 332.1626, observed 332.1621. 
 
(E)-2-(4-Methoxystyryl)-5-(3-(trifluoromethyl)phenyl)pyridine (31) 
 
t-BuLi (1.6 M in pentane) (175 µL, 0.28 mmol) was added dropwise to a stirred 
solution of diethyl (5-(3-(trifluoromethyl)phenyl)pyridin-2-yl)methylphosphonate (28) 
(100 mg, 0.27 mmol) in anhydrous THF (2 mL) at 0 °C, under Ar. The reaction 
mixture was stirred for 10 min at 0 °C before 4-methoxybenzaldehyde (32.8 µL, 
0.27 mmol) in anhydrous THF (2 mL) was added. The reaction mixture was stirred 
for a further 3 h at 0 °C and then quenched with sat. aq. NH4Cl (5 mL). An 
extraction into EtOAc (2 x 10 mL) was completed and the combined organic layers 
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were dried (MgSO4), filtered and concentrated in vacuo to yield a crude orange oil. 
Purification by flash column chromatography (0-20% Et2O/Pet. Ether) yielded ((E)-
2-(4-methoxystyryl)-5-(3-(trifluoromethyl)phenyl)pyridine (31) as a white solid (52 
mg, 0.15 mmol, 54%); Rf. 0.31 (30% Et2O/Pet. Ether); 1H NMR (600 MHz, CDCl3) 
 8.83 (1H, d, J = 1.9, CHN), 7.87 (1H, dd, J = 8.1, 2.1, CHCCHN), 7.84 (1H, s, 
CCHCCF3), 7.79 (1H, d, J = 7.5, CHCCHCCF3), 7.64-7.68 (2H, m, CH=CH & 
CHCCF3), 7.61 (1H, t, J = 7.5, CHCHCCF3), 7.56 (2H, d, J = 8.7, 2 x 
CHCHCOMe), 7.47 (1H, d, J = 8.3, CHCN), 7.11 (1H, d, J = 16.2, CH=CH), 6.93 
(2H, d, J = 8.7, 2 x CHCHCOMe), 3.85 (3H, s, OCH3); 13C NMR (150 MHz, CDCl3) 
 160.2 (COMe), 155.7 (CN), 148.0 (CHN), 138.7 (CCHCCF3), 135.1 (CHCCHN), 
133.2 (CHCH=CH), 133.1 (CCHN), 131.7 (q, J = 32.8, CCF3), 130.2 
(CHCCHCCF3), 129.7 (CHCHCCF3), 129.4 (CCH=CH), 128.7 (2 x CHCCH=CH), 
125.0 (CH=CHC), 124.7 (q, J = 3.8, CHCHCCF3), 123.7 (q, J = 3.6, CCHCCF3), 
121.9 (CHCN), 122.3 (d, J = 273.0, CF3), 114.4 (2 x CHCOMe), 55.5 (OCH3); m/z 
(CI) 356 (100%, [M+H]+); HRMS (CI) calcd for C21H16F3NO [M+H]+ 356.12568, 
observed 356.124318. 
 
In the presence of light 31 dimerised to form 6,6'-(3,4-bis(4-
methoxyphenyl)cyclobutane-1,2-diyl)bis(3-(3-(trifluoromethyl)phenyl)pyridine) (32). 
Data for 32: 
 
Rf. 0.14 (30% Et2O/Pet. Ether); 1H NMR (600 MHz, CDCl3)  8.74 (2H, d, J = 1.9, 2 
x CHN), 7.74 (2H, s, 2 x CHCCHN), 7.69 (2H, d, J = 7.5, 2 x CHCCHCCF3), 7.63 
(2H, dd, J = 8.3, 2.3, 2 x CHCCHN), 7.60 (2H, d, J = 7.9, 2 x CHCCF3), 7.55 (2H, t, 
J = 7.5, 2 x CHCHCCF3), 7.14 (4H, d, J = 8.7, 4 x CHCHCOMe), 7.09 (2H, d, J = 
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7.9, 2 x CHCN), 6.68 (4H, d, J = 8.7, 4 x CHCHCOMe), 4.88 (2H, dd, J = 10.0, 7.3, 
2 x cyclobutane-CH), 4.72 (2H, dd, J = 10.0, 7.3, 2 x cyclobutane-CH), 3.69 (6H, s, 
6 x OCH3); 13C NMR (150 MHz, CDCl3)  160.2 (2 x CN), 157.9 (2 x COMe), 147.3 
(2 x CHN), 138.8 (2 x CCHCCF3), 134.3 (2 x CHCCHN), 132.5 (2 x CCHN), 132.4 
(2 x CCHCHCOMe), 131.5 (q, J = 32.8, 2 x CCF3), 130.3 (2 x CHCCHCCF3), 129.6 
(2 x CHCHCCF3), 129.2 (4 x CHCHCOMe), 124.6 (q, J = 3.6, 2 x CHCHCCF3), 
123.8 (q, J = 3.8, 2 x CCHCCF3), 123.7 (2 x CHCN), 124.1 (d, J = 272.4, 2 x CF3), 
113.5 (4 x CHCOMe), 55.2 (2 x OCH3), 49.1 (2 x cyclobutane-CH), 45.2 (2 x 
cyclobutane-CH); m/z (ES-) 709 (100%, [M+H]+); HRMS (ES-) calcd for 
C42H31F6N2O2 [M-H]+ 709.2290, observed 709.2286. 
 
(E)-2-(3-Methoxystyryl)-5-(3-(trifluoromethyl)phenyl)pyridine (33) 
 
t-BuLi (1.6 M in pentane) (200 µL, 0.32 mmol) was added dropwise to a stirred 
solution of diethyl (5-(3-(trifluoromethyl)phenyl)pyridin-2-yl)methylphosphonate (28) 
(109 mg, 0.29 mmol) in anhydrous THF (1.3 mL) at 0 °C, under Ar. The reaction 
mixture was stirred for 10 min at 0 °C before 3-methoxybenzaldehyde (35.5 µL, 
0.29 mmol) was added. The reaction mixture was stirred for a further 1 h at 0 °C 
and then quenched with sat. aq. NH4Cl (5 mL). An extraction into EtOAc (2 x 10 
mL) was completed and the combined organic layers were dried (MgSO4), filtered 
and concentrated in vacuo to yield a crude orange oil. Purification by flash column 
chromatography (0-20% Et2O/Pet. Ether) yielded ((E)-2-(3-methoxystyryl)-5-(3-
(trifluoromethyl)phenyl)pyridine (33) (95.1 mg, 0.27 mmol, 92%) as a waxy solid; 
1H NMR (600 MHz, CDCl3)  8.85 (1H, d, J = 2.3, CHN), 7.89 (1H, dd, J = 8.1, 2.3, 
122 
 
CHCCHN), 7.84 (1H, s, CCHCCF3), 7.79 (1H, d, J = 7.5, CHCCHCCF3), 7.66 (1H, 
d, J = 7.9, CHCCF3), 7.66 (1H, d, J = 15.8, CH=CH) 7.62 (1H, t, J = 7.5, 
CHCHCCF3), 7.51 (1H, d, J = 8.3, CHCN), 7.31 (1H, t, J = 7.9, CHCHCOMe), 7.23 
(1H, d, J = 15.8, CH=CH), 7.21 (1H, d, J = 7.5, CHCCHCOMe), 7.15 (1H, s, 
CCHCOMe), 6.88 (1H, dd, J = 7.9, 2.3, CHCHCOMe), 3.86 (3H, s, OCH3); 13C 
NMR (150 MHz, CDCl3)  160.0 (COMe), 155.2 (CN), 148.1 (CHN), 138.6 
(CCHCCF3), 138.0 (CCH=CH), 135.1 (CHCCHN), 133.6 (CCHN), 133.5 (CH=CH), 
131.7 (q, J = 32.2, CCF3), 130.3 (CHCCHCCF3), 129.9 (CHCHCOMe), 129.8 
(CHCHCCF3), 127.6 (CH=CH), 124.8 (q, J = 3.6, CHCHCCF3), 123.8 (q, J = 4.2, 
CCHCCF3), 124.1 (d, J = 273.0, CF3), 122.2 (CHCN), 120.1 (CHCCHCOMe), 
114.6 (CHCHCOMe), 112.3 (CCHCOMe), 55.4 (OCH3); m/z (ES+) 356 (100%, 
[M+H]+); HRMS (ES+) calcd for C21H16F3NO [M+H]+ 356.1262, observed 356.1272. 
 
(E)-2-(3,5-Dimethoxystyryl)-5-(3-(trifluoromethyl)phenyl)pyridine (34) 
 
t-BuLi (1.6 M in pentane) (200 µL, 0.32 mmol) was added dropwise to a stirred 
solution of diethyl (5-(3-(trifluoromethyl)phenyl)pyridin-2-yl)methylphosphonate (28) 
(109 mg, 0.29 mmol) in anhydrous THF (1.3 mL) at 0 °C, under Ar. The reaction 
mixture was stirred for 10 min at 0 °C before 3,5-dimethoxybenzaldehyde (48.5 µL, 
0.29 mmol) in anhydrous THF (2 mL) was added. The reaction mixture was stirred 
for a further 1 h at 0 °C and then quenched with sat. aq. NH4Cl (5 mL). An 
extraction into EtOAc (2 x 10 mL) was completed and the combined organic layers 
were dried (MgSO4), filtered and concentrated in vacuo to yield a crude orange oil. 
Purification by flash column chromatography (0-10% EtOAc/Pet. Ether) yielded 
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((E)-2-(3,5-dimethoxystyryl)-5-(3-(trifluoromethyl)phenyl)pyridine (34) (92.0 mg, 
0.24 mmol, 82%) as a fluorescent yellow solid; 1H NMR (600 MHz, CDCl3)  8.85 
(1H, d, J = 1.9, CHN), 7.90 (1H, dd, J = 8.1, 1.9, CHCCHN), 7.84 (1H, s, 
CCHCCF3), 7.79 (1H, d, J = 7.5, CHCCHCCF3), 7.67 (1H, d, J = 7.9, CHCCF3), 
7.60-7.64 (2H, m, CH=CH & CHCHCCF3), 7.52 (1H, d, J = 8.3, CHCN), 7.22 (1H, 
d, J = 16.2, CH=CH), 6.77 (2H, d, J = 1.9, 2 x CHCOMe), 6.45 (1H, d, J = 1.9, 
CHCOMe), 3.85 (6H, s, 2 x OCH3); 13C NMR (150 MHz, CDCl3)  161.1 (2 x 
COMe), 155.1 (CN), 148.0 (CHN), 138.5 (CCHCOMe), 135.2 (CHCCHN), 133.7 
(CCHCCF3 & CH=CH), 131.7 (q, J = 31.6, CCF3), 130.3 (CHCCHCCF3 & CCHN), 
129.8 (CHCHCCF3), 127.7 (CH=CH), 124.9 (q, J = 3.6, CHCHCCF3), 123.8 (q, J = 
3.6, CCHCCF3), 124.1 (d, J = 273.0, CF3), 122.2 (CHCN), 105.3 (2 x CHCOMe), 
101.1 (CHCOMe), 55.5 (2 x OCH3); m/z (ES+) 386 (100%, [M+H]+); HRMS (CI) 
calcd for C22H18F3NO2 [M+H]+ 386.13624, observed 386.13763. 
 
(E)-Methyl 3-(2-(5-(3-(trifluoromethyl)phenyl)pyridin-2-yl)vinyl)benzoate 
(35) 
 
t-BuLi (1.6 M in pentane) (580 µL, 0.924 mmol) was added dropwise to a stirred 
solution of diethyl (5-(3-(trifluoromethyl)phenyl)pyridin-2-yl)methylphosphonate (28) 
(312.8 mg, 0.84 mmol) in anhydrous THF (1.3 mL) at 0 °C, under Ar. The reaction 
mixture was stirred for 10 min at 0 °C before methyl 3-formylbenzoate (137.9 mg, 
0.84 mmol) was added. The reaction mixture was stirred for a further 1 h at 0 °C 
and then quenched with sat. aq. NH4Cl (5 mL). An extraction into EtOAc (2 x 10 
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mL) was completed and the combined organic layers were dried (MgSO4), filtered 
and concentrated in vacuo to yield a crude orange oil. Purification by flash column 
chromatography (0-20% EtOAc/Pet. Ether) yielded (E)-methyl 3-(2-(5-(3-
(trifluoromethyl)phenyl)pyridin-2-yl)vinyl)benzoate (35) (272 mg, 0.71 mmol, 84%) 
as a pale yellow solid; 1H NMR (600 MHz, CDCl3)  8.86 (1H, d, J = 2.3, CHN), 
8.31 (1H, s, CCHCCOOMe), 7.98 (1H, d, J = 7.5,  CHCHCCOOMe), 7.91 (1H, dd, 
J = 7.9, 2.3, CHCCHN), 7.85 (1H, s, CCHCCF3), 7.80 (1H, d, J = 7.9, 
CHCCHCCF3), 7.77 (1H, d, J = 7.5,  CHCCHCCOOMe), 7.74 (1H, d, J = 15.8, 
CH=CH), 7.67 (1H, d, J = 7.9, CHCCF3), 7.62 (1H, t, J = 7.5, CHCHCCF3), 7.51 
(1H, d, J = 8.3, CHCN), 7.47 (1H, app. t, J = 7.9,  CHCHCCOOMe), 7.31 (1H, d, J 
= 15.8, CH=CH), 3.96 (3H, s, OCH3); 13C NMR (150 MHz, CDCl3)  167.0 (C=O), 
154.9 (CN), 148.2 (CHN), 138.5 (CCHCCF3), 137.0 (CCHCCOOMe), 135.2 
(CHCCHN), 133.8 (CCHN), 132.4 (CH=CH), 131.8 (CHCCHCCOOMe), 131.7 (q, J 
= 32.8, CCF3), 130.8 (CCOOMe) 130.3 (CHCCHCCF3), 129.8 (CHCHCCF3), 129.5 
(CHCHCCOOMe), 129.0 (CHCHCCOOMe), 128.5 (CH=CH), 128.1 
(CCHCCOOMe), 124.9 (q, J = 3.6, CHCHCCF3), 123.8 (q, J = 3.6, CCHCCF3), 
124.1 (d, J = 272.4, CF3), 122.5 (CHCN), 52.4 (OCH3); m/z (ES+) 384 (100%, 
[M+H]+); HRMS (CI) calcd for C22H16F3NO2 [M+H]+ 384.12059, observed 
384.121101. 
 
(E)-3-(2-(5-(3-(Trifluoromethyl)phenyl)pyridin-2-yl)vinyl)benzoic acid 
(36) 
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A solution of (E)-methyl 3-(2-(5-(3-(trifluoromethyl)phenyl)pyridin-2-
yl)vinyl)benzoate (35) (83.0 mg, 0.22 mmol) in EtOH (0.5 mL) and aq. NaOH (1M, 
1 mL) was refluxed at 80 °C for 40 min. Once cool the solution was acidified with 
conc. HCl, cooled to 0 °C and the precipitate was filtered and dried under vacuum 
to yield (E)-3-(2-(5-(3-(trifluoromethyl)phenyl)pyridin-2-yl)vinyl)benzoic acid (36) 
(33.2 mg, 0.09 mmol, 41%) as a white solid; 1H NMR (600 MHz, MeOH-d4)  9.10 
(1H, d, J = 1.9, CHN), 8.85 (1H, dd, J = 8.7, 2.3, CHCCHN), 8.48 (1H, d, J = 8.7, 
CHCN), 8.37 (1H, s, CCHCCOOH), 8.17 (1H, s, CCHCCF3), 8.12 (1H, d, J = 7.9, 
CHCCHCCF3), 8.06-8.10 (2H, m, CHCHCCOOH & CH=CH), 8.00 (1H, d, J = 8.3,  
CHCCHCCOOH), 7.86 (1H, d, J = 7.9, CHCCF3), 7.81 (1H, t, J = 7.9, CHCHCCF3), 
7.61 (1H, t, J = 7.7, CHCHCCOOH), 7.51 (1H, d, J = 16.6, CH=CH), 3.95 (1H, s, 
OH); 13C NMR (150 MHz, MeOH-d4)  169.0 (C=O), 151.0 (CN), 144.8 (CHCCHN), 
141.8 (CH=CH), 140.8 (CHN), 137.7 (CCHN), 136.5 (CCHCCOOH), 136.2 
(CCHCCF3), 133.3 (CHCCHCCOOH), 133.1 (CCOOH), 132.7 (CHCCOOH), 133.0 
(q, J = 32.8, CCF3), 132.2 (CHCCHCCF3), 131.7 (CHCHCCF3), 130.6 
(CHCHCCOOH), 130.4 (CCHCCOOH), 127.6 (q, J = 3.6, CHCHCCF3), 125.6 
(CHCN), 125.1 (q, J = 4.2, CCHCCF3), 125.4 (d, J = 271.2, CF3), 120.2 (CH=CH); 
m/z (ES+) 370 (100%, [M+H]+). 
 
(E)-(3-(2-(5-(3-(Trifluoromethyl)phenyl)pyridin-2-
yl)vinyl)phenyl)methanol (37) 
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LiAlH4 (1.0 M in THF) (220 µL, 0.22 mmol) was added dropwise to a stirred 
solution of (E)-methyl 3-(2-(5-(3-(trifluoromethyl)phenyl)pyridin-2-yl)vinyl)benzoate 
(35) (86.2 mg, 0.22 mmol) in anhydrous THF (1 mL) under Ar. The reaction mixture 
was stirred for 40 min and then quenched with aq. NaOH (1M). An extraction into 
EtOAc (2 x 10 mL) was completed and the combined organic layers were dried 
(MgSO4), filtered and concentrated in vacuo to yield a crude orange oil. Purification 
by flash column chromatography (0-20% EtOAc/CH2Cl2) yielded (E)-(3-(2-(5-(3-
(trifluoromethyl)phenyl)pyridin-2-yl)vinyl)phenyl)methanol (37) (47.3 mg, 0.13 
mmol, 61%) as a waxy pale yellow solid; 1H NMR (600 MHz, CDCl3)  8.85 (1H, d, 
J = 1.9, CHN), 7.90 (1H, dd, J = 8.3, 2.3, CHCCHN), 7.84 (1H, s, CCHCCF3), 7.80 
(1H, d, J = 7.5, CHCCHCCF3), 7.71 (1H, d, J = 16.2, CH=CH), 7.67 (1H, d, J = 7.5, 
CHCCF3), 7.64 (1H, bs, CHCCH2OH), 7.62 (1H, t, J = 7.5, CHCHCCF3), 7.54 (1H, 
d, J = 7.9, CHCCHCCH2OH), 7.50 (1H, d, J = 7.9, CHCN), 7.40 (1H, t, J = 7.5, 
CHCHCCH2OH), 7.33 (1H, d, J = 7.5, CHCCH2OH), 7.26 (1H, d, J = 16.2, 
CH=CH), 4.76 (2H, d, J = 4.9, CH2OH), 1.78 (1H, bt, J = 4.9, OH); 13C NMR (150 
MHz, CDCl3)  155.2 (CN), 148.1 (CHN), 141.5 (CCH2OH) 138.6 (CCHCCF3), 
136.9 (CCHCCH2OH), 135.2 (CHCCHN), 133.6 (CCHN), 133.3 (CH=CH), 131.7 
(q, J = 32.2, CCF3), 130.3 (CHCCHCCF3), 129.8 (CHCHCCF3), 129.2 
(CHCHCCH2OH), 127.6 (CH=CH), 127.3 (CHCCH2OH), 126.8 (CHCCHCCH2OH), 
125.6 (CHCCH2OH), 124.8 (q, J = 3.6, CHCHCCF3), 123.8 (q, J = 3.6, CCHCCF3), 
124.1 (d, J = 273.6, CF3), 122.3 (CHCN), 65.4 (CH2); m/z (ES+) 356 (100%, 
[M+H]+); HRMS (CI) calcd for C21H16F3NO [M+H]+ 356.12568, observed 
356.126750. 
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(E)-Ethyl 2-(2-(5-(3-(trifluoromethyl)phenyl)pyridin-2-
yl)vinyl)cyclopropanecarboxylate (38) 
 
t-BuLi (1.6 M in pentane) (463 µL, 0.74 mmol) was added dropwise to a stirred 
solution of diethyl (5-(3-(trifluoromethyl)phenyl)pyridin-2-yl)methylphosphonate (28) 
(252 mg, 0.68 mmol) in anhydrous THF (2 mL) at 0 °C, under Ar. The reaction 
mixture was stirred for 10 min at 0 °C before ethyl 2-formyl-1-
cyclopropanecarboxylate (89.5 µL, 0.68 mmol) was added. The reaction mixture 
was stirred for a further 1 h at 0 °C and then quenched with sat. aq. NH4Cl (5 mL). 
An extraction into EtOAc (2 x 10 mL) was completed and the combined organic 
layers were dried (MgSO4), filtered and concentrated in vacuo to yield a crude 
orange oil. Purification by flash column chromatography (0-20% EtOAc/Pet. Ether) 
yielded (E)-ethyl 2-(2-(5-(3-(trifluoromethyl)phenyl)pyridin-2-
yl)vinyl)cyclopropanecarboxylate (38) (203 mg, 0.56 mmol, 83%) as a pale yellow 
solid; 1H NMR (600 MHz, CDCl3)  8.75 (1H, d, J = 2.3, CHN), 7.83 (1H, dd, J = 
8.1, 2.4, CHCCHN), 7.80 (1H, s, CCHCCF3), 7.76 (1H, d, J = 7.5, CHCCHCCF3), 
7.65 (1H, d, J = 7.5, CHCHCCF3), 7.60 (1H, t, J = 7.5, CHCHCCF3), 7.27 (1H, d, J 
= 7.9, CHCN), 6.68 (1H, d, J = 15.4, CH=CH), 6.37 (1H, dd, J = 15.4, 9.4, CH=CH), 
4.16 (2H, q, J = 6.9, CH2CH3), 2.25 (1H, dddd, J = 9.4, 9.0, 5.8, 3.8, CHCH=CH), 
1.87 (1H, ddd, J = 8.5, 5.1, 3.8, CHCOOEt), 1.54 (1H, ddd, J = 9.0, 5.1, 4.7, 
cyclopropane-CHH), 1.28 (3H, t, J = 7.2, CH2CH3), 1.19 (1H, ddd, J = 8.6, 5.9, 4.7, 
cyclopropane-CHH); 13C NMR (150 MHz, CDCl3)  173.3 (C=O), 154.8 (CN), 148.0 
(CHN), 138.6 (CCHCCF3), 136.1 (CH=CH), 135.1 (CHCCHN), 133.4 (CCHN), 
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131.6 (q, J = 32.2, CCF3), 130.2 (CHCCHCCF3), 129.7 (CHCHCCF3), 129.3 
(CH=CH), 124.7 (q, J = 3.0, CHCHCCF3), 123.8 (q, J = 3.6, CCHCCF3), 124.1 (d, J 
= 272.4, CF3), 121.5 (CHCN), 60.9 (CH2CH3), 25.6 (CHCH=CH), 22.8 (CHCOOEt), 
16.4 (cyclopropyl-CH2), 14.4 (CH2CH3); m/z (ES+) 362 (100%, [M+H]+); HRMS (CI) 
calcd for C20H18F3NO2 [M+H]+ 362.13624, observed 362.137134. 
 
(E)-(2-(2-(5-(3-(Trifluoromethyl)phenyl)pyridin-2-
yl)vinyl)cyclopropyl)methanol (39) 
 
LiAlH4 (1.0 M in THF) (340 µL, 0.34 mmol) was added dropwise to a stirred 
solution of (E)-ethyl 2-(2-(5-(3-(trifluoromethyl)phenyl)pyridin-2-
yl)vinyl)cyclopropanecarboxylate (38) (123 mg, 0.34 mmol) in anhydrous THF (1 
mL) under Ar. The reaction mixture was stirred for 1 h and then quenched with aq. 
NaOH (1M). An extraction into EtOAc (2 x 10 mL) was completed and the 
combined organic layers were dried (MgSO4), filtered and concentrated in vacuo to 
yield a crude orange oil. Purification by flash column chromatography (0-50% 
EtOAc/Pet. Ether) yielded (E)-(2-(2-(5-(3-(trifluoromethyl)phenyl)pyridin-2-
yl)vinyl)cyclopropyl)methanol (39) (56.2 mg, 0.18 mmol, 52%) as a pale yellow 
solid; 1H NMR (600 MHz, CDCl3)  8.74 (1H, d, J = 2.4, CHN), 7.81 (1H, dd, J = 
8.2, 2.4, CHCCHN), 7.80 (1H, s, CCHCCF3), 7.75 (1H, d, J = 7.7, CHCCHCCF3), 
7.64 (1H, d, J = 7.7, CHCHCCF3), 7.59 (1H, t, J = 7.7, CHCHCCF3), 7.26 (1H, d, J 
= 8.2, CHCN), 6.61 (1H, d, J = 15.4, CH=CH), 6.40 (1H, dd, J = 15.4, 9.4, CH=CH), 
3.55-3.64 (2H, m, CH2OH), 1.61-1.64 (1H, m, CHCH=CH), 1.39-1.45 (2H, m, 
CHCOOH & OH), 0.87-0.93 (2H, m, cyclopropane-CH2); 13C NMR (150 MHz, 
CDCl3)  155.3 (CN), 147.9 (CHN), 139.0 (CH=CH), 138.7 (CCHCCF3), 135.1 
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(CHCCHN), 133.0 (CCHN), 131.6 (q, J = 32.8, CCF3), 130.2 (CHCCHCCF3), 129.7 
(CHCHCCF3), 127.2 (CH=CH), 124.6 (q, J = 3.6, CHCHCCF3), 123.7 (q, J = 3.6, 
CCHCCF3), 124.1 (d, J = 272.4, CF3), 121.1 (CHCN), 66.2 (CH2OH), 24.2 
(CCH2OH), 20.7 (CHCH=CH), 12.8 (cyclopropyl-CH2); m/z (ES+) 320 (100%, 
[M+H]+); HRMS (CI) calcd for C18H16F3NO [M+H]+ 320.12568, observed 
320.126290. 
 
(E)-2-(2-(Pyridin-3-yl)vinyl)-5-(3-(trifluoromethyl)phenyl)pyridine (40) 
 
t-BuLi (1.6 M in pentane) (193 µL, 0.31 mmol) was added dropwise to a stirred 
solution of diethyl (5-(3-(trifluoromethyl)phenyl)pyridin-2-yl)methylphosphonate (28) 
(106 mg, 0.28 mmol) in anhydrous THF (1.3 mL) at 0 °C, under Ar. The reaction 
mixture was stirred for 10 min at 0 °C before nicotinaldehyde (26.6 µL, 0.28 mmol) 
was added. The reaction mixture was stirred for a further 1 h at 0 °C and then 
quenched with sat. aq. NH4Cl (5 mL). An extraction into EtOAc (2 x 10 mL) was 
completed and the combined organic layers were dried (MgSO4), filtered and 
concentrated in vacuo to yield a crude orange oil. Purification by flash column 
chromatography (0-30% EtOAc/Pet. Ether) yielded (E)-2-(2-(pyridin-3-yl)vinyl)-5-(3-
(trifluoromethyl)phenyl)pyridine (40) (75.6 mg, 0.23 mmol, 83%) as a pale yellow 
solid; 1H NMR (600 MHz, CDCl3)  8.87 (1H, d, J = 2.3, CHNC), 8.84 (1H, s, 
CHNCH), 8.55 (1H, d, J = 4.5, CHNCH), 7.97 (1H, d, J = 7.9, CHCHCHN), 7.93 
(1H, dd, J = 8.3, 2.3, CHCCHN), 7.85 (1H, s, CCHCCF3), 7.80 (1H, d, J = 7.5, 
CHCCHCCF3), 7.72 (1H, d, J = 15.8, CH=CH), 7.69 (1H, d, J = 8.3, CHCCF3), 7.63 
(1H, t, J = 8.3, CHCHCCF3), 7.52 (1H, d, J = 8.3, CHCN), 7.38 (1H, dd, J = 7.9, 
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4.9, CHCHN), 7.31 (1H, d, J = 15.8, CH=CH); 13C NMR (150 MHz, CDCl3)  154.3 
(CN), 148.7 (CHCHN), 148.5 (CHNCH), 148.2 (CCHN), 138.4 (CCHCCF3), 135.3 
(CHCCHN), 134.3 (CHCHCHN), 134.2 (CCHNC), 132.7 (CHCH=CH), 131.8 (q, J = 
32.2, CCF3), 130.3 (CHCCHCCF3), 129.8 (CHCHCCF3), 129.5 (CH=CH & 
CH=CH), 125.0 (q, J = 3.6, CHCHCCF3), 124.1 (CHCHN), 123.9 (q, J = 3.8, 
CCHCCF3), 124.1 (d, J = 272.4, CF3), 122.7 (CHCN); m/z (ES+) 327 (100%, 
[M+H]+); HRMS (CI) calcd for C19H13F3N2 [M+H]+ 327.11036, observed 
327.111715. 
 
Methyl 7-hydroxyhept-2-enoate146 (41) 
 
Conc. HCl (37%) (0.34 mL, 11.2 mmol) was added to a stirred solution of 3,4-
dihydro-2H-pyran (22.5 mL, 247 mmol) in H2O (30 mL) at 0 °C. The reaction 
mixture was stirred at 0 °C for 2 h before solid K2CO3 (34.2 g, 247 mmol), methyl 2-
(dimethoxyphosphoryl)acetate (20 mL, 124 mmol) and DMSO (60 mL) were added. 
The reaction mixture was stirred in air at 50 °C for 6 h. Once cool the solution was 
partitioned between t-BME (250 mL) and H2O (100 mL). The organic layer was 
dried (hydrophobic frit) and concentrated in vacuo to yield a crude colourless liquid. 
Purification by automated column chromatography (0-100% EtOAc/cyclohexane) 
yielded methyl 7-hydroxyhept-2-enoate (41) (11.5 g, 72.6 mmol, 59%) as a 
colourless oil, in a 1:5 ratio of Z:E isomers; Rf. 0.46 (45% EtOAc/Pet. Ether); 1H 
NMR (400 MHz, Acetone-d6)  6.95 (1H, dt, J = 15.6, 7.0, E-AcCH=CH), 6.31 
(0.2H, dt, J = 11.5, 7.6, Z-AcCH=CH), 5.85 (1H, dt, J = 15.7, 1.6, E-AcCH=CH), 
5.79 (0.2 H, dt, J = 11.5, 1.6, Z-AcCH=CH), 3.68 (3H, s, E-COOCH3), 3.67 (0.6H, 
s, Z-COOCH3), 3.51-3.60 (3.6H,m, E-CH2OH, Z-CH2OH, E-OH & Z-OH), 2.64-2.71 
(0.4H, m, Z-CH2), 2.23-2.29 (2H, m, E-CH2), 1.53-1.58 ppm (4.8H, m, 2 x E-CH2 & 
2 x Z-CH2); 13C NMR (150 MHz, CDCl3)  167.3 (E-C=O), 167.0 (Z-C=O), 150.6 (Z-
AcCH=CH), 149.3 (E-AcCH=CH), 121.3 (E-AcCH=CH), 119.7 (Z-AcCH=CH), 62.7 
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(E-CH2OH), 62.6 (Z-CH2OH), 51.6 (E-COOCH3), 51.2 (Z-COOCH3), 32.2 (E-
CH=CHCH2), 32.0 (Z-CH2CH2OH), 32.0 (E-CH2CH2OH), 28.6 (Z-CH=CHCH2), 
25.2 (Z-CH2), 24.3 (E-CH2); IR (thin film) 3397 (br) (O-H), 2940 (C-H), 2865 (C-H), 
1722 (C=O), 1656 (C=C), 1438 (C-H), 1274 (C-O), 1202 (C-O), 1035 (C-O), 984 
(=C-H) cm-1; m/z (ES+) 159 (100%, [M+H]+); HRMS (CI) calcd for C8H15O3 [M+H]+ 
159.10212, observed 159.10254. Data agrees with that reported by Nieto et al.146 
and Tufariello et al..147  
 
A single fraction containing pure E-product was concentrated in vacuo to give (E)-
methyl 7-hydroxyhept-2-enoate (41) (340 mg, 2.15 mmol, 2% yield) as a colourless 
oil; 1H NMR (400 MHz, Acetone-d6)  6.95 (1H, dt, J = 15.6, 6.9, AcCH=CH), 5.86 
(1H, dt, J = 15.6, 1.5, AcCH=CH), 3.68 (3H, s, COOCH3), 3.54-3.60 (2H, m, 
CH2OH), 3.48 (1H, t, J = 5.0, OH), 2.23-2.30 (2H, m, CH2), 1.53-1.59 ppm (4H, m, 
2 x CH2); 13C NMR (100 MHz, Acetone-d6)  166.2 (C=O), 149.2 (AcCH=CH), 
120.9 (AcCH=CH), 61.2 (CH2OH), 50.5 (COOCH3), 32.2 (CH=CHCH2), 31.6 
(CH2CH2OH), 24.4 (CH2); IR (thin film) 3390 (br) (O-H), 2938 (C-H), 2865 (C-H), 
1720 (C=O), 1655 (C=C), 1436 (C-H), 1271 (C-O), 1199 (C-O), 1031 (C-O), 982 
(=C-H) cm-1; m/z (ES+) 159 (100%, [M+H]+); HRMS (CI) calcd for C8H15O3 [M+H]+ 
159.1017, observed 159.1016. Data agrees with that reported by Nieto et al..146  
 
(E)-Methyl 7-iodohept-2-enoate148 (42) 
 
Solid I2 (18.3 g, 72.1 mmol) was added to a stirred solution of methyl 7-
hydroxyhept-2-enoate (41) (1:5 Z:E isomers) (11.4 g, 72.1 mmol), PPh3 (22.7 g, 
86.0 mmol) and imidazole (9.81 g, 144 mmol) in 2-MeTHF (200 mL) at 0 °C, under 
N2. The reaction mixture was stirred at 20 °C for 2 h before being filtered under 
vacuum to remove precipitated triphenylphosphine oxide. The filtrate solvents were 
concentrated in vacuo to yield a crude colourless oil with white precipitate. 
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Purification by automated column chromatography (0-25% EtOAc/cyclohexane) 
yielded still crude colourless oil with white precipitate. A second purification by 
automated column chromatography (0-25% EtOAc/cyclohexane) yielded (E)-
methyl 7-iodohept-2-enoate (42) (6.14 g, 22.9 mmol, 32%) as a colourless oil; Rf 
0.38 (20% EtOAc/cyclohexane); 1H NMR (400 MHz, Acetone-d6)  6.94 (1H, dt, J = 
15.6, 7.0, AcCH=CH), 5.88 (1H, dt, J = 15.6, 1.6, AcCH=CH), 3.69 (3H, s, 
COOCH3), 3.32 (2H, t, J = 7.0, CH2I), 2.30 (2H, tdd, J = 7.3, 7.0, 1.6, CH2), 1.87 
(2H, tt, J = 7.7, 7.0, CH2), 1.62 (2H, tt, J = 7.7, 7.3, CH2); 13C NMR (100 MHz, 
Acetone-d6)  166.1 (C=O), 148.5 (AcCH=CH), 121.3 (AcCH=CH), 50.6 
(COOCH3), 32.9 (CH2), 30.6 (CH2), 28.7 (CH2), 6.2 (CH2I); IR (thin film) 2937 (C-
H), 2858 (C-H), 1719 (C=O), 1656 (C=C), 1434 (C-H), 1270 (C-O), 1177 (C-H), 
1038 (C-O), 974, 845, 718 cm-1; m/z (ES+) 269 (100%, [M+H]+); HRMS (CI) calcd 
for C8H14IO2 [M+H]+ 269.0033, observed 269.0038. Data agrees with that reported 
by Zhou et al..148  
 
(1R*,2S*)-Methyl 2-(2-(tert-butoxy)-2-oxoethyl)cyclohexanecarboxylate 
(43) 
 
n-BuLi (1.6 M in hexanes) (70.0 mL, 112 mmol) was added to a stirred solution of 
DIPA (15.7 mL, 112 mmol) in anhydrous THF (30 mL) at -78 °C, under Ar. The 
solution was stirred at -78 °C for 20 mins. A solution of tert-butyl acetate (15.0 mL, 
112 mmol) was added and stirring continued for 30 min at -78 °C. Next, a solution 
of (E)-methyl 7-iodohept-2-enoate (42) (13.7 g, 51 mmol) in anhydrous THF (15 
mL) was added. The reaction mixture was stirred for a further 30 min at -78 °C. 
Finally, solid KOt-Bu (12.6 g, 112 mmol) was added and stirring continued for a 
further 1 h at -78 °C. The reaction mixture was quenched with sat. aq. NH4Cl (100 
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mL) and diluted with H2O (50 mL). An extraction into EtOAc (2 x 100 mL) was 
completed and the combined organic layers were dried (MgSO4), filtered and 
concentrated in vacuo to yield a crude pale yellow liquid. Multiple purifications by 
flash column chromatography (0-2% Et2O/CH2Cl2), (0-10% Et2O/Pet. Ether) and 
(0-2% Et2O/toluene) yielded (1R*,2S*)-methyl 2-(2-(tert-butoxy)-2-
oxoethyl)cyclohexanecarboxylate (43) (3.1 g, 12 mmol, 24%) as a colourless liquid; 
bp. 110-115 °C (at 2.1 mbar); 1H NMR (600 MHz, CDCl3)  3.66 (3H, s, COOCH3), 
2.26 (1H, d, J = 10.9, CHHCOOtBu), 2.12 (1H, dt, J = 11.2, 3.6, C2H), 2.05-1.98 
(2H, m, C1H & CHHCOOtBu), 1.89 (1H, qd, J = 1.9, 13.2, C3HH), 1.84 (1H, dd, J = 
2.1, 13.0, C6HH), 1.74 (1H, dtd, J = 12.8, 3.4, 1.1, C4HH), 1.72-1.68 (1H, m, 
C5HH), 1.47 (1H, td, J = 12.4, 2.6, C3HH), 1.43 (9H, s, C(CH3)3), 1.30 (1H, tq, J = 
12.8, 3.4, C5 HH), 1.21 (1H, tq, J = 13.2, 3.8, C4HH), 1.04 (1H, dq, J = 13.2, 3.4, 
C6HH); 13C NMR (150 MHz, CDCl3)  176.1 (C=OCOMe), 171.8 (C=OCOtBu), 80.4 
(C(CH3)3), 51.7 (CH3), 49.0 (C2H), 40.9 (CH2COOtBu), 36.3 (C1H), 31.3 (C6H), 30.0 
(C3H), 28.2 (C(CH3)3), 25.5 (C5H), 25.4 (C4H); IR (thin film) 2982 (C-H), 2930 (C-
H), 2854 (C-H), 1713 (C=O), 1451 (C-H), 1366 (C-O), 1247 (C-O), 1151, 1108, 
1025, 845 cm-1; m/z (ES+) 257 (100%, [M+H]+); HRMS (CI) calcd for C13H11O3 [M-
OMe]+ 225.14907, observed 225.14872. 
 
rac-tert-Butyl 1,9-dioxododecahydronaphtho[2,3-c]furan-4-carboxylate 
(44) 
 
t-BuLi (2.5 M in hexane) (3.43 ml, 8.58 mmol) was added dropwise to a stirred 
solution of distilled TMP (1.46 ml, 8.58 mmol) in anhydrous THF (10 mL) at -78 °C, 
under Ar. The solution was warmed to 0 °C and then re-cooled to -78 °C. A 
solution of (1R*,2S*)-methyl 2-(2-(tert-butoxy)-2-oxoethyl)cyclohexanecarboxylate 
(43) (1.00 g, 3.90 mmol) in anhydrous THF (10 mL) was added, via cannular, and 
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stirring continued for 45 min at -78 °C. Next, a solution of 2(5H)-furanone (0.41 mL, 
0.59 mmol) in anhydrous THF (5 mL) was added, via cannular, and stirring 
continued for 1 h at -78 °C. Finally, solid KOt-Bu (962 mg, 8.58 mmol) was added. 
The reaction mixture was warmed to -40 °C, stirred for a further 3 h and then 
quenched with sat. aq. NH4Cl (20 mL). An extraction into EtOAc (2 x 40 mL) was 
completed and the combined organic layers were dried (MgSO4), filtered and 
concentrated in vacuo to yield a crude yellow oily solid. Multiple purification by 
flash column chromatography yielded (3aS*,4R*,4aS*,8aS*,9aS*)-tert-butyl 1,9-
dioxododecahydronaphtho[2,3-c]furan-4-carboxylate (45) (40 mg, 0.13 mmol, 3%), 
(1R*,2R*)-methyl 2-((R*)-2-tert-butoxy-2-oxo-1-((R*)-5-oxotetrahydrofuran-3-
yl)ethyl)cyclohexanecarboxylate (46) (38 mg, 0.11 mmol, 3%), 
(3aS*,4R*,4aR*,8aR*,9aS*)-tert-butyl 1,9-dioxododecahydronaphtho[2,3-c]furan-4-
carboxylate (47) (240 mg, 0.78 mmol, 20%), a mixture of two undetermined 
stereoisomers in a ratio of 1:0.9 of rac-methyl 2-(2-tert-butoxy-1-(2,5'-
dioxooctahydro-3,3'-bifuran-4-yl)-2-oxoethyl)cyclohexanecarboxylate (48) (50 mg, 
0.12 mmol, 4%) and a 1:0.9 mixture of (3aS*,4S*,4aR*,8aR*,9aR*)-tert-butyl 1,9-
dioxo-9a-((R*)-5-oxotetrahydrofuran-3-yl)dodecahydronaphtho[2,3-c]furan-4-
carboxylate and (3aS*,4S*,4aR*,8aR*,9aS*)-tert-butyl 1,9-dioxo-9a-((S*)-5-
oxotetrahydrofuran-3-yl)dodecahydronaphtho[2,3-c]furan-4-carboxylate (49) (24 
mg, 0.06 mmol, 2%) as white solids. 
 
Data for (3aS*,4R*,4aS*,8aS*,9aS*)-tert-butyl 1,9-dioxododecahydronaphtho[2,3-
c]furan-4-carboxylate (45): 
 
1H NMR (600 MHz, CDCl3)  4.22 (1H, d, J = 3.8, C3HH), 4.21 (1H, s, C3HH),  3.49 
(1H, d, J = 7.5, C9aH), 3.15 (1H, ddd, J = 11.5, 7.5, 3.8, C3aH), 2.41 (1H, t, J = 11.5, 
C4H), 2.14-2.10 (1H, m, C8HH), 2.01-1.96 (1H, m, C8aH), 1.82-1.66 (4H, m, C4aH, 
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C5HH, C6HH & C7HH), 1.48 (9H, s, C(CH3)3), 1.46-1.41 (1H, m, C8HH), 1.25-1.12 
(3H, m, C5HH, C6HH & C7HH); 13C NMR (150 MHz, CDCl3)  201.9 (C9=O), 172.4 
(C=OOtBu), 171.5 (C1=O), 82.5 (C(CH3)3), 70.5 (C3H2), 53.3 (C9aH), 51.3 (C8aH), 
51.0 (C4H), 42.8 (C4aH), 42.8 (C3aH), 31.5 (C8H2), 28.2 (C(CH3)3), 25.1 (C5H2), 25.0 
(C6H2), 24.8 (C7H2); IR (thin film) 2974 (C-H), 2929 (C-H), 2856 (C-H), 1795 (C=O), 
1715 (C=O), 1367 (C-H), 1244 (C-O), 1157, 1021, 845 cm-1; m/z (ES+) 326 (100%, 
[M+NH4]+); HRMS (EI) calcd for C17H24O5 [M+H]+ 308.1618, observed 308.1613. 
 
Data for (1R*,2R*)-methyl 2-((R*)-2-tert-butoxy-2-oxo-1-((R*)-5-oxotetrahydrofuran-
3-yl)ethyl)cyclohexanecarboxylate (46):  
 
1H NMR (600 MHz, CDCl3)  4.47 (1H, t, J = 8.8, C3HH), 3.81 (1H, t, J = 8.8, 
C3HH), 3.69 (3H, s, OCH3), 2.97 (1H, ddq, J = 11.3, 10.2, 8.8, C3aH), 2.59 (1H, dd, 
J = 17.5, 10.2, C=OCHH), 2.46 (1H, td, J = 11.7, 3.8, C8aH), 2.39 (1H, dd, J = 11.3, 
2.6, C4H), 2.37 (1H, dd, J = 17.5, 10.2, C=OCHH), 2.00 (1H, br. dt, J = 13.2, 3.0, 
C8HH), 1.81-1.72 (4H, m, C4aH, C5HH, C6HH & C7HH), 1.45 (9H, s, C(CH3)3), 1.36 
(1H, qd, J = 12.8, 3.4, C8HH), 1.25-1.17 (2H, m, C6HH & C7HH), 1.03 (1H, bqd, J = 
12.0, 3.8, C5HH); 13C NMR (150 MHz, CDCl3)  176.4 (C1=O), 175.9 (C=OOMe), 
171.3 (C=OOtBu), 81.9(C(CH3)3), 72.5 (C3H2), 51.8 (C4H), 51.8 (OCH3), 47.4 
(C8aH), 39.9 (C4aH), 35.0 (C3aH), 32.3 (C=OCH2), 31.3 (C8H2), 28.2 (C(CH3)3), 25.8 
(C5H2), 25.8 (C6H2), 25.7 (C7H2); IR (thin film) 2933 (C-H), 2830 (C-H), 1778 
(C=O), 1721 (C=O), 1369 (C-H), 1260 (C-O), 1165, 1148, 1112, 1080, 1048 cm-1; 
m/z (ES+) 371 (100%, [M+MeOH]+). 
 
Data for (3aS*,4R*,4aR*,8aR*,9aS*)-tert-butyl 1,9-dioxododecahydronaphtho[2,3-
c]furan-4-carboxylate (47): 
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1H NMR (600 MHz, CDCl3)  4.39 (1H, dd, J = 9.2, 8.4, C3HH), 3.94 (1H, dd, J = 
10.2, 9.2, C3HH), 3.71 (1H, d, J = 9.0, C9aH), 3.25 (1H, ddd, J = 10.2, 9.0, 8.4, 
C3aH), 2.65 (1H, td, J = 11.9, 3.8, C8aH), 2.53 (1H, d, J = 4.5, C4H), 2.04-1.90 (1H, 
m, C8HH), 1.88-1.82 (1H, m, C4aH), 1.84-1.75 (3H, m, C5HH, C6HH & C7HH), 1.50 
(9H, s, C(CH3)3), 1.49-1.41 (1H, m, C8HH), 1.35-1.16 (3H, m, C5HH, C6HH & 
C7HH); 13C NMR (150 MHz, CDCl3)  203.9 (C9=O), 172.1 (C=OOtBu), 171.8 
(C1=O), 82.5 (C(CH3)3), 69.5 (C3H2), 52.9 (C9aH), 48.2 (C8aH), 44.9 (C4H), 40.5 
(C4aH), 40.3 (C3aH), 31.4 (C8H2), 28.3 (C(CH3)3), 25.9 (C5H2), 25.7 (C6H2), 25.1 
(C7H2); IR (thin film) 2926 (C-H), 2850 (C-H), 1778 (C=O), 1715 (C=O), 1698 
(C=O), 1365 (C-H), 1204 (C-O), 1138, 1002, 845 cm-1; m/z (ES+) 326 (100%, 
[M+NH4]+); HRMS (ES-) calcd for C17H23O5 [M-H]+ 307.1546, observed 307.1545. 
 
Data for rac-methyl 2-(2-tert-butoxy-1-(2,5'-dioxooctahydro-3,3'-bifuran-4-yl)-2-
oxoethyl)cyclohexanecarboxylate (48): 
 
1H NMR (600 MHz, CDCl3)  4.54 (1H, dd, J = 9.6, 7.7, C3HH), 4.54 (1H, dd, J = 
8.8, 8.3, C3HH), 4.44 (1H, dd, J = 7.9, 1.9, C10HH), 4.42 (1H, dd, J = 7.5, 1.9, 
C10HH), 4.33 (1H, dd, J = 8.8, 8.3, C3HH), 4.29 (1H, dd, J = 9.6, 8.5, C3HH), 4.05 
(1H, dd, J = 10.0, 4.7, C10HH), 4.00 (1H, dd, J = 10.0, 5.1, C10HH), 3.68 (6H, s, 2 x 
OCH3), 2.87 (1H, dddd, J = 9.4, 8.5, 7.7, 7.2, C3aH), 2.84 (1H, dddd, J = 9.4, 8.3, 
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7.7, 7.2, C3aH), 2.63-2.73 (4H, m, 2 x C11HH & 2 x C10aH), 2.60-2.49 (6H, m, 2 x 
C4aH, 2 x C9aH & 2 x C11HH), 2.47 (1H, dd, J = 7.2, 2.6, C4H), 2.45 (1H, dd, J = 
7.5, 2.6, C4H), 2.04-1.99 (2H, m, 2 x C8HH), 1.83-1.78 (4H, m, 2 x C6HH & 2 x 
C7HH), 1.78-1.71 (2H, m, 2 x C5HH), 1.46 (18H, d, J = 1.5, 2 x C(CH3)3), 1.43-1.34 
(2H, m, 2 x C8HH), 1.27-1.16 (4H, m, 2 x C6HH & 2 x C7HH), 1.05 (2H, qd, J = 
12.7, 3.2, 2 x C5HH); 13C NMR (150 MHz, CDCl3)  176.1 (C10=O), 175.9 (C10=O), 
175.9 (C=OOMe), 175.8 (C=OOMe), 175.5 (C1=O), 175.3 (C1=O), 171.2 
(C=OOtBu), 171.1 (C=OOtBu), 82.6 (2 x C(CH3)3), 70.7 (C10H2), 70.7 (C10H2), 70.6 
(C3H2), 70.3 (C3H2), 52.0 (C4H), 52.0 (C4H), 51.3 (OCH3), 50.9 (OCH3), 47.5 
(C9aH), 47.4 (C9aH), 44.9 (C10aH), 44.2 (C10aH), 39.5 (C4aH), 39.2 (C4aH), 39.2 (2 x 
C8aH), 37.1 (C3aH), 37.0 (C3aH), 33.0 (C11H), 31.6 (C11H), 31.1 (C8H2), 28.3 
(C(CH3)3), 28.3 (C(CH3)3), 26.6 (C5H2), 26.5 (C5H2), 25.7 (C6H2), 25.6 (C6H2), 25.6 
(C7H2), 25.5 (C7H2). 
 
Data for (3aS*,4S*,4aR*,8aR*,9aR*)-tert-butyl 1,9-dioxo-9a-((R*)-5-
oxotetrahydrofuran-3-yl)dodecahydronaphtho[2,3-c]furan-4-carboxylate and 
(3aS*,4S*,4aR*,8aR*,9aS*)-tert-butyl 1,9-dioxo-9a-((S*)-5-oxotetrahydrofuran-3-
yl)dodecahydronaphtho[2,3-c]furan-4-carboxylate (1:0.9) (49): 
 
1H NMR (600 MHz, CDCl3)  4.52 (1H, dd, J = 9.4, 7.5, C10HH), 4.47 (1H, dd, J = 
10.5, 7.2, C3HH), 4.45 (1H, dd, J = 10.9, 7.9, C3HH), 4.41 (1H, dd, J = 9.8, 7.9, 
C10HH), 4.33 (1H, dd, J = 9.4, 8.3, C10HH), 4.24 (1H, dd, J = 10.9, 2.3, C3HH), 4.22 
(1H, dd, J = 10.9, 2.6, C3HH), 4.17 (1H, dd, J = 10.2, 7.2, C10HH), 3.13 (1H, dddd, 
J = 9.2, 8.7, 8.3, 7.5, C10aH), 3.08 (1H, dddd, J = 9.4, 7.9, 7.8, 7.2, C10aH), 2.89-
2.84 (3H, m, 2 x C4H), 2.80 (1H, ddd, J = 8.7, 6.8, 2.3, C3aH), 2.73 (1H, dd, J = 
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17.7, 7.9, C11HH), 2.63 (1H, dd, J = 17.5, 9.2, C11HH), 2.58 (1H, dd, J = 17.7, 9.4, 
C11HH), ), 2.46 (1H, ddd, J = 12.8, 11.7, 3.4, C8aH), 2.40 (1H, ddd, J = 12.8, 11.7, 
3.4, C8aH), 2.32 (1H, dd, J = 17.7, 8.7, C11HH), 2.32-2.26 (2H, m, 2 x C8HH), 1.88-
1.83 (4H, m, 2 x C6HH & 2 x C7HH), 1.82-1.77 (2H, m, 2 x C5HH), 1.74-1.67 (2H, 
m, 2 x C4aH), 1.47 (9H, s, C(CH3)3), 1.46 (9H, s, C(CH3)3), 1.30-1.17 (6H, m, 2 x 
C5HH,  2 x C6HH & 2 x C7HH), 1.11-1.03 (2H, m, 2 x C8HH); 13C NMR (150 MHz, 
CDCl3)  203.7 (C9=O), 203.4 (C9=O), 175.1 (C10=O), 174.9 (C10=O), 171.1 
(C1=O), 171.1 (C1=O), 171.0 (C=OOtBu), 170.9 (C=OOtBu), 83.9 (2 x C(CH3)3), 
69.5 (C10H2), 69.3 (C10H2), 68.7 (C3H2), 68.6 (C3H2), 56.5 (C9aH), 56.4 (C9aH), 48.8 
(C4H), 48.7 (C4H), 48.3 (C8aH), 48.3 (C8aH), 42.5 (C3aH), 42.5 (C3aH), 42.0 (C10aH), 
41.5 (C10aH), 41.5 (C4aH), 41.4 (C4aH), 31.4 (2 x C5H2), 31.1 (C11H), 30.8 (C11H), 
28.1 (2 x C(CH3)3), 27.8 (C8H2), 27.5 (C8H2), 25.9 (C6H2), 25.8 (C6H2), 25.7 (2 x 
C7H2). 
 
Methyl pent-3-enoate149 (50) 
 
Conc. H2SO4 (0.75 mL) was added to a stirred solution of pent-3-enoic acid (1.40 
mL, 13.8 mmol) in MeOH (10 mL). The reaction mixture was stirred at 20 °C for 12 
h before being neutralised with sat. aq. NaHCO3. An extraction into CH2Cl2 (3 x 20 
mL) was completed and the combined organic layers were dried (Na2SO4), filtered 
and concentrated in vacuo to yield methyl pent-3-enoate (50) (1.39 g, 1.22 mmol, 
89%) as a colourless oil which was used with no further purification; 1H NMR (500 
MHz, CDCl3)  5.62-5.50 (2H, m, CH=CH & CH=CH), 3.68 (3 H, s, OCH3), 3.02 
(2H, s, CH2CH=CH), 1.71-1.68 (3H, m, CH=CHCH3); 13C NMR (126 MHz, CDCl3)  
172.7 (C=O), 129.5 (CH2CH=CH), 122.7 (CH=CHCH3), 51.8 (OCH3), 38.0 
(CH2CH=CH), 18.0 (CH=CHCH3); IR (thin film) 2978 (C-H), 1788, 1734 (C=O), 
1716, 1376 (C-H), 1352 (C-H), 1335 (C-H), 1201 (C-O), 1146 (C-O), 1108, 1016, 
908, 885, 701, 690 cm-1. Data agrees with that reported by Scarborough.149  
 
4-Hydroxy-5-methyldihydrofuran-2-(3H)-one150 (51)  
139 
 
 
AD-mix-β (10.0 g) was added to a stirred solution of methyl pent-3-enoate (50) 
(860 mg, 7.53 mmol) in a 1:1 mix of t-BuOH (22 mL) and H2O (22 mL) at 0 °C. The 
reaction mixture was stirred at RT for 4 days, quenched with solid Na2SO3 and 
diluted with H2O (50 mL). An extraction into CH2Cl2 (5 x 50 mL) was completed and 
the combined organic layers were dried (Na2SO4), filtered and concentrated in 
vacuo to yield 4-hydroxy-5-methyldihydrofuran-2-(3H)-one (51) (376 mg, 3.24 
mmol, 43%) as a colourless oil; 1H NMR (600 MHz, CDCl3)  4.56 (1H, dq, J = 6.4, 
3.8, CHCH3), 4.45 (1H, ddd, J = 5.6, 3.8, 1.1, CHOH), 2.80 (1H, dd, J = 17.7, 5.6, 
CHcisH), 2.56 (1H, dd, J = 17.7, 1.1, CHHtrans), 1.44 (3H, d, J = 6.4, CH3); 13C NMR 
(126 MHz, CDCl3)  80.8 (CHCH3), 69.3 (CHOH), 39.4 (CH2), 13.8 (CH3). Data 
agrees with that reported by Takahata et al..150  
 
5-Methyl-2(5H)-furanone151 (52)  
 
NEt3 (994 µL, 7.12 mmol) and MeSO2Cl (289 µL, 3.73 mmol) were added to a 
stirred solution of 4-hydroxy-5-methyldihydrofuran-2-(3H)-one (51) (394 mg, 3.39 
mmol) in CH2Cl2 (10 mL) at 0 °C. The reaction mixture was stirred at RT for 1 h, 
quenched with sat. aq. NH4Cl (5 mL) and diluted with H2O (10mL). An extraction 
into CH2Cl2 (3 x 20 mL) was completed and the combined organic layers were 
dried (MgSO4), filtered and concentrated in vacuo to yield a crude oil. Purification 
by flash column chromatography (0-10% EtOAc/Pet. Ether) yielded 5-methyl-
2(5H)-furanone (52) (162 mg, 1.65 mmol, 49%) as a colourless oil; 1H NMR (600 
MHz, CDCl3)  7.45 (1H, dd, J = 5.6, 1.2, CH=CH), 6.10 (1H, dd, J = 5.6, 1.9, 
CH=CHC=O), 5.14 (1H, qdd, J = 6.8, 1.9, 1.2, CHCH3), 1.45 (3H, d, J = 6.8, CH3); 
13C NMR (126 MHz, CDCl3)  173.1 (C=O), 157.4 (CH=CH), 121.3 (CH=CHC=O), 
79.7 (CHCH3), 18.9 (CH3); IR (thin film) 2983 (C-H), 2936 (C-H), 1750 (C=O), 1736 
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(C=O), 1322 (C-O), 1166, 1105, 1075, 958, 941, 891, 816 cm-1; m/z (CI) 99 (100%, 
[M+H]+). Data agrees with that reported by Takadoi et al..151 
 
tert-Butyl 3-methyl-1,9-dioxododecahydronaphtho[2,3-c]furan-4-
carboxylate127 (53) 
 
n-BuLi (2.5 M in hexane) (3.60 ml, 9.00 mmol) was added dropwise to a stirred 
solution of distilled TMP (1.54 mL, 9.00 mmol) in anhydrous THF (10 mL) at -78 °C, 
under Ar. The solution was warmed to 0 °C and then re-cooled to -78 °C. A 
solution of (1R*,2S*)-methyl 2-(2-(tert-butoxy)-2-oxoethyl)cyclohexanecarboxylate 
(43) (1.10 g, 4.30 mmol) in anhydrous THF (5 mL) was added, dropwise, and 
stirring continued for 45 min at -78 °C. Next, a solution of 5-methyl-2(5H)-furanone 
(52) (294 mg, 0.30 mmol) in anhydrous THF (5 mL) was added, dropwise, and 
stirring continued for 1 h at -78 °C. Finally, KOt-Bu (1.00 g, 9.00 mmol) was added. 
The reaction mixture was warmed to -40 °C, stirred for a further 3 h and then 
quenched with sat. aq. NH4Cl (20 mL). An extraction into EtOAc (2 x 40 mL) was 
completed and the combined organic layers were dried (MgSO4), filtered and 
concentrated in vacuo to yield a crude yellow oily solid. Multiple purifications by 
flash column chromatography yielded (3R,3aR,4R,4aR,8aR,9aR)-tert-butyl 3-
methyl-1,9-dioxododecahydronaphtho[2,3-c]furan-4-carboxylate (54) (47.5 mg, 
0.15 mmol, 5%), (3R,3aS,4R,4aR,8aR,9aS)-tert-butyl 3-methyl-1,9-
dioxododecahydronaphtho[2,3-c]furan-4-carboxylate (55) (117 mg, 0.36 mmol, 
12%) and (3R,3aS,4S,4aR,8aR,9aS)-tert-butyl 3-methyl-1,9-
dioxododecahydronaphtho[2,3-c]furan-4-carboxylate (56) (47.5 mg, 0.15 mmol, 
5%) as white solids. 
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Data for (3R,3aR,4R,4aR,8aR,9aR)-tert-butyl 3-methyl-1,9-
dioxododecahydronaphtho[2,3-c]furan-4-carboxylate (54): 
 
1H NMR (600 MHz, CDCl3)  4.53 (1H, q, J = 6.4, C3HMe), 3.64 (1H, d, J = 7.9, 
C9aH), 2.84 (1H, dd, J = 11.7, 7.9, C3aH), 2.37 (1H, dd, J = 11.7, 11.3, C4H), 2.14-
2.11 (1H, m, C8HH), 1.97 (1H, td, J = 11.2, 3.6, C8aH), 1.82-1.79 (1H, m, C6HH), 
1.79-1.71 (2H, m, C5HH & C7HH), 1.71-1.63 (1H, m, C4aH), 1.49 (9H, s, C(CH3)3), 
1.33 (3H, d, J = 6.4, C3HCH3), 1.20-1.15 (4H, m, C5HH, C6HH, C7HH & C8HH); 13C 
NMR (150 MHz, CDCl3)  201.9 (C9=O), 172.5 (C=OOtBu), 171.1 (C1=O), 82.4 
(C(CH3)3), 79.5 (C3HMe), 51.9 (C4H), 51.6 (C8aH), 51.5 (C9aH), 47.6 (C3aH), 42.5 
(C4aH), 31.5 (C5H2), 28.3 (C(CH3)3), 25.1 (C8H2), 25.1 (C6H2), 24.8 (C7H2), 19.4 
(C3HCH3); IR (thin film) 2925 (C-H), 2853 (C-H), 1776 (C=O), 1714 (C=O), 1700 
(C=O), 1205 (C-O), 1153, 1138, 1001, 845, 750, 577 cm-1; m/z (EI) 322 (100%, 
[M]+); HRMS (EI) calcd for C18H26O5 [M]+ 322.1775, observed 322.1776. 
 
Data for (3R,3aS,4R,4aR,8aR,9aS)-tert-butyl 3-methyl-1,9-
dioxododecahydronaphtho[2,3-c]furan-4-carboxylate (55): 
 
1H NMR (600 MHz, CDCl3)  4.24 (1H, dd, J = 10.2, 6.0, C3HMe), 3.77 (1H, d, J = 
8.3, C9aH), 2.71-2.66 (1H, m, C8aH), 2.51 (1H, d, J = 4.9, C4H), 2.01-1.96 (1H, m, 
C8HH), 1.84-1.72 (4H, m, C4aH, C5HH, C6HH & C7HH), 1.50 (9H, s, C(CH3)3), 1.42 
(3H, d, J = 6.0, C3HCH3), 1.33-1.23 (2H, m, C5HH & C8HH ), 1.22-1.14 (2H, m, 
C6HH & C7HH); 13C NMR (150 MHz, CDCl3)  204.0 (C9=O), 172.0 (C=OOtBu), 
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171.1 (C1=O), 82.5 (C(CH3)3), 77.6 (C3HMe), 54.5 (C9aH), 48.4 (C3aH), 48.1 (C8aH), 
44.1 (C4H), 41.0 (C4aH), 31.4 (C5H2), 28.3 (C(CH3)3), 25.7 (C8H2), 25.5 (C6H2), 25.0 
(C7H2), 19.1 (C3HCH3); IR (thin film) 2988 (C-H), 2918 (C-H), 2855 (C-H), 1790 
(C=O), 1727 (C=O), 1705 (C=O), 1198 (C-O), 1197, 1133, 1061, 913, 835 cm-1; 
m/z (CI) 267 (100%, [M-C4H9]+); HRMS (CI) calcd for C18H27O5 [M+H]+ 323.1853, 
observed 323.1855. 
 
Data for (3R,3aS,4S,4aR,8aR,9aS)-tert-butyl 3-methyl-1,9-
dioxododecahydronaphtho[2,3-c]furan-4-carboxylate (56): 
 
1H NMR (600 MHz, CDCl3)  4.54 (1H, dq, J = 10.2, 6.0, C3HMe), 3.48 (1H, d, J = 
8.7, C9aH), 2.94 (1H, ddd, J = 10.2, 8.7, 5.3, C3aH), 2.81 (1H, dd, J = 11.5, 5.3, 
C4H), 2.08 (1H, td, J = 11.8, 3.2, C8aH), 1.96-1.88 (3H, m, C4aH, C5HH & C8HH), 
1.84-1.80 (1H, m, C6HH), 1.75-1.71 (1H, m, C7HH), 1.48 (9H, s, C(CH3)3), 1.36 
(3H, d, J = 6.0, C3HCH3), 1.39-1.34 (1H, m, C8HH), 1.26-1.17 (2H, m, C6HH & 
C7HH), 1.13-1.05 (1H, m, C5HH); 13C NMR (150 MHz, CDCl3)  203.0 (C9=O), 
171.6 (C=OOtBu), 170.2 (C1=O), 82.5 (C(CH3)3), 77.3 (C3HMe), 56.3 (C9aH), 52.4 
(C8aH), 48.0 (C3aH & C4H), 41.5 (C4aH), 32.0 (C5H2), 28.3 (C(CH3)3), 25.1 (C8H2), 
24.9 (C6H2), 24.8 (C7H2), 20.3 (C3HCH3); IR (thin film) 2978 (C-H), 2933 (C-H), 
2857 (C-H), 1784 (C=O), 1717 (C=O), 1367, 1194 (C-O), 1146, 1066, 985, 751 cm-
1; m/z (CI) 267 (100%, [M-C4H9]+); HRMS (CI) calcd for C18H27O5 [M+H]+ 323.1853, 
observed 323.1856. 
 
(3R,3aS,4R,4aR,8aR,9aS)-3-Methyl-1,9-dioxododecahydronaphtho[2,3-
c]furan-4-carboxylic acid (57) 
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TFA (0.5 mL) was added dropwise to a stirred solution of 
(3R,3aS,4R,4aR,8aR,9aS)-tert-butyl 3-methyl-1,9-dioxododecahydronaphtho[2,3-
c]furan-4-carboxylate (55) (86.0 mg, 0.27 mmol) in CH2Cl2 (0.5 mL) at 0 °C, under 
Ar. The reaction mixture was stirred at 20 °C for 16 h before being concentrated in 
vacuo. The residue was azeotroped with toluene to yield 
(3R,3aS,4R,4aR,8aR,9aS)-3-methyl-1,9-dioxododecahydronaphtho[2,3-c]furan-4-
carboxylic acid (57) (69.8 mg, 0.26 mmol, 99%) as a white solid; 1H NMR (600 
MHz, MeOH-d4)  4.39 (1H, td, J = 11.7, 6, C3HMe), 3.82 (1H, d, J = 8.7, C9aH), 
2.87 (1H, dd, J = 10.4, 8.7, C3aH), 2.76 (1H, td, J = 11.7, 3.4, C8aH), 2.71 (1H, d, J 
= 4.9, C4H), 1.97 (1H, dddd, J = 12.4, 11.7, 4.9, 3.8, C4aH), 1.96-1.92 (1H, m, 
C8HH), 1.87-1.82 (1H, m, C5HH), 1.81-1.74 (2H, m, C6HH & C7HH), 1.42 (3H, d, J 
= 6.0, C3HCH3), 1.40-1.36 (1H, m, C5HH), 1.31-1.21 (3H, m, C6HH, C7HH & 
C8HH); 13C NMR (150 MHz, MeOH-d4)  206.3 (C9=O), 176.3 (C=OOH), 173.7 
(C1=O), 79.6 (C3HMe), 49.6 (C3aH), 49.2 (C8aH), 49.0 (C9aH), 44.0 (C4H), 41.5 
(C4aH), 32.5 (C5H2), 26.7 (C8H2), 26.5 (C6H2), 26.1 (C7H2), 18.9 (C3HCH3); IR (thin 
film) 2928 (C-H), 2859 (C-H), 1775 (C=O), 1702 (C=O), 1581, 1416, 1201 (C-O), 
1052 cm-1; m/z (EI) 267 (100%, [M+H]+); HRMS (EI) calcd for C14H18O5 [M+H]+ 
266.1149, observed 266.1150. 
 
(3R,3aR,4R,4aR,8aR,9aS)-S-Ethyl 3-methyl-1,9-
dioxododecahydronaphtho[2,3-c]furan-4-carbothioate (58) 
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DCC (149 mg, 0.72 mmol) was added to a stirred solution of 
(3R,3aS,4R,4aR,8aR,9aS)-3-methyl-1,9-dioxododecahydronaphtho[2,3-c]furan-4-
carboxylic acid (57) (160 mg, 0.60 mmol), ethanethiol (173 µL, 2.40 mmol) and 
DMAP (37.0 mg, cat.) in CH2Cl2 (5 mL) at 0 °C, under Ar. The reaction mixture was 
stirred at 20 °C for 16 h before being filtered under vacuum to remove the 
precipitate. The filtrate solvents were concentrated in vacuo to yield a crude 
colourless oil. Purification by flash column chromatography (0-2% Et2O/CH2Cl2) 
yielded (3R,3aR,4R,4aR,8aR,9aS)-S-ethyl 3-methyl-1,9-
dioxododecahydronaphtho[2,3-c]furan-4-carbothioate (58) (128 mg, 0.41 mmol, 
69%) as a white solid; Rf 0.64 (8% Et2O/CH2Cl2); 1H NMR (600 MHz, CDCl3)  
4.24 (1H, dq, J = 10.5, 6.0, C3HMe), 3.73 (1H, d, J = 8.7, C9aH), 2.96 (1H, q, J = 
6.5, SCHHCH3), 2.92 (1H, q, J = 6.5, SCHHCH3), 2.84 (1H, td, J = 11.9, 3.4, C8aH), 
2.75 (1H, d, J = 4.5, C4H), 2.65 (1H, dd, J = 10.5, 8.7, C3aH), 2.00-1.95 (1H, m, 
C8HH), 1.86-1.74 (4H, m, C4aH, C5HH, C6HH & C7HH), 1.44 (3H, d, J = 6.0, 
C3HCH3), 1.40-1.32 (1H, m, C5HH), 1.30 (3H, t, J = 7.3, SCH2CH3), 1.28-1.11 (3H, 
m, C6HH, C7HH & C8HH); 13C NMR (150 MHz, CDCl3)  203.8 (C9=O), 200.3 
(C=OSEt), 170.7 (C1=O), 77.3 (C3HMe), 54.7 (C9aH), 50.6 (C4H), 48.8 (C8aH), 48.3 
(C3aH), 41.8 (C4aH), 31.4 (C5H2), 25.7 (C8H2), 25.3 (C6H2), 24.8 (C7H2), 24.1 
(CH2CH3), 18.9 (C3HCH3), 14.6 (CH2CH3); IR (thin film) 2930 (C-H), 2854 (C-H), 
1785 (C=O), 1708 (C=O), 1672, 1197 (C-O), 1059, 958 cm-1; m/z (EI) 252 (100%, 
[M-SEt-Me+OH]+); HRMS (EI) calcd for C16H22O4S [M+H]+ 310.1233, observed 
310.1233. 
 
(3R,3aS,4aS,8aR,9aS)-3-Methyl-1,9-dioxododecahydronaphtho[2,3-
c]furan-4-carbaldehyde (59) 
 
Neat triethylsilane (263 µL, 1.65 mmol) was added to a stirred suspension of 
(3R,3aR,4R,4aR,8aR,9aS)-S-ethyl 3-methyl-1,9-dioxododecahydronaphtho[2,3-
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c]furan-4-carbothioate (58) (128 mg, 0.41 mmol), palladium on carbon (10%) (44.0 
mg, 0.04 mmol) and MgSO4 (to dry) in degassed acetone (5 mL) under Ar. The 
reaction mixture was stirred at 20 °C for 16 h before it was filtered over celite and 
concentrated in vacuo. Purification by flash column chromatography (0-2% 
Et2O/CH2Cl2) gave partial racemisation at C4 to yield (3R,3aS,4aS,8aR,9aS)-3-
methyl-1,9-dioxododecahydronaphtho[2,3-c]furan-4-carbaldehyde (59) (4S:4R; 
1:0.16) (50 mg, 0.20 mmol, 48%) as a colourless film; Rf 0.44 (8% Et2O/CH2Cl2); 
1H NMR (600 MHz, CDCl3)  10.14 (1H, s, 4S-CHO), 4.29 (1H, dq, J = 10.2, 6.0, 
4S-C3HMe), 3.67 (1H, d, J = 8.7, 4S-C9aH), 2.88 (1H, dd, J = 10.2, 8.7, 4S-C3aH), 
2.80 (1H, d, J = 4.9, 4S-C4H), 2.20 (1H, ddd, J = 12.4, 12.0, 3.4, 4S-C8aH), 2.09-
1.96 (3H, m, 4S-C4aH, 4S-C5HH & 4S-C8HH), 1.88-1.81 (2H, m, 4S-C6HH & 4S-
C7HH), 1.68 (1H, qd, J = 12.4, 3.4, 4S-C5HH), 1.42 (3H, d, J = 6.0, C3HCH3), 1.36-
1.32 (1H, m, 4S-C8HH), 1.23-1.17 (2H, m, 4S-C6HH & 4S-C7HH); 13C NMR (150 
MHz, CDCl3)  202.8 (4S-C9=O), 202.7 (4S-CHO), 170.5 (4S-C1=O), 77.2 (4S-
C3HMe), 54.5 (4S-C9aH), 49.4 (4S-C8aH), 49.1 (4S-C4H), 44.9 (4S-C3aH), 41.6 (4S-
C4aH), 30.7 (4S-C5H2), 26.0 (4S-C8H2), 25.3 (4S-C6H2), 24.8 (4S-C7H2), 19.1 (4S-
C3HCH3). 
 
(3R,3aS,4aS,8aR,9aS)-3-Methyl-4-((E)-2-(5-(3-
(trifluoromethyl)phenyl)pyridin-2-yl)vinyl)octahydronaphtho[2,3-
c]furan-1,9(3H,9aH)-dione (60) 
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n-BuLi (1.6 M in hexanes) (150 µL, 0.24 mmol) was added dropwise to a stirred 
solution of diethyl (5-(3-(trifluoromethyl)phenyl)pyridin-2-yl)methylphosphonate (28) 
(75 mg, 0.20 mmol) in anhydrous THF (1 mL) at 0 °C, under Ar. The solution was 
stirred at 0 °C for 10 min before (3R,3aS,4aS,8aR,9aS)-3-methyl-1,9-
dioxododecahydronaphtho[2,3-c]furan-4-carbaldehyde (59) (50 mg, 0.20 mmol) 
was added. The reaction mixture was stirred at 0 °C for 45 min and then quenched 
with sat. aq. NH4Cl (5 mL). An extraction into EtOAc (10 mL) was completed and 
the organic layer was dried (MgSO4), filtered and concentrated in vacuo to yield a 
crude yellow oil. Purification by flash column chromatography (0-15% Et2O/CH2Cl2) 
and then (20-35% Et2O/toluene) yielded (3R,3aS,4R,4aS,8aR,9aS)-3-methyl-4-
((E)-2-(5-(3-(trifluoromethyl)phenyl)pyridin-2-yl)vinyl)octahydronaphtho[2,3-c]furan-
1,9(3H,9aH)-dione (61) (39 mg, 0.08 mmol, 41%) and (3R,3aS,4S,4aS,8aR,9aS)-
3-methyl-4-((E)-2-(5-(3-(trifluoromethyl)phenyl)pyridin-2-
yl)vinyl)octahydronaphtho[2,3-c]furan-1,9(3H,9aH)-dione (62) (14 mg, 0.03 mmol, 
15%) as white solids. 
 
Data for (3R,3aS,4R,4aS,8aR,9aS)-3-methyl-4-((E)-2-(5-(3-
(trifluoromethyl)phenyl)pyridin-2-yl)vinyl)octahydronaphtho[2,3-c]furan-
1,9(3H,9aH)-dione (61): 
 
[α]D20 = +14 (MeOH); 1H NMR (600 MHz, CDCl3)  8.82 (1H, d, J = 2.3, CHN), 7.89 
(1H, dd, J = 8.3, 2.3, CHCCHN), 7.82 (1H, s, CHCCF3), 7.78 (1H, d, J = 7.5, 
CHCCHCCF3), 7.68 (1H, d, J = 7.5, CHCHCCF3), 7.62 (1H, t, J = 7.9, 
CHCHCCF3), 7.35 (1H, d, J = 7.9, CHCN), 7.10 (1H, dd, J = 15.4, 9.8, CH=CH), 
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6.66 (1H, d, J = 15.4, CH=CH), 4.42 (1H, dq, J = 10.2, 6.0, C3HMe), 3.66 (1H, d, J 
= 8.7, C9aH), 2.71 (1H, dd, J = 10.2, 8.7, C3aH), 2.59 (1H, dd, J = 9.6, 4.0, C4H), 
2.44 (1H, td, J = 12.0, 3.6, C8aH), 2.05-1.99 (1H, m, C8HH), 1.88 (1H, tt, J = 12.3, 
4, C4aH), 1.82-1.77 (1H, m, C7HH), 1.77-1.72 (1H, m, C6HH), 1.71-1.66 (1H, m, 
C5HH), 1.48 (3H, d, J = 6.0, C3HCH3), 1.46-1.40 (1H, m, C5HH), 1.40-1.34 (1H, m, 
C8HH), 1.23-1.17 (2H, m, C6HH & C7HH); 13C NMR (150 MHz, CDCl3)  203.8 
(C9=O), 170.9 (C1=O), 154.0 (CN), 148.3 (CHN), 138.4 (CCHCCF3), 135.3 
(CHCCHN), 134.2 (CCHN), 132.8 (CH=CH), 132.4 (CH=CH), 131.7 (q, J = 32.8, 
CCF3), 130.3 (CHCCHCCF3), 129.8 (CHCHCCF3), 125.0 (q, J = 4.0, CHCHCCF3), 
123.8 (q, J = 4.0, CCHCCF3), 122.3 (d, J = 247.6, CF3), 122.3 (CHCN), 78.0 
(C3HMe), 54.1 (C9aH), 51.8 (C3aH), 48.3 (C8aH), 42.2 (C4aH), 41.1 (C4H), 31.8 
(C5H2), 25.5 (C8H2), 25.4 (C6H2), 24.9 (C7H2), 19.2 (C3HCH3); IR (thin film) 2921 
(C-H), 2852 (C-H), 1783 (C=O), 1719 (C=O), 1447, 1335, 1265, 1167 (C-O), 1127, 
804, 730 cm-1; m/z (ES+) 470 (100%, [M+H]+); HRMS (ES+) calcd for C27H27NO3F3 
[M+H]+ 470.1943, observed 470.1920. 
 
Data for (3R,3aS,4S,4aS,8aR,9aS)-3-methyl-4-((E)-2-(5-(3-
(trifluoromethyl)phenyl)pyridin-2-yl)vinyl)octahydronaphtho[2,3-c]furan-
1,9(3H,9aH)-dione (62): 
 
1H NMR (600 MHz, CDCl3)  8.80 (1H, d, J = 2.4, CHN), 7.87 (1H, dd, J = 8.1, 2.4, 
CHCCHN), 7.81 (1H, s, CHCCF3), 7.76 (1H, d, J = 7.9, CHCCHCCF3), 7.67 (1H, d, 
J = 7.9, CHCHCCF3), 7.61 (1H, t, J = 7.9, CHCHCCF3), 7.31 (1H, d, J = 8.1, 
CHCN), 6.66 (1H, d, J = 15.4, CH=CH), 6.60 (1H, dd, J = 15.4, 9.4, CH=CH), 4.57 
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(1H, dq, J = 9.4, 6.0, C3HMe), 3.58 (1H, d, J = 7.9, C9aH), 2.90-2.83 (2H, m, C3aH & 
C4H), 2.18 (1H, td, J = 11.6, 3.2, C8aH), 1.99-1.92 (2H, m, C5HH & C8HH), 1.86-
1.81 (1H, m, C6HH), 1.78-1.69 (2H, m, C4aH & C7HH), 1.44 (3H, d, J = 6.0, 
C3HCH3), 1.42-1.38 (1H, m, C8HH), 1.24-1.16 (2H, m, C6HH & C7HH), 1.11-1.01 
(1H, m, C5HH); 13C NMR (150 MHz, CDCl3)  203.9 (C9=O), 170.8 (C1=O), 153.9 
(CN), 148.4 (CHN), 138.5 (CCHCCF3), 135.2 (CHCCHN), 134.5 (CH=CH), 134.1 
(CCHN), 131.9 (CH=CH), 131.7 (q, J = 32.1, CCF3), 130.3 (CHCCHCCF3), 129.8 
(CHCHCCF3), 124.9 (q, J = 3.8, CHCHCCF3), 123.8 (q, J = 3.8, CCHCCF3), 124.1 
(d, J = 271.7, CF3), 122.0 (CHCN), 77.3 (C3HMe), 56.7 (C9aH), 53.1 (C8aH), 52.5 
(C3aH), 45.5 (C4H), 43.3 (C4aH), 33.1 (C5H2), 25.3 (C8H2), 25.0 (C6H2), 24.8 (C7H2), 
21.9 (C3HCH3); IR (thin film) 2922 (C-H), 2855 (C-H), 1781 (C=O), 1714 (C=O), 
1440, 1335, 1268, 1123 (C-O), 1074, 810, 703 cm-1; m/z (EI) 469 (100%, [M]+); 
HRMS (EI) calcd for C27H26NO3F3 [M]+ 469.1859, observed 469.1859. 
 
(3R,3aS,4R,4aS,8aR,9aS)-9-Hydroxy-3-methyl-4-((E)-2-(5-(3-
(trifluoromethyl)phenyl)pyridin-2-yl)vinyl)decahydronaphtho[2,3-
c]furan-1(3H)-one (63) 
 
NaBH4 (2.13 mg, 0.06 mmol) was added to a stirred solution of 
(3R,3aS,4R,4aS,8aR,9aS)-3-methyl-4-((E)-2-(5-(3-(trifluoromethyl)phenyl)pyridin-
2-yl)vinyl)octahydronaphtho[2,3-c]furan-1,9(3H,9aH)-dione (61) (24.0 mg, 0.05 
mmol) in anhydrous THF (2 mL) and MeOH (2 mL) at 0 °C, under Ar. The reaction 
mixture was stirred at 0 °C for 15 min and then quenched with sat. aq. NH4Cl (0.5 
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mL). An extraction into Et2O (5 mL) was completed and the organic layer was dried 
(MgSO4), filtered and concentrated in vacuo to yield a crude yellow gum. 
Purification by flash column chromatography (0-2% Et2O/CH2Cl2) yielded 
(3R,3aS,4R,4aS,8aR,9R,9aS)-9-hydroxy-3-methyl-4-((E)-2-(5-(3-
(trifluoromethyl)phenyl)pyridin-2-yl)vinyl)decahydronaphtho[2,3-c]furan-1(3H)-one 
(63) as a mixture of isomers. Purification by preparative thin layer chomatography 
(0-2% Et2O/CH2Cl2) yielded (3R,3aS,4R,4aS,8aR,9R,9aS)-9-hydroxy-3-methyl-4-
((E)-2-(5-(3-(trifluoromethyl)phenyl)pyridin-2-yl)vinyl)decahydronaphtho[2,3-c]furan-
1(3H)-one (64) (9 mg, 0.02 mmol, 38%) and (3R,3aS,4R,4aS,8aR,9S,9aS)-9-
hydroxy-3-methyl-4-((E)-2-(5-(3-(trifluoromethyl)phenyl)pyridin-2-
yl)vinyl)decahydronaphtho[2,3-c]furan-1(3H)-one (65) (7 mg, 0.02 mmol, 29%) as 
white solids. 
 
Data for (3R,3aS,4R,4aS,8aR,9R,9aS)-9-hydroxy-3-methyl-4-((E)-2-(5-(3-
(trifluoromethyl)phenyl)pyridin-2-yl)vinyl)decahydronaphtho[2,3-c]furan-1(3H)-one 
(64): 
 
1H NMR (600 MHz, CDCl3)  8.80 (1H, d, J = 1.9, CHN), 7.86 (1H, dd, J = 8.1, 1.9, 
CHCCHN), 7.82 (1H, s, CHCCF3), 7.77 (1H, d, J = 7.5, CHCCHCCF3), 7.66 (1H, d, 
J = 7.5, CHCHCCF3), 7.61 (1H, t, J = 7.9, CHCHCCF3), 7.35 (1H, d, J = 8.1, 
CHCN), 6.88 (1H, dd, J = 15.4, 9.8, CH=CH), 6.55 (1H, d, J = 15.4, CH=CH), 4.54 
(1H, dq, J = 10.4, 6.0, C3HMe), 3.47 (1H, ddd, J = 10.9, 9.8, 1.1, C9HOH), 2.74 
(1H, dd, J = 9.8, 7.9, C9aH), 2.54 (1H, d, J = 1.9, OH), 2.40 (1H, dd, J = 9.6, 4.0, 
C4H), 2.36-2.30 (2H, m, C3aH & C8HH), 1.78-1.72 (2H, m, C6HH & C7HH), 1.58-
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1.49 (3H, m, C4aH, C5HH & C8aH), 1.47 (1H, d, J = 6.0, C3HCH3),1.32-1.16 (4H, m, 
C5HH, C6HH, C7HH & C8HH); 13C NMR (150 MHz, CDCl3)  177.9 (C1=O), 154.6 
(CN), 148.1 (CHN), 131.8 (CCHCCF3), 131.5 (CHCCHN), 131.3 (CH=CH), 130.9 
(q, J = 32.1, CCF3), 130.3 (CH=CH & CHCCHCCF3), 129.9 (CCHN), 129.8 
(CHCHCCF3), 124.9 (q, J = 3.6, CHCHCCF3), 123.8 (q, J = 3.6, CCHCCF3), 124.1 
(d, J = 272.1, CF3), 121.6 (CHCN), 78.5 (C3HMe), 73.2 (C9HOH), 49.5 (C3aH), 47.7 
(C9aH), 41.1 (C4H), 40.2 (C4aH), 38.7 (C8aH), 32.1 (C5H2), 31.2 (C8H2), 26.1 (C6H2) 
25.5 (C7H2), 19.5 (C3HCH3); IR (thin film) 2921 (C-H), 2851 (C-H), 1764 (C=O), 
1440, 1334, 1267, 1166 (C-O), 1124, 1075, 1051, 804, 755 cm-1; m/z (ES+) 472 
(100%, [M]+); HRMS (EI) calcd for C27H28NO3F3 [M-H]+ 471.2016, observed 
471.2016. 
 
Data for (3R,3aS,4R,4aS,8aR,9S,9aS)-9-hydroxy-3-methyl-4-((E)-2-(5-(3-
(trifluoromethyl)phenyl)pyridin-2-yl)vinyl)decahydronaphtho[2,3-c]furan-1(3H)-one 
(65): 
 
1H NMR (600 MHz, CDCl3)  8.79 (1H, d, J = 1.9, CHN), 7.85 (1H, dd, J = 8.1, 1.9, 
CHCCHN), 7.81 (1H, s, CHCCF3), 7.76 (1H, d, J = 7.5, CHCHCCF3), 7.66 (1H, d, J 
= 7.5, CHCCHCCF3), 7.61 (1H, t, J = 7.9, CHCHCCF3), 7.32 (1H, d, J = 8.3, 
CHCN), 6.87 (1H, dd, J = 15.4, 10.2, CH=CH), 6.52 (1H, d, J = 15.4, CH=CH), 4.74 
(1H, dq, J = 10.5, 6.0, C3HMe), 4.09 (1H, td, J = 4.9, 2.3, C9H), 2.93 (1H, dd, J = 
8.3, 4.9, C9aH), 2.48 (1H, dd, J = 10.2, 4.2, C4H), 2.21 (1H, dd, J = 10.5, 8.3, C3aH), 
2.11 (1H, d, J = 4.9, OH), 1.92 (1H, tt, J = 11.7, 4.5, C4aH), 1.78-1.70 (2H, m, C6HH 
& C7HH), 1.59-1.54 (3H, m, C5HH, C8HH & C8aH), 1.51-1.44 (1H, m, C8HH), 1.44 
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(3H, d, J = 6.0, C3HCH3), 1.31-1.19 (3H, m, C5HH, C6HH & C7HH); 13C NMR (150 
MHz, CDCl3)  177.4 (C1=O), 154.7 (CN), 148.1 (CHN), 138.6 (CCHCCF3), 135.4 
(CH=CH), 135.1 (CHCCHN), 133.7 (CCHN), 131.7 (q, J = 32.1, CCF3), 130.8 
(CH=CH), 130.3 (CHCCHCCF3), 129.8 (CHCHCCF3), 124.8 (q, J = 4.0, 
CHCHCCF3), 123.8 (q, J = 4.0, CCHCCF3), 124.1 (d, J = 271.7, CF3), 121.9 
(CHCN), 79.7 (C3HMe), 69.0 (C9HOH), 48.4 (C3aH), 45.8 (C9aH), 41.3 (C4H), 38.4 
(C8aH2), 31.7 (C4aH), 31.4 (C5H2), 28.9 (C8H2), 26.4 (C6H2), 26.1 (C7H2), 19.3 
(C3HCH3); IR (thin film) 2924 (C-H), 2853 (C-H), 1761 (C=O), 1440, 1334, 1267, 
1165 (C-O), 1124, 1075, 1050, 803, 700 cm-1; m/z (ES+) 472 (100%, [M]+); HRMS 
(ES+) calcd for C27H29NO3F3 [M]+ 472.2100, observed 472.2089. 
 
(3R,3aS,4S,4aR,8aR,9aS)-3-Methyl-1,9-dioxododecahydronaphtho[2,3-
c]furan-4-carboxylic acid (66) 
 
TFA (0.3 mL) was added dropwise to a stirred solution of 
(3R,3aS,4S,4aR,8aR,9aS)-tert-butyl 3-methyl-1,9-dioxododecahydronaphtho[2,3-
c]furan-4-carboxylate (56) (29.0 mg, 0.09 mmol) in CH2Cl2 (0.3 mL) at 0 °C, under 
Ar. The reaction mixture was stirred at 20 °C for 16 h before being concentrated in 
vacuo. The residue was azeotroped with toluene to yield 
(3R,3aS,4S,4aR,8aR,9aS)-3-methyl-1,9-dioxododecahydronaphtho[2,3-c]furan-4-
carboxylic acid (66) (24 mg, 0.09 mmol, 99%) as a white solid; 1H NMR (600 MHz, 
MeOH-d4)  4.50 (1H, dq, J = 10.2, 6.0, C3HMe), 3.74 (1H, d, J = 8.7, C9aH), 3.08 
(1H, dd, J = 10.2, 5.8, C3aH), 2.99 (1H, td, J = 11.5, 5.8, C4H), 2.30 (1H, td, J = 
11.6, 3.2, C8aH), 2.01-1.96 (1H, m, C5HH), 1.91 (1H, dtd, J = 11.9, 11.5, 3.4, C4aH), 
1.90-1.86 (1H, m, C8HH), 1.84-1.79 (1H, m, C6HH), 1.76-1.71 (1H, m, C7HH), 1.34 
(3H, d, J = 6.0, C3HCH3), 1.39-1.31 (1H, m, C8HH), 1.33-1.23 (2H, m, C6HH & 
C7HH), 1.17-1.10 (1H, m, C8HH); 13C NMR (150 MHz, MeOH-d4)  205.7 (C9=O), 
175.5 (C=OOH), 172.9 (C1=O), 78.8 (C3HMe), 52.5 (C8aH), 49.6 (C3aH), 47.5 
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(C4H), 42.1 (C4aH), 33.2 (C5H2), 26.2 (C8H2), 25.9 (C6H2), 25.8 (C7H2), 20.1 
(C3HCH3), N.B. Peak for C9aH under solvent peak; IR (thin film) 2929 (C-H), 2858 
(C-H), 1778 (C=O), 1707 (C=O), 1320, 1190 (C-O), 1067, 752, 668 cm-1; m/z (EI) 
266 (100%, [M]+); HRMS (EI) calcd for C14H18O5 [M]+ 266.1149, observed 
266.1148. 
 
(3R,3aR,4S,4aR,8aR,9aS)-S-Ethyl 3-methyl-1,9-
dioxododecahydronaphtho[2,3-c]furan-4-carbothioate (67) 
 
EDCl (12.9 mg, 0.08 mmol) was added to a stirred solution of 
(3R,3aS,4S,4aR,8aR,9aS)-3-methyl-1,9-dioxododecahydronaphtho[2,3-c]furan-4-
carboxylic acid (66) (14.7 mg, 0.06 mmol), ethanethiol (15.9 µL, 0.22 mmol) and 
DMAP (0.37 mg, cat.) in CH2Cl2 (1 mL) at 0 °C, under Ar. The reaction mixture was 
stirred at 20 °C for 3 h before being diluted with CH2Cl2 (5 mL), washed (H2O), 
dried (MgSO4), filtered and concentrated in vacuo to yield a crude colourless oil. 
Purification by flash column chromatography (0-10% Et2O/CH2Cl2) yielded 
(3R,3aR,4S,4aR,8aR,9aS)-S-ethyl 3-methyl-1,9-dioxododecahydronaphtho[2,3-
c]furan-4-carbothioate (67) (4 mg, 0.01 mmol, 23%) as a white solid; 1H NMR (600 
MHz, CDCl3)  4.53 (1H, dq, J = 10.2, 6.0, C3HMe), 3.51 (1H, d, J = 8.7, C9aH), 
3.13 (1H, dd, J = 10.5, 5.3, C4H), 2.99 (1H, td, J = 9.3, 5.5, C3aH), 2.94 (1H, q, J = 
7.5, SCH2CH3), 2.14-2.07 (2H, m, C4aH & C8aH), 1.97-1.92 (1H, m, C8HH), 1.89-
1.81 (2H, m, C6HH & C7HH), 1.75-1.70 (1H, m, C5HH), 1.42-1.35 (1H, m, C8HH), 
1.29 (3H, t, J = 7.5, SCH2CH3), 1.26 (3H, d, J = 6.0, C3HCH3), 1.24-1.17 (2H, m, 
C6HH & C7HH), 1.13-1.06 (1H, m, C5HH); 13C NMR (150 MHz, CDCl3)  202.4 
(C9=O), 199.7 (C=OSEt), 169.8 (C1=O), 77.6 (C3HMe), 56.1 (C9aH), 55.7 (C4H), 
52.3 (C8aH), 48.8 (C3aH), 41.4 (C4aH), 31.9 (C5H2), 25.0 (C8H2), 24.8 (C6H2), 24.8 
(C7H2), 23.9 (CH2CH3), 20.3 (C3HCH3), 14.7 (CH2CH3); IR (thin film) 2930 (C-H), 
2855 (C-H), 1774 (C=O), 1714 (C=O), 1678 (C=O), 1262, 1196 (C-O), 1098, 960, 
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729 cm-1; m/z (EI) 252 (100%, [M-SEt-Me+OH]+); HRMS (EI) calcd for C16H22O4S 
[M+H]+ 310.1233, observed 310.1231. 
 
1-(4-Methoxybenzyl) 5-methyl 3-(4-iodobutyl)pentanedioate (68) 
 
n-BuLi (2.5 M in hexanes) (15.6 mL, 39.0 mmol) was added dropwise to a stirred 
solution of DIPA (5.56 mL, 39.0 mmol) in anhydrous 2-MeTHF (30 mL) at -78 °C, 
under N2. The reaction mixture was stirred at -78 °C for 15 min before 4-
methoxybenzyl acetate (6.39 mL, 39.0 mmol) was added dropwise and stirring 
continued for 30 min at -78 °C. Next, a solution of 43 (5.23 g, 19.51 mmol) in 
anhydrous 2-MeTHF (10 mL) was added and stirring continued for 45 min at -78 
°C. Finally, solid KOt-Bu (4.38 g, 39.0 mmol) was added. The reaction mixture was 
stirred for a further 1 h and then quenched with sat. aq. NH4Cl (100 mL). An 
extraction into 2-MeTHF (2 x 100 mL) was completed and the combined organic 
layers were dried (hydrophobic frit) and concentrated in vacuo to yield a crude 
yellow oil. Purification by automated column chromatography (0-30% 
EtOAc/cyclohexane) yielded 1-(4-methoxybenzyl) 5-methyl 3-(4-
iodobutyl)pentanedioate (68) (1.81 g, 4.04 mmol, 21%) as a colourless oil and 
some impure rac-methyl 2-(2-((4-methoxybenzyl)oxy)-2-
oxoethyl)cyclohexanecarboxylate (69). Further purification by MDAP (MeCN/H2O 
with an (NH4)HCO3 modifier) yielded 69 (32 mg, 0.1 mmol, 0.5%). 
 
Data for 1-(4-methoxybenzyl) 5-methyl 3-(4-iodobutyl)pentanedioate (68): 
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1H NMR (400 MHz, Acetone-d6)  7.35 (2H, d, J = 8.6, 2 x Ar-CH), 6.94 (2H, d, J = 
8.7, 2 x Ar-CH), 5.06 (2H, s, Bn-CH2), 3.82 (3H, s, Bn-OCH3), 3.63 (3H, s, 
COOCH3), 3.26 (2H, d, J = 6.8, CH2I), 2.43-2.30 (5H, m, CH2COOMe, CH2COOBn 
& CHCH2COOMe), 1.83-1.75 (2H, m, CH2CH2I), 1.48-1.35 (4H, m, 2 x CH2); 13C 
NMR (100 MHz, Acetone-d6)  172.3 (C=OOMe), 171.7 (C=OOBn), 159.8 (Ar-
COMe), 130.0 (2 x Ar-CH), 128.6 (Ar-CCH2), 113.8 (2 x Ar-CH), 65.4 (Bn-CH2), 
54.7 (Ar-OCH3), 50.7 (COOCH3), 38.1 (CH2C=O), 37.8 (CH2C=O), 33.4 (CH2CH2I), 
32.4 (CHCH2COOMe), 31.9 (CH2), 27.2 (CH2), 6.5 (CH2I); IR (thin film) 2936 (C-H), 
2838 (C-H), 1731 (C=O), 1613 (ArC-C), 1515 (ArC-C), 1247 (C-O), 1172, 1150, 
1033, 823 cm-1; m/z (ES+) 466 (100%, M[NH4]+); HRMS (EI) calcd for C18H25O5I 
[M+H]+ 448.0741, observed 448.0756. 
 
Data for rac-Methyl 2-(2-((4-methoxybenzyl)oxy)-2-
oxoethyl)cyclohexanecarboxylate (69): 
 
1H NMR (400 MHz, Acetone-d6)  7.33 (2H, d, J = 8.7, 2 x Ar-CH), 6.94 (2H, d, J = 
8.7, 2 x Ar-CH), 5.04 (2H, s, Bn-CH2), 3.81 (3H, s, Bn-OCH3), 3.62 (3H, s, 
COOCH3), 2.38 (1H, dd, J = 15.0, 3.7, C2H), 2.21-2.12 (1H, m, C1H), 2.12 (2H, d, J 
= 14.9, CH2COOBn), 1.92-1.85 (1H, m, C3HH), 1.84-1.77 (1H, m, C6HH), 1.76-1.67 
(2H, m, C4HH & C5HH), 1.50-1.39 (1H, m, C3HH), 1.33-1.23 (2H, m, C4HH & 
C5HH), 1.14-1.03 (1H, m, C6HH); 13C NMR (100 MHz, Acetone-d6)  174.9 
(C=OOMe), 171.4 (C=OOBn), 159.7 (Ar-COMe), 129.9 (2 x Ar-CH), 128.6 (Ar-
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CCH2), 113.7 (2 x Ar-CH), 65.3 (Bn-CH2), 54.7 (Ar-OCH3), 50.7 (COOCH3), 48.4 
(C2H), 39.1 (C1H), 36.1 (CH2C=O), 31.0 (C6H2), 29.7 (C3H2), 25.3 (C5H2), 25.0 
(C4H2); IR (thin film) 2933 (C-H), 2857 (C-H), 1730 (C=O), 1613 (ArC-C), 1515 
(ArC-C), 1447, 1247 (C-O), 1151, 1105, 1032, 976, 822 cm-1; m/z (ES+) 320 
(100%, [M+H]+); HRMS (EI) calcd for C18H24O5 [M+H]+ 320.1618, observed 
320.1613. 
  
(1R*,2S*)-Methyl 2-(2-((4-methoxybenzyl)oxy)-2-
oxoethyl)cyclohexanecarboxylate (69) 
 
LDA (2 M in THF/pentane/ethylbenzene) (2.52 mL, 5.04 mmol) was added 
dropwise to a stirred solution of 1-(4-methoxybenzyl) 5-methyl 3-(4-
iodobutyl)pentanedioate (68) (1.41 g, 3.15 mmol) in anhydrous 2-MeTHF (7 mL) at 
-78 °C, under N2. The reaction mixture was stirred at -78 °C for 3 h and then 
quenched with sat. aq. NH4Cl (10 mL). An extraction into 2-MeTHF (25 mL) was 
completed and the organic layer was dried (hydrophobic frit) and concentrated in 
vacuo to yield a crude yellow oil. Purification by automated column 
chromatography (0-25% t-BME/cyclohexane) yielded rac-methyl 2-(2-((4-
methoxybenzyl)oxy)-2-oxoethyl)cyclohexanecarboxylate (69) (917 mg, 2.86 mmol, 
91%) as a colourless oil. See data above. 
 
(S)-3-Acetyl-4-isopropyloxazolidin-2-one (70) 
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n-BuLi (1.6 M in hexanes) (5.81 mL, 9.29 mmol) was added dropwise to a stirred 
solution of (S)-4-isopropyloxazolidin-2-one (1.00 g, 7.74 mmol) in anhydrous 2-
MeTHF (20 mL) at -78 °C, under N2. The reaction mixture was stirred at -78 °C for 
30 min before acetyl chloride (1 M in CH2Cl2) (9.29 mL, 9.29 mmol) was added. 
The reaction mixture was stirred for a further 30 min and then quenched with sat. 
aq. NH4Cl (10 mL). An extraction into 2-MeTHF (2 x 20 mL) was completed and 
the organic layer was dried (hydrophobic frit) and concentrated in vacuo to yield a 
crude yellow oil. Purification by automated column chromatography (0-50% 
EtOAc/cyclohexane) yielded (S)-3-acetyl-4-isopropyloxazolidin-2-one (70) (1.18 g, 
6.90 mmol, 89%) as a colourless oil; 1H NMR (400 MHz, Acetone-d6)  4.46 (1H, 
ddd, J = 8.2, 3.8, 3.0, CHN), 4.38 (1H, dd, J = 8.9, 8.2, CHHCHN), 4.32 (1H, dd, J 
= 8.9, 3.0, CHHCHN), 2.43 (3H, s, CH3), 2.33 (1H, td, J = 7.0, 3.8, CH(CH3)2), 0.93 
(3H, d, J = 7.0, CH(CH3)2), 0.88 (3H, d, J = 7.0, CH(CH3)2); 13C NMR (100 MHz, 
Acetone-d6)  169.4 (C=O), 154.3 (C=OCH3), 63.3 (CH2), 58.2 (CHN), 28.6 
(CH(CH3)2), 22.8 (C=OCH3), 17.1 (CH(CH3)2), 14.1 (CH(CH3)2); IR (thin film) 2964 
(C-H), 1776 (C=O), 1697 (C-O), 1373, 1302, 1205, 1150 (C-O), 1062, 968, 773, 
620 cm-1; m/z (ES+) 172 (100%, [M+H]+); HRMS (EI) calcd for C8H13NO3 [M]+ 
171.0890, observed 171.0899. 
 
Pyridin-2-yl acetate152 (71) 
 
Acetyl chloride (1 M in CH2Cl2) (21.0 mL, 21.0 mmol) was added dropwise to a 
stirred solution of pyridin-2(1H)-one (2.00 g, 21.0 mmol) and pyridine (1.70 mL, 
21.0 mmol) in CH2Cl2 (50 mL) at 0 °C, under N2. The reaction mixture was stirred 
at 20 °C for 2 h before being concentrated in vacuo to half its volume. The organic 
layer was washed with sat. aq. brine (10 mL), dried (hydrophobic frit) and 
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concentrated in vacuo to yield a crude yellow oil. Purification by automated column 
chromatography (0-100% EtOAc/cyclohexane) yielded pyridin-2-yl acetate (71) 
(937 mg, 6.8 mmol, 33%) as a colourless oil; 1H NMR (600 MHz, CDCl3)  8.43 
(1H, ddd, J = 4.9, 2.0, 0.9, CHCHCN), 7.81 (1H, ddd, J = 8.1, 7.4, 2.0, CHN), 7.25 
(1H, ddd, J = 7.4, 4.9, 0.9, CHCN), 7.10 (1H, dt, J = 8.1, 0.9, CHCHN), 2.36 (3H, s, 
CH3); 13C NMR (150 MHz, CDCl3) 169.0 (C=O), 157.8 (CN), 148.5 (CHCHCN), 
139.6 (CHN), 122.1 (CHCN), 116.5 (CHCHN), 21.2 (CH3); IR (thin film) 2955 (C-H), 
1643 (ArC-C), 1595 (ArC-C), 1539 (ArC-C), 1464 (ArC-N), 1426 (ArC-N), 1224, 
1155 (C-O), 989, 770, 726, 560, 514 cm-1; m/z (ES+) 138 (100%, [M+H]+). Data 
agrees with that reported by Usami et al..152 
 
rac-4-Methoxybenzyl 1,9-dioxododecahydronaphtho[2,3-c]furan-4-
carboxylate (72) 
 
n-BuLi (1.6 M in hexanes) (3.76 mL, 6.01 mmol) was added dropwise to a stirred 
solution of distilled TMP (1.02 mL, 6.01 mmol) in anhydrous 2-MeTHF (5 mL) 
stirred at -78 °C, under N2. The solution was warmed to 0 °C and then re-cooled to 
-78 °C. A solution of (1R*,2S*)-methyl 2-(2-((4-methoxybenzyl)oxy)-2-
oxoethyl)cyclohexanecarboxylate (69) (917 mg, 2.86 mmol) in anhydrous 2-MeTHF 
(5 mL) was added dropwise and stirring continued for 45 min at -78 °C. Next, neat 
furan-2(5H)-one (0.12 mL, 1.72 mmol) was added and stirring continued for 2 h at -
78 °C. Finally, solid KOt-Bu (674 mg, 6.01 mmol) was added. The reaction mixture 
was warmed to -40 °C, stirred for a further 3 h and then quenched with sat. aq. 
NH4Cl (20 mL). An extraction into 2-MeTHF (20 mL) was completed and the 
organic layer was dried (hydrophobic frit) and concentrated in vacuo to yield a 
crude yellow oil with white precipitate. Purification by automated column 
chromatography (0-50% EtOAc/cyclohexane) yielded several crude samples of 
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varying stereoisomers. Further purifications by MDAP (MeCN/H2O with an 
(NH4)HCO3 modifier) yielded (3aS*,4R*,4aS*,8aS*,9aS*)-4-methoxybenzyl 1,9-
dioxododecahydronaphtho[2,3-c]furan-4-carboxylate (73) (20 mg, 0.05 mmol, 2%) 
and (3aS*,4S*,4aS*,8aS*,9aS*)-4-methoxybenzyl 1,9-
dioxododecahydronaphtho[2,3-c]furan-4-carboxylate (74) (20 mg, 0.05 mmol, 2%) 
as white solids. 
 
Data for (3aS*,4R*,4aS*,8aS*,9aS*)-4-methoxybenzyl 1,9-
dioxododecahydronaphtho[2,3-c]furan-4-carboxylate (73): 
 
1H NMR (600 MHz, CDCl3)  7.31 (2H, d, J = 8.7, 2 x Ar-CH), 6.92 (2H, d, J = 8.7, 
2 x Ar-CH), 5.17 (1H, d, J = 11.9, Bn-CHH), 5.13 (1H, d, J = 11.9, Bn-CHH), 4.16 
(1H, d, J = 1.3, C3HH), 4.16 (1H, d, J = 3.8, C3HH), 3.84 (3H, s, Bn-OCH3), 3.50 
(1H, d, J = 7.6, C9aH), 3.19 (1H, dddd, J = 11.4, 7.6, 3.8, 1.3, C3aH), 2.56 (1H, t, J = 
11.4, C4H), 2.17-2.12 (1H, m, C8HH), 2.04-1.98 (1H, m, C8aH), 1.84-1.63 (4H, m, 
C4aH, C5HH, C6HH & C7HH), 1.26-1.10 (4H, m, C5HH, C6HH, C7HH & C8HH); 13C 
NMR (150 MHz, CDCl3)  201.4 (C9=O), 172.8 (C=OOBn), 171.1 (C1=O), 160.0 
(Ar-COMe), 130.3 (2 x Ar-CH), 127.3 (Ar-CCH2), 114.1 (2 x Ar-CH), 70.3 (C3H2), 
67.0 (Bn-CH2), 55.3 (Ar-OCH3), 53.2 (C9aH), 51.1 (C8aH), 50.2 (C4H), 42.7 (C4aH), 
42.5 (C3aH), 31.6 (C5H2), 25.0 (C8H2), 24.9 (C6H2), 24.6 (C7H2); IR (thin film) 2932 
(C-H), 2857 (C-H), 1778 (C=O), 1723 (C-O), 1613 (ArC-C), 1515 (ArC-C), 1247, 
1163 (C-O), 1029, 996, 916, 823, 733 cm-1; m/z (ES+) 390 (100%, M[NH4+]+); 
HRMS (EI) calcd for C21H24O6 [M+H]+ 372.1567, observed 372.1569. 
 
Data for (3aS*,4S*,4aS*,8aS*,9aS*)-4-methoxybenzyl 1,9-
dioxododecahydronaphtho[2,3-c]furan-4-carboxylate (74): 
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1H NMR (600 MHz, CDCl3)  7.33 (2H, d, J = 8.7, 2 x Ar-CH), 6.93 (2H, d, J = 8.7, 
2 x Ar-CH), 5.18 (1H, d, J = 11.8, Bn-CHH), 5.14 (1H, d, J = 11.8, Bn-CHH), 4.38 
(1H, dd, J = 9.1, 8.2, C3HH), 3.95 (1H, dd, J = 10.6, 9.1, C3HH), 3.84 (3H, s, Bn-
OCH3), 3.73 (1H, d, J = 8.8, C9aH), 3.26 (1H, dddd, J = 10.6, 8.8, 8.2, 1.2, C3aH), 
2.68 (1H, dd, J = 4.9, 1.2, C4H), 2.61 (1H, td, J = 12.0, 3.7, C8aH), 2.04-1.99 (1H, 
m, C8HH), 1.92-1.86 (1H, m, C4aH), 1.81-1.70 (3H, m, C5HH, C6HH & C7HH), 1.34-
1.26 (1H, m, C8HH), 1.23-1.08 (3H, m, C5HH, C6HH & C7HH); 13C NMR (150 MHz, 
CDCl3)  203.3 (C9=O), 172.6 (C=OOBn), 171.4 (C1=O), 160.0 (Ar-COMe), 130.5 
(2 x Ar-CH), 127.2 (Ar-CCH2), 114.1 (2 x Ar-CH), 69.2 (C3H2), 66.9 (Bn-CH2), 55.3 
(Ar-OCH3), 52.6 (C9aH), 48.1 (C8aH), 44.0 (C4H), 40.4 (C4aH), 40.0 (C3aH), 31.2 
(C5H2), 25.7 (C8H2), 25.5 (C6H2), 24.6 (C7H2); IR (thin film) 2933 (C-H), 2858 (C-H), 
1790 (C=O), 1721 (C=O), 1613 (ArC-C), 1515 (ArC-C), 1448 (ArC-C), 1303 (C-O), 
1249 (C-O), 1202, 1169, 1032, 948, 823, 731 cm-1; m/z (ES+) 390 (100%, 
M[NH4+]+); HRMS (EI) calcd for C21H24O6 [M+H]+ 372.1567, observed 372.1568. 
 
rac-tert-Butyl 1,9-dioxododecahydronaphtho[2,3-c]furan-4-carboxylate 
(44) 
 
n-BuLi (2.7 M in heptanes) (12.8 mL, 34.5 mmol) was added dropwise to a stirred 
solution of distilled TMP (5.87 mL, 34.5 mmol) in anhydrous 2-MeTHF (40 mL) at -
78 °C, under N2. The solution was warmed to 0 °C and then re-cooled to -78 °C. A 
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solution of (1R*,2S*)-methyl 2-(2-(tert-butoxy)-2-oxoethyl)cyclohexanecarboxylate 
(43) (4.21 g, 16.4 mmol) in anhydrous 2-MeTHF (40 mL) was added dropwise and 
stirring continued for 30 min at -78 °C. Next, neat furan-2(5H)-one (0.58 mL, 8.21 
mmol) was added dropwise. The reaction mixture was stirred for a further 3 h, 
quenched with sat. aq. NH4Cl (50 mL) and diluted with H2O (25 mL). An extraction 
into EtOAc (2 x 50 mL) was completed and the combined organic layers were 
washed with sat. aq. brine (30 mL), dried (hydrophobic frit) and concentrated in 
vacuo to yield a crude yellow oil with white precipitate. Purification by automated 
column chromatography (0-100% EtOAc/cyclohexane) yielded 
(3aS*,4R,4aS*,8aS*,9aS*)-tert-butyl 1,9-dioxododecahydronaphtho[2,3-c]furan-4-
carboxylate (45) (663 mg, 2.15 mmol, 26%) and (3aS*,4R*,4aR*,8aR*,9aS*)-tert-
butyl 1,9-dioxododecahydronaphtho[2,3-c]furan-4-carboxylate (47) (644 mg, 2.09 
mmol, 25%) as white solids. Further purification by MDAP (MeCN/H2O with an 
(NH4)HCO3 modifier) yielded (3aS*,4R*,4aS*,8aS*,9aS*)-tert-butyl1,9-
dioxododecahydronaphtho[2,3-c]furan-4-carboxylate (75) (25 mg, 0.04 mmol, 1%) 
as a white solid. 
 
Data for (3aS*,4R*,4aS*,8aS*,9aS*)-tert-butyl 1,9-dioxododecahydronaphtho[2,3-
c]furan-4-carboxylate (45): 
 
1H NMR (600 MHz, CDCl3)  4.22 (1H, d, J = 3.8, C3HH), 4.21 (1H, s, C3HH), 3.49 
(1H, d, J = 7.5, C9aH), 3.15 (1H, ddd, J = 11.5, 7.5, 3.8, C3aH), 2.41 (1H, t, J = 11.5, 
C4H), 2.14-2.10 (1H, m, C8HH), 2.01-1.96 (1H, m, C8aH), 1.82-1.66 (4H, m, C4aH, 
C5HH, C6HH & C7HH), 1.48 (9H, s, C(CH3)3), 1.46-1.41 (1H, m, C8HH), 1.25-1.12 
(3H, m, C5HH, C6HH & C7HH); 13C NMR (150 MHz, CDCl3)  201.9 (C9=O), 172.4 
(C=OOtBu), 171.5 (C1=O), 82.5 (C(CH3)3), 70.5 (C3H2), 53.3 (C9aH), 51.3 (C8aH), 
51.0 (C4H), 42.8 (C4aH), 42.8 (C3aH), 31.5 (C8H2), 28.2 (C(CH3)3), 25.1 (C5H2), 25.0 
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(C6H2), 24.8 (C7H2); IR (thin film) 2974 (C-H), 2929 (C-H), 2856 (C-H), 1795 (C=O), 
1715 (C=O), 1367 (C-H), 1244 (C-O), 1157, 1021, 845 cm-1; m/z (ES+) 326 (100%, 
M[NH4+]+); HRMS (EI) calcd for C17H24O5 [M+H]+ 308.1618, observed 308.1613. 
 
Data for (3aS*,4R*,4aR*,8aR*,9aS*)-tert-butyl 1,9-dioxododecahydronaphtho[2,3-
c]furan-4-carboxylate (47): 
 
1H NMR (600 MHz, CDCl3)  4.39 (1H, t, J = 8.3, C3HH), 3.94 (1H, t, J = 9.8, 
C3HH), 3.72 (1H, d, J = 8.7, C9aH), 3.25 (1H, ddd, J = 9.8, 8.7, 8.3, C3aH), 2.66 
(1H, td, J = 12.0, 3.6, C8aH), 2.53 (1H, d, J = 4.5, C4H), 2.03 (1H, d, J = 14.7, 
C8HH), 1.85 (1H, tdd, J = 12.0, 4.5, 3.4, C4aH), 1.84-1.76 (3H, m, C5HH, C6HH & 
C7HH), 1.50 (9H, s, C(CH3)3), 1.49-1.42 (1H, m, C8HH), 1.36-1.15 (3H, m, C5HH, 
C6HH & C7HH); 13C NMR (150 MHz, CDCl3)  203.8 (C9=O), 172.0 (C=OOtBu), 
171.8 (C1=O), 82.5 (C(CH3)3), 69.5 (C3H2), 52.9 (C9aH), 48.2 (C8aH), 44.9 (C4H), 
40.6 (C4aH), 40.3 (C3aH), 31.4 (C8H2), 28.3 (C(CH3)3), 25.9 (C5H2), 25.7 (C6H2), 
25.1 (C7H2); IR (thin film) 2926 (C-H), 2850 (C-H), 1778 (C=O), 1715 (C=O), 1698 
(C=O), 1365 (C-H), 1204 (C-O), 1138, 1002, 845 cm-1; m/z (ES+) 326 (100%, 
M[NH4+]+); HRMS (ES-) calcd for C17H23O5 [M-H]+ 307.1545, observed 307.1546. 
 
Data for (3aS*,4R*,4aS*,8aS*,9aS*)-tert-butyl1,9-dioxododecahydronaphtho[2,3-
c]furan-4-carboxylate (75): 
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1H NMR (600 MHz, CDCl3)  4.27 (1H, dd, J = 9.8, 7.8, C3HH), 4.18 (1H, dd, J = 
11.2, 9.8, C3HH), 3.43 (1H, d, J = 8.2, C9aH), 3.38 (1H, dddd, J = 11.4, 8.2, 7.8, 
5.2, C3aH), 2.84 (1H, dd, J = 11.3, 5.2, C4H), 2.13 (1H, td, J = 11.7, 3.0, C8aH), 
2.00-1.90 (2H, m, C4aH & C8HH), 1.90-1.82 (2H, m, C6HH & C7HH), 1.82-1.75 (1H, 
m, C5HH,), 1.50 (9H, s, C(CH3)3), 1.48-1.37 (1H, m, C8HH), 1.29-1.17 (3H, m, 
C5HH, C6HH & C7HH); 13C NMR (150 MHz, CDCl3)  202.8 (C9=O), 171.4 
(C=OOtBu), 171.0 (C1=O), 82.4 (C(CH3)3), 68.4 (C3H2), 54.3 (C9aH), 52.3 (C8aH), 
48.3 (C4H), 41.1 (C4aH), 40.6 (C3aH), 32.1 (C8H2), 28.3 (C(CH3)3), 25.2 (C5H2), 25.0 
(C6H2), 24.7 (C7H2); IR (thin film) 2974 (C-H), 2929 (C-H), 2856 (C-H), 1795 (C=O), 
1715 (C=O), 1367 (C-H), 1244 (C-O), 1157, 1021, 845 cm-1; m/z (ES+) 326 (100%, 
M[NH4+]+); HRMS (EI) calcd for C17H24O5 [M]+ 308.1618, observed 308.1614. 
 
5-(3-(Trifluoromethyl)phenyl)pyrimidin-2-ol (76) 
 
A solution of 5-bromopyrimidin-2-ol (2.00 g, 11.4 mmol), (3-
(trifluoromethyl)phenyl)boronic acid (2.60 g, 13.7 mmol), PdCl2(dppf) (0.04 g, 0.06 
mmol) and K2CO3 (4.74 g, 34.3 mmol) in a deoxygenated mixture of iPrOH (15 mL) 
and H2O (3 mL) was heated in a sealed microwave vessel at 120 °C for 30 min 
using a Biotage Initiator 60. Once cooled, the reaction mixture was diluted with 
H2O (10 mL). An extraction into EtOAc (25 mL) was completed and the organic 
layer was dried (hydrophobic frit) and concentrated in vacuo to yield a crude black 
oily solid. Purification by automated column chromatography (0-25% EtOAc/3:1 
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EtOAc:EtOH) yielded 5-(3-(trifluoromethyl)phenyl)pyrimidin-2-ol (76) (200 mg, 0.83 
mmol, 7%) as a brown solid; 1H NMR (400 MHz, MeOH-d4)  8.67 (2H, s, 2 x 
CHN), 7.91-7.89 (1H, m, CCHCCF3), 7.88-7.84 (1H, m, CHCHCCF3), 7.70 (1H, d, 
J = 1.2, CHCCHCCF3), 7.69-7.68 (1H, m, CHCHCCF3); 13C NMR (150 MHz, 
CDCl3)  158.5 (COH), 135.7 (2 x CHN), 132.7 (CCHCCF3), 131.3 (q, J = 32.2, 
CCF3), 130.6 (CHCCHCCF3), 129.2 (CHCHCCF3), 125.6 (q, J = 3.6, CCHCCF3), 
123.6 (q, J = 3.6, CHCHCCF3), 118.8 (CCHN), 123.9 (d, J = 271.8, CF3); IR (thin 
film) 1693, 1477 (ArC-C), 1381 (ArC-C), 1328 (ArC-N), 1275 (ArC-N), 1222 (C-O), 
1164, 1122, 1077, 1048, 1011, 930, 804, 705 cm-1; m/z (ES+) 241 (100%, [M+H]+); 
HRMS (ES+) calcd for C11H8N2OF3 [M+H]+ 241.0589, observed 241.0585. 
 
5-(3-(Trifluoromethyl)phenyl)pyrimidin-2-yl trifluoromethanesulfonate 
(77) 
 
N,N-Bis(triflouromethylsulfonyl)analine (1.44 g, 3.71 mmol) was added to a stirred 
solution of 5-(3-(trifluoromethyl)phenyl)pyrimidin-2-ol (76) (0.89 g, 3.71 mmol) and 
K2CO3 (1.54 g, 11.1 mmol) in DMF (10 mL) under N2. The reaction mixture was 
stirred at 20 °C for 1 h and then quenched with sat. aq. NH4Cl (5 mL). An 
extraction into 2-MeTHF (2 x 10 mL) was completed and the combined organic 
layers were dried (hydrophobic frit) and concentrated in vacuo to yield a crude 
brown oil. Purification by automated column chromatography (0-25% MeOH/t-
BME) yielded a crude orange oil. Further purification by automated column 
chromatography (0-25% EtOAc/cyclohexane) yielded a still crude yellow oil. 
Finally, purification by MDAP (MeCN/H2O with an (NH4)HCO3 modifier) yielded 5-
(3-(trifluoromethyl)phenyl)pyrimidin-2-yl trifluoromethanesulfonate (77) (96.3 mg, 
0.26 mmol, 7%) as a colourless oil; 1H NMR (400 MHz, MeOH-d4)  9.20 (2H, s, 2 
x CHN), 8.10 (1H, s, CCHCCF3), 8.04 (1H, d, J = 7.8, CHCHCCF3), 7.85 (1H, d, J 
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= 7.8, CHCCHCCF3), 7.78 (1H, d, J = 7.8, CHCHCCF3); 13C NMR (100 MHz, 
MeOH-d4)  159.1 (2 x CHN), 158.0 (OCN), 133.8 (CHCCHCCF3), 133.7 
(CCHCCF3), 131.5 (q, J = 32.8, CCF3), 130.9 (CHCHCCF3), 130.1 (CCHN), 125.8 
(q, J = 3.6, CHCHCCF3), 123.8 (q, J = 3.6, CCHCCF3), 124.0 (d, J = 271.5, CF3), 
113.1 (d, J = 271.8, SCF3); IR (thin film) 3382, 2490, 1414 (ArC-C), 1337 (ArC-C), 
1287 (ArC-N), 1214 (C-F), 1127 (S=O), 902 cm-1; m/z (ES+) 373 (86%, [M+H]+); 
HRMS (EI) calcd for C12H6N2O3F6 [M]+ 371.9998, observed 371.9996. 
 
2-Ethynyl-5-(3-(trifluoromethyl)phenyl)pyrimidines (79) 
 
A solution of 5-(3-(trifluoromethyl)phenyl)pyrimidin-2-yl trifluoromethanesulfonate 
(77) (95.0 mg, 0.26 mmol), ethynyltrimethylsilane (0.07 mL, 0.51 mmol), 
PdCl2(PPh3)2 (9.00 mg, 0.01 mmol), CuI (2.43 mg, 0.01 mmol) and NEt3 (0.12 mL, 
0.77 mmol) in DMSO (0.2 mL) was heated in a sealed microwave vessel at 100 °C 
for 10 min using a Biotage Initiator 60. Based on LCMS analysis the desired 
intermediate, 5-(3-(trifluoromethyl)phenyl)-2-((trimethylsilyl)ethynyl)pyrimidine (78), 
had been formed. A solution of NaOH in MeOH (1M, 0.25 mL) was added. The 
reaction mixture was stirred for 1 h before being acidified with aq. HCl and then 
basified with solid K2CO3. An extraction into t-BME (2 x 5 mL) was completed and 
the combined organic layers dried (hydrophobic frit) and concentrated in vacuo to 
yield 2-ethynyl-5-(3-(trifluoromethyl)phenyl)pyrimidine (79) as a crude colourless 
oil. Purification by MDAP (MeCN/H2O with a formic acid modifier) yielded no 
product. The formation of the intermediate and the desired product was assumed 
based on LCMS analysis.  
 
Data for 5-(3-(trifluoromethyl)phenyl)-2-((trimethylsilyl)ethynyl)pyrimidine (78): 
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LCMS (System B) Rt. 1.39 min (64%) ES +ve m/z 321 (M+H)+ 
 
Data for 2-ethynyl-5-(3-(trifluoromethyl)phenyl)pyrimidine (79): 
 
LCMS (System B) Rt. 1.04 min (11%) ES +ve m/z 249 (M+H)+ 
 
5-(3-(Trifluoromethyl)phenyl)pyrimidine (80) 
 
A solution of 5-bromopyrimidine (100 mg, 0.63 mmol), (3-
(trifluoromethyl)phenyl)boronic acid (155 mg, 0.82 mmol), PdCl2(dppf) (23.0 mg, 
0.03 mmol) and K3PO4 (267 mg, 1.26 mmol) in deoxygenated iPrOH (2 mL) and 
H2O (0.5 mL) was heated in a Biotage Initiator 60 to 120 °C for 1 h. Once cooled, 
the reaction mixture was diluted with H2O (2 mL). An extraction into EtOAc (5 mL) 
was completed and the organic layer was dried (hydrophobic frit) and concentrated 
in vacuo to yield a crude brown oily solid. Purification by automated column 
chromatography (0-100% EtOAc/cyclohexane) yielded 5-(3-
(trifluoromethyl)phenyl)pyrimidine (80) (143 mg, 0.60 mmol, 96%) as a yellow solid; 
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1H NMR (400 MHz, CDCl3)  9.29 (1H, s, NCHN), 9.00 (2H, s, 2 x CHN), 7.87-7.83 
(1H, m, CCHCCF3), 7.82-7.74 (2H, m, CHCHCCF3 & CHCCHCCF3), 7.69 (1H, t, J 
= 7.7, CHCHCCF3); 13C NMR (150 MHz, CDCl3)  160.5 (NCN), 157.7 (2 x CHN), 
140.4 (CCHCCF3), 133.4 (q, J = 32.2, CCF3), 132.9 (CCHN), 130.6 
(CHCCHCCF3), 129.2 (CHCHCCF3), 128.2 (q, J = 3.6, CCHCCF3), 126.4 (q, J = 
3.6, CHCHCCF3), 124.0 (d, J = 271.8, CF3); IR (thin film) 1559 (ArC-C), 1407 (ArC-
C), 1335 (ArC-N), 1275 (ArC-N), 1172, 1118, 803, 722, 699 cm-1; m/z (ES+) 225 
(97%, [M+H]+); HRMS (ES+) calcd for C11H8N2F3 [M+H]+ 225.0649, observed 
225.0640.  
 
5,5'-Bis(3-(trifluoromethyl)phenyl)-4,4'-bipyrimidine (81) 
 
n-BuLi (1.6 M in hexanes) (0.89 mL, 1.43 mmol) was added to a stirred solution of 
distilled TMP (0.24 mL, 1.43 mmol) in anhydrous 2-MeTHF (1 mL) at -78 °C, under 
N2. The solution was warmed to 0 °C and then re-cooled to -78 °C. A solution of 5-
(3-(trifluoromethyl)phenyl)pyrimidine (80) (80.0 mg, 0.36 mmol) in anhydrous 2-
MeTHF (1 mL) was added dropwise and stirring continued for 2 h at -78 °C. Next, a 
solution of I2 (362 mg, 1.43 mmol) in anhydrous 2-MeTHF (1 mL) was added 
dropwise. The reaction mixture was stirred for a further 1 h and then quenched with 
sat. aq. NH4Cl (5 mL). An extraction into 2-MeTHF (2 x 5 mL) was completed and 
the combined organic layers were dried (hydrophobic frit) and concentrated in 
vacuo to yield a crude brown solid. Purification by automated column 
chromatography (0-100% EtOAc/cyclohexane) yielded 5,5'-bis(3-
(trifluoromethyl)phenyl)-4,4'-bipyrimidine (81) (43 mg, 0.10 mmol, 27%) as an 
orange solid; 1H NMR (400 MHz, Acetone-d6)  9.38 (2H, s, 2 x NCHN), 8.90 (2H, 
s, 2 x CHN), 7.67 (2H, d, J = 7.8, 2 x CHCCHCCF3), 7.48 (2H, t, J = 7.8, 2 x 
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CHCHCCF3), 7.12-7.06 (4H, m, 2 x CCHCCF3 & CHCHCCF3); 13C NMR (150 MHz, 
CDCl3)  165.9 (NCCN), 163.7 (2 x NCHN), 163.1 (2 x CCHN), 139.7 (2 x 
CCHCCF3), 137.6 (CHCCHCCF3), 137.2 (CCHN), 137.1 (CHCHCCF3), 136.2 (q, J 
= 32.2, 2 x CCF3), 134.8 (q, J = 3.6, 2 x CCHCCF3), 130.6 (q, J = 3.6, 2 x 
CHCHCCF3), 128.9 (q, J = 180, 2 x CF3); IR (thin film) 1571 (ArC-C), 1420 (ArC-
C), 1335 (ArC-N), 1213 (ArC-N), 1170, 1118, 905, 808, 702, 597, 521 cm-1; m/z 
(ES+) 447 (100%, [M+H]+); HRMS (ES+) calcd for C22H13N4F6 [M+H]+ 447.1044, 
observed 447.1040. 
 
(3aS*,4R*,4aR*,8aR*,9aS*)-1,9-Dioxododecahydronaphtho[2,3-c]furan-4-
carboxylic acid (82) 
 
TFA (0.3 mL) was added dropwise to a stirred solution of 
(3aS*,4R*,4aR*,8aR*,9aS*)-tert-butyl 1,9-dioxododecahydronaphtho[2,3-c]furan-4-
carboxylate (47) (50.0 mg, 0.16 mmol) in anhydrous CH2Cl2 (0.3 mL) at 0 °C, under 
Ar. The reaction mixture was stirred at RT for 16 h before being concentrated in 
vacuo. The residue was azeotroped with toluene to yield 
(3aS*,4R*,4aR*,8aR*,9aS*)-1,9-dioxododecahydronaphtho[2,3-c]furan-4-carboxylic 
acid (82) (40.0 mg, 0.16 mmol, 99%) as a white solid; 1H NMR (600 MHz, MeOH-
d4)  4.43 (1H, dd, J = 9.2, 8.3, C3HH), 4.05 (1H, dd, J = 9.8, 9.2, C3HH), 3.75 (1H, 
d, J = 9.0, C9aH), 3.37 (1H, ddd, J = 9.8, 9.0, 8.3, C3aH), 2.72 (1H, d, J = 4.9, C4H), 
2.69-2.64 (1H, m, C8aH), 1.98-1.95 (1H, m, C8HH), 1.98 (1H, dddd, J = 13.2, 12.0, 
4.9, 3.0, C4aH), 1.87-1.82 (1H, m, C5HH), 1.82-1.75 (2H, m, C6HH & C7HH), 1.44-
1.35 (1H, m, C5HH), 1.32-1.21 (3H, m, C6HH, C7HH & C8HH); 13C NMR (150 MHz, 
MeOH-d4)  206.3 (C9=O), 176.4 (C=OOH), 174.6 (C1=O), 71.3 (C3H2), 54.1 
(C9aH), 49.4 (C8aH), 44.9 (C4H), 41.2 (C3aH), 41.0 (C4aH), 32.5 (C5H2), 27.0 (C8H2), 
26.7 (C6H2), 26.3 (C7H2); IR (thin film) 2936 (C-H), 2857 (C-H), 1759 (C=O), 1701 
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(C=O), 1170, 1000, 839, 800, 719, 645, 549 cm-1; m/z (ES+) 253 (100%, [M+H]+); 
HRMS (ES-) calcd for C13H15O5 [M-H]+ 251.0920, observed 251.0919. 
 
(3aR*,4R*,4aR*,8aR*,9aS*)-S-Ethyl 1,9-dioxododecahydronaphtho[2,3-
c]furan-4-carbothioate (83) 
 
DCC (29.7 mg, 0.14 mmol) was added to a stirred solution of 
(3aS*,4R*,4aR*,8aR*,9aS*)-1,9-dioxododecahydronaphtho[2,3-c]furan-4-carboxylic 
acid (82) (30.0 mg, 0.12 mmol), ethanethiol (26.0 µL, 0.36 mmol) and DMAP (7.00 
mg, cat.) in DMF (1 mL) at 0 °C, under Ar. The reaction mixture was stirred at 20 
°C for 2 h before being diluted with CH2Cl2 (10 mL) and washed with H2O (2 x 5 
mL). The organic layer was dried (MgSO4), filtered and concentrated in vacuo to 
yield a crude pink solid. Purification by column chromatography (0-50% Et2O/Pet. 
Ether) yielded (3aR*,4R*,4aR*,8aR*,9aS*)-S-ethyl 1,9-
dioxododecahydronaphtho[2,3-c]furan-4-carbothioate (83) (10.5 mg, 0.035 mmol, 
29%) as a white solid; 1H NMR (600 MHz, CDCl3)  4.38 (1H, dd, J = 9.0, 8.1, 
C3HH), 3.93 (1H, dd, J = 10.8, 9.0, C3HH), 3.68 (1H, d, J = 8.7, C9aH), 3.19 (1H, 
ddd, J = 10.9, 8.7, 8.1, C3aH), 2.94 (2H, qd, J = 7.5, 2.6, CH2CH3), 2.79 (1H, td, J = 
12.2, 12.0, 3.8, C8aH), 2.78 (1H, d, J = 4.5, C4H), 2.02-1.97 (1H, m, C8HH), 1.87 
(1H, dddd, J = 12.2, 12.0, 4.5, 3.8, C4aH), 1.83-1.75 (3H, m, C5HH, C6HH & C7HH), 
1.40-1.32 (1H, m, C8HH), 1.30 (3H, t, J = 7.5, CH2CH3), 1.28-1.21 (1H, m, C5HH), 
1.21-1.15 (2H, m, C6HH & C7HH); 13C NMR (150 MHz, CDCl3)  203.7 (C9=O), 
200.4 (C=OSEt), 171.5 (C1=O), 69.1 (C3H2), 53.1 (C9aH), 51.4 (C4H), 48.4 (C8aH), 
41.2 (C4aH), 40.7 (C3aH), 31.5 (C5H2), 25.7 (C8H2), 25.6 (C6H2), 24.8 (C7H2), 24.1 
(CH2CH3), 14.6 (CH2CH3); IR (thin film) 2931 (C-H), 2887 (C-H), 1793 (C=O), 1708 
(C=O), 1672 (C=O), 1203, 1137, 982, 897 cm-1; m/z (ES+) 297 (100%, [M+H]+); 
HRMS (ES-) calcd for C15H19O4S [M-H]+ 295.1003, observed 295.1004. 
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(3aS*,4aS*,8aR*,9aS*)-1,9-Dioxododecahydronaphtho[2,3-c]furan-4-
carbaldehyde (84) 
 
Neat triethylsilane (15 µL, 0.09 mmol) was added to a stirred suspension of 
(3aR*,4R*,4aR*,8aR*,9aS*)-S-ethyl 1,9-dioxododecahydronaphtho[2,3-c]furan-4-
carbothioate (83) (10.0 mg, 0.03 mmol), palladium on carbon (4.00 mg, 0.003 
mmol) in degassed acetone (0.2 mL). The reaction mixture was stirred at 20 °C for 
16 h before being filtered over celite and concentrated in vacuo. Purification by 
flash column chromatography (0-2% Et2O/CH2Cl2) gave partial racemisation at C4 
to yield (3aS*,4aS*,8aR*,9aS*)-1,9-dioxododecahydronaphtho[2,3-c]furan-4-
carbaldehyde (84) (4S:4R; 0.7:1) (7.00 mg, 0.03 mmol, 99%) as a white solid; 1H 
NMR (600 MHz, CDCl3)  10.11 (1H, s, 4S-CHO), 9.90 (1H, d, J = 1.5, 4R-CHO), 
4.47-4.44 (1H, m, 4R-C3HH), 4.38 (1H, dd, J = 9.0, 7.9, 4S-C3HH), 4.04-3.96 (2H, 
m, 4R-C3HH & 4S-C3HH), 3.61 (1H, d, J = 9.0, 4S-C9aH), 3.47-3.40 (3H, m, 4R-
C9aH, 4R-C3aH & 4S-C3aH), 3.09 (1H, dd, J = 11.7, 3.0, 4R-C4H), 2.83 (1H, d, J = 
4.5, 4S-C4H), 2.22 (1H, td, J = 11.7, 3.4, 4R-C8aH), 2.17 (1H, td, J = 11.7, 3.8, 4S-
C8aH), 2.11-1.94 (6H, m, 4R-C4aH, 4S-C4aH, 4R-C7HH, 4S-C7HH, 4R-C8HH & 4S-
C8HH), 1.90-1.74 (3H, m, 4R-C5HH, 4R-C7HH & 4S-C7HH), 1.71-1.63 (1H, m, 4S-
C5HH), 1.47-1.39 (1H, m, 4R-C8HH), 1.37-1.15 (7H, m, 4R-C5HH, 4S-C5HH, 4R-
C6HH, 4S-C6HH, 4R-C7HH, 4S-C7HH & 4S-C8HH); 13C NMR (150 MHz, CDCl3)  
202.8 (4S-C9=O), 202.8 (4R-C9=O), 202.6 (4R-CHO), 201.3 (4S-CHO), 171.4 (4R-
C1=O), 171.0 (4S-C1=O), 69.4 (4R-C3H2), 68.0 (4S-C3H2), 54.0 (4S-C9aH), 52.9 
(4S-C4H), 52.9 (4R-C9aH), 52.6 (4S-C8aH), 50.0 (4R-C4H), 49.4 (4R-C8aH), 41.0 
(4R-C4aH), 40.2 (4S-C4aH), 39.0 (4S-C3aH), 36.8 (4R-C3aH), 32.0 (4S-C5H2), 30.6 
(4R-C5H2), 26.0 (4R-C8H2), 25.7 (4S-C8H2), 24.9 (4S-C6H2 & 4R-C6H2), 24.8 (4R-
C7H2), 24.6 (4S-C7H2); IR (thin film) 2928 (C-H), 2858 (C-H), 1779 (C=O), 1705 
(C=O), 1208, 1165, 1120, 1016, 750 cm-1; m/z (ES+) 237 (100%, [M+H]+); HRMS 
(EI) calcd for C13H16O4 [M-H]+ 236.1043, observed 236.1044. 
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(3aS*,4aS*,8aR*,9aS*)-4-((E)-2-(5-(3-(Trifluoromethyl)phenyl)pyridin-2-
yl)vinyl)octahydronaphtho[2,3-c]furan-1,9(3H,9aH)-dione (85) 
 
n-BuLi (1.6 M in hexanes) (144 µL, 0.23 mmol) was added dropwise to a stirred 
solution of diethyl ((5-(3-(trifluoromethyl)phenyl)pyridin-2-yl)methyl)phosphonate 
(28) (79.0 mg, 0.21 mmol) in anhydrous THF (1 mL) at 0 °C, under Ar. The solution 
was stirred at 0 °C for 10 min before a solution of (3aS*,4aS*,8aR*,9aS*)-1,9-
dioxododecahydronaphtho[2,3-c]furan-4-carbaldehyde (84) (50 mg, 0.21 mmol) in 
anhydrous THF (1 mL) was added. The reaction mixture was stirred at 0 °C for 45 
min and then quenched with sat. aq. NH4Cl (10 mL). An extraction into EtOAc (2 x 
5 mL) was completed and the combined organic layers were dried (MgSO4), 
filtered and concentrated in vacuo to yield a crude yellow gum. Purification by flash 
column chromatography (0-2% Et2O/CH2Cl2) yielded (3aS*,4aS*,8aR*,9aS*)-4-
((E)-2-(5-(3-(trifluoromethyl)phenyl)pyridin-2-yl)vinyl)octahydronaphtho[2,3-c]furan-
1,9(3H,9aH)-dione (85) as a mixture of isomers. Purification by preparative TLC (0-
2% Et2O/CH2Cl2) yielded (3aS*,4R*,4aS*,8aR*,9aS*)-4-((E)-2-(5-(3-
(trifluoromethyl)phenyl)pyridin-2-yl)vinyl)octahydronaphtho[2,3-c]furan-
1,9(3H,9aH)-dione (86) (47.3 mg, 0.10 mmol, 49%) and 
(3aS*,4S*,4aS*,8aR*,9aS*)-4-((E)-2-(5-(3-(trifluoromethyl)phenyl)pyridin-2-
yl)vinyl)octahydronaphtho[2,3-c]furan-1,9(3H,9aH)-dione (87) (24.5 mg, 0.05 mmol, 
26%) as white solids. 
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Data for (3aS*,4R*,4aS*,8aR*,9aS*)-4-((E)-2-(5-(3-(trifluoromethyl)phenyl)pyridin-
2-yl)vinyl)octahydronaphtho[2,3-c]furan-1,9(3H,9aH)-dione (86): 
 
1H NMR (600 MHz, CDCl3)  8.82 (1H, s, CHN), 7.88 (1H, dd, J = 7.9, 2.3, 
CHCCHN), 7.82 (1H, s, CHCCF3), 7.77 (1H, d, J = 7.9, CHCCHCCF3), 7.67 (1H, d, 
J = 7.5, CHCHCCF3), 7.62 (1H, t, J = 7.5, CHCHCCF3), 7.34 (1H, d, J = 8.3, 
CHCN), 7.08 (1H, dd, J = 15.4, 9.8, CH=CH), 6.65 (1H, d, J = 15.1, CH=CH), 4.47 
(1H, t, J = 8.5, C3HH), 4.11 (1H, t, J = 9.8, C3HH), 3.61 (1H, d, J = 9.0, C9aH), 3.23 
(1H, ddd, J = 9.8, 9.0, 8.5, C3aH), 2.60 (1H, dd, J = 9.8, 3.6, C4H), 2.42 (1H, td, J = 
12.2, 3.6, C8aH), 2.07-2.02 (1H, m, C8HH), 1.91 (1H, tt, J = 12.2, 3.6, C4aH), 1.83-
1.78 (1H, m, C7HH), 1.78-1.73 (1H, m, C6HH), 1.72-1.67 (1H, m, C5HH), 1.48-1.40 
(2H, m, C8HH), 1.40-1.34 (1H, m, C5HH), 1.23-1.15 (2H, m, C6HH & C7HH); 13C 
NMR (150 MHz, CDCl3)  203.8 (C9=O), 171.6 (C1=O), 154.0 (CN), 148.2 (CHN), 
138.4 (CCHCCF3), 135.3 (CHCCHN), 134.2 (CCHN), 132.7 (CH=CH), 132.4 
(CH=CH), 131.8 (q, J = 32.1, CCF3), 130.3 (CHCCHCCF3), 129.8 (CHCHCCF3), 
125.0 (q, J = 3.6, CCHCCF3), 123.8 (q, J = 3.6, CHCHCCF3), 124.1 (d, J = 271.7, 
CF3), 122.3 (CHCN), 70.0 (C3H2), 52.5 (C9aH), 48.5 (C8aH), 43.5 (C3aH), 42.1 
(C4H), 41.6 (C4aH), 31.7 (C5H2), 25.8 (C8H2), 25.5 (C6H2), 25.0 (C7H2); IR (thin film) 
2930 (C-H), 2855 (C-H), 1784 (C=O), 1708 (C=O), 1478, 1440, 1335, 1164, 1124, 
1018, 755 cm-1; m/z (ES+) 456 (100%, [M+H]+); HRMS (ES-) calcd for 
C26H23NO3F3 [M-H]+ 454.1631, observed 454.1630. 
 
Purification by chiral column chromatography gave (+)-(3aS,4R,4aS,8aR,9aS)-4-
((E)-2-(5-(3-(trifluoromethyl)phenyl)pyridin-2-yl)vinyl)octahydronaphtho[2,3-c]furan-
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1,9(3H,9aH)-dione ((+)-86) with an [α]D25 = +13.2 (MeOH) and (-)-
(3aS,4R,4aS,8aR,9aS)-4-((E)-2-(5-(3-(trifluoromethyl)phenyl)pyridin-2-
yl)vinyl)octahydronaphtho[2,3-c]furan-1,9(3H,9aH)-dione ((-)-86) with an [α]D25 = -
13.4 (MeOH). 
 
Data for (3aS*,4S*,4aS*,8aR*,9aS*)-4-((E)-2-(5-(3-(trifluoromethyl)phenyl)pyridin-
2-yl)vinyl)octahydronaphtho[2,3-c]furan-1,9(3H,9aH)-dione (87): 
 
1H NMR (600 MHz, CDCl3)  8.79 (1H, d, J = 2.3, CHN), 7.87 (1H, dd, J = 8.1, 2.3, 
CHCCHN), 7.81 (1H, s, CHCCF3), 7.76 (1H, d, J = 7.5, CHCCHCCF3), 7.67 (1H, d, 
J = 7.5, CHCHCCF3), 7.61 (1H, t, J = 7.5, CHCHCCF3), 7.32 (1H, d, J = 8.3, 
CHCN), 6.70 (1H, d, J = 15.4, CH=CH), 6.49 (1H, dd, J = 15.4, 9.8, CH=CH), 4.43 
(1H, dd, J = 9.0, 8.3, C3HH), 4.15 (1H, dd, J = 11.7, 9.0, C3HH), 3.51 (1H, d, J = 
8.7, C9aH), 3.32 (1H, dddd, J = 11.7, 8.7, 8.3, 5.6, C3aH), 2.87 (1H, ddd, J = 11.3, 
9.8, 5.6, C4H), 2.21 (1H, td, J = 11.7, 3.0, C8aH), 2.00-1.93 (2H, m, C5HH & C8HH), 
1.87-1.82 (1H, m, C7HH), 1.75 (2H, qd, J = 11.3, 3.4, C4aH & C6HH), 1.49-1.40 
(1H, m, C8HH), 1.28-1.15 (2H, m, C6HH & C7HH), 1.13-1.05 (1H, m, C5HH); 13C 
NMR (150 MHz, CDCl3)  203.8 (C9=O), 171.7 (C1=O), 153.9 (CN), 148.2 (CHN), 
138.4 (CCHCCF3), 135.2 (CHCCHN), 134.2 (CCHN), 133.2 (CH=CH), 132.4 
(CH=CH), 131.8 (q, J = 32.1, CCF3), 130.3 (CHCCHCCF3), 129.8 (CHCHCCF3), 
125.0 (q, J = 3.6, CHCHCCF3), 123.8 (q, J = 3.6, CCHCCF3), 124.7 (d, J = 272.0, 
CF3), 122.0 (CHCN), 68.2 (C3H2), 54.7 (C9aH), 52.9 (C8aH), 45.3 (C4H), 44.6 
(C3aH), 42.9 (C4aH), 33.0 (C5H2), 25.2 (C8H2), 24.9 (C6H2), 24.8 (C7H2); IR (thin 
film) 2923 (C-H), 2853 (C-H), 1782 (C=O), 1703 (C=O), 1333, 1160, 1119, 1074, 
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1010, 801, 699 cm-1; m/z (ES+) 456 (100%, [M+H]+); HRMS (ES-) calcd for 
C26H23NO3F3 [M-H]+ 454.1616, observed 454.1630. 
 
Purification by chiral column chromatography gave (+)-(3aS,4S,4aS,8aR,9aS)-4-
((E)-2-(5-(3-(trifluoromethyl)phenyl)pyridin-2-yl)vinyl)octahydronaphtho[2,3-c]furan-
1,9(3H,9aH)-dione ((+)-87) with an [α]D25 = +30.4 (MeOH) and (-)-
(3aS,4S,4aS,8aR,9aS)-4-((E)-2-(5-(3-(trifluoromethyl)phenyl)pyridin-2-
yl)vinyl)octahydronaphtho[2,3-c]furan-1,9(3H,9aH)-dione ((-)-87) with an [α]D25 = -
31.6 (MeOH). 
 
(3aS*,4R*,4aS*,8aR*,9aS*)-9-Hydroxy-4-((E)-2-(5-(3-
(trifluoromethyl)phenyl)pyridin-2-yl)vinyl)decahydronaphtho[2,3-
c]furan-1(3H)-one (88) 
 
NaBH4 (0.58 mg, 0.015 mmol) was added to a stirred solution of 
(3aS*,4R*,4aS*,8aR*,9aS*)-4-((E)-2-(5-(3-(trifluoromethyl)phenyl)pyridin-2-
yl)vinyl)octahydronaphtho[2,3-c]furan-1,9(3H,9aH)-dione (86) (6.4 mg, 0.014 
mmol) in anhydrous THF (0.5 mL) and MeOH (0.5 mL) at 0 °C, under Ar. The 
reaction mixture was stirred at 0 °C for 15 min and then quenched with sat. aq. 
NH4Cl (0.5 mL). An extraction into Et2O (5 mL) was completed and the organic 
layer was dried (MgSO4), filtered and concentrated in vacuo to yield a crude yellow 
gum. Purification by flash column chromatography (0-2% Et2O/CH2Cl2) yielded 
(3aS*,4R*,4aS*,8aR*,9aS*)-9-hydroxy-4-((E)-2-(5-(3-
(trifluoromethyl)phenyl)pyridin-2-yl)vinyl)decahydronaphtho[2,3-c]furan-1(3H)-one 
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(88) as a mixture of isomers. Purification by preparative TLC (0-2% Et2O/CH2Cl2) 
yielded (3aS*,4R*,4aS*,8aR*,9S*,9aS*)-9-hydroxy-4-((E)-2-(5-(3-
(trifluoromethyl)phenyl)pyridin-2-yl)vinyl)decahydronaphtho[2,3-c]furan-1(3H)-one 
(89) (1.56 mg, 0.0034 mmol, 24%) and (3aS*,4R*,4aS*,8aR*,9R*,9aS*)-9-hydroxy-
4-((E)-2-(5-(3-(trifluoromethyl)phenyl)pyridin-2-yl)vinyl)decahydronaphtho[2,3-
c]furan-1(3H)-one (90) (0.48 mg, 0.001 mmol, 8%) as white solids. 
 
Data for (3aS*,4R*,4aS*,8aR*,9S*,9aS*)-9-hydroxy-4-((E)-2-(5-(3-
(trifluoromethyl)phenyl)pyridin-2-yl)vinyl)decahydronaphtho[2,3-c]furan-1(3H)-one 
(89): 
 
1H NMR (600 MHz, CDCl3)  8.80 (1H, d, J = 1.9, CHN), 7.86 (1H, dd, J = 7.9, 1.9, 
CHCCHN), 7.81 (1H, s, CHCCF3), 7.77 (1H, d, J = 7.5, CHCCHCCF3), 7.66 (1H, d, 
J = 7.5, CHCHCCF3), 7.61 (1H, t, J = 7.5, CHCHCCF3), 7.34 (1H, d, J = 8.3, 
CHCN), 6.89 (1H, dd, J = 15.2, 10.0, CH=CH), 6.54 (1H, d, J = 15.2, CH=CH), 4.44 
(1H, t, J = 8.7, C3HH), 4.17 (1H, dd, J = 11.7, 8.7, C3HH), 3.46 (1H, t, J = 10.0, 
C9H), 2.87 (1H, dt, J = 11.3, 8.7, C3aH), 2.69 (1H, dd, J = 9.6, 8.1, C9aH), 2.50 (1H, 
d, J = 1.5, OH), 2.41 (1H, dd, J = 9.8, 3.8, C4H), 2.36-2.31 (1H, m, C8HH), 1.78-
1.72 (2H, m, C6HH & C7HH), 1.55-1.45 (3H, m, C4aH, C5HH & C8aH), 1.37-1.17 
(4H, m, C5HH, C6HH, C7HH & C8HH); 13C NMR (150 MHz, CDCl3)  178.6 (C1=O), 
154.6 (CN), 148.2 (CHN), 138.6 (CCHCCF3), 135.1 (CHCCHN), 134.4 (CH=CH), 
133.8 (CCHN), 131.6 (CH=CH), 131.7 (q, J = 32.1, CCF3), 130.3 (CHCCHCCF3), 
129.8 (CHCHCCF3), 124.9 (q, J = 3.6, CHCHCCF3), 123.8 (q, J = 3.6, CCHCCF3), 
124.1 (d, J = 272.4, CF3), 121.7 (CHCN), 72.9 (C9H), 70.0 (C3H2), 46.0 (C9aH), 
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41.4 (C3aH), 41.3 (C4H), 38.8 (C4aH), 38.3 (C8aH), 31.1 (C5H2), 29.0 (C6H2 & C7H2), 
26.1 (C8H2); IR (thin film) 2924 (C-H), 2853 (C-H), 1773 (C=O), 1441, 1334, 1266, 
1165, 1123, 1010, 753 cm-1; m/z (ES+) 458 (100%, [M+H]+); HRMS (ES+) calcd for 
C26H27NO3F3 [M]+ 458.1943, observed 458.1947. 
 
Data for (3aS*,4R*,4aS*,8aR*,9R*,9aS*)-9-hydroxy-4-((E)-2-(5-(3-
(trifluoromethyl)phenyl)pyridin-2-yl)vinyl)decahydronaphtho[2,3-c]furan-1(3H)-one 
(90): 
 
1H NMR (600 MHz, CDCl3)  8.79 (1H, d, J = 2.3, CHN), 7.85 (1H, dd, J = 8.3, 2.3, 
CHCCHN), 7.81 (1H, s, CHCCF3), 7.76 (1H, d, J = 7.5, CHCHCCF3), 7.66 (1H, d, J 
= 7.9, CHCCHCCF3), 7.61 (1H, t, J = 7.9, CHCHCCF3), 7.31 (1H, d, J = 7.9, 
CHCN), 6.88 (1H, dd, J = 15.4, 9.8, CH=CH), 6.52 (1H, d, J = 15.4, CH=CH), 4.36 
(2H, d, J = 9.8, C3H2), 4.11 (1H, t, J = 4.3, C9H), 2.87 (1H, dd, J = 8.3, 4.9, C9aH), 
2.74 (1H, td, J = 9.8, 8.3, C3aH), 2.51 (1H, dd, J = 9.8, 5.3, C4H), 2.00 (1H, d, J = 
4.5, OH), 1.99-1.94 (1H, m, C4aH), 1.79-1.70 (2H, m, C7HH & C8HH), 1.61-1.55 
(2H, m, C5HH, C6HH & C8aH), 1.32-1.20 (4H, m, C5HH, C6HH, C7HH & C8HH); 13C 
NMR (150 MHz, CDCl3)  178.2 (C1=O), 154.7 (CN), 148.2 (CHN), 138.6 
(CCHCCF3), 135.1 (CHCCHN & CH=CH), 133.7 (CCHN), 131.0 (CH=CH), 130.9 
(q, J = 32.8, CCF3), 130.3 (CHCCHCCF3), 129.8 (CHCHCCF3), 124.8 (q, J = 3.8, 
CHCHCCF3), 123.8 (q, J = 3.8, CCHCCF3), 124.1 (d, J = 272.4, CF3), 121.9 
(CHCN), 71.4 (C3H2), 69.2 (C9HOH), 44.1 (C9aH), 41.5 (C4H), 40.3 (C3aH), 38.6 
(C8aH2), 31.5 (C4aH), 29.8 (C5H2), 28.9 (C8H2), 26.4 (C6H2), 26.1 (C7H2); IR (thin 
film) 2925 (C-H), 2854 (C-H), 1755 (C=O), 1334, 1266, 1165, 1126, 1010, 753 cm-
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1; m/z (ES+) 458 (100%, [M+H]+); HRMS (ES+) calcd for C26H27NO3F3 [M]+ 
458.1943, observed 458.1951. 
 
 (3aS*,4R*,4aS*,8aS*,9aS*)-1,9-Dioxododecahydronaphtho[2,3-c]furan-
4-carboxylic acid (91) 
 
TFA (3.00 mL, 38.9 mmol) was added to a stirred solution of 
(3aS*,4R*,4aS*,8aS*,9aS*)-tert-butyl 1,9-dioxododecahydronaphtho[2,3-c]furan-4-
carboxylate (45) (1.09 g, 3.53 mmol) in CH2Cl2 (6 mL) at 0 °C, under N2. The 
reaction mixture was stirred at 20 °C for 16 h before being concentrated in vacuo. 
The residue was azeotroped with toluene (25 mL) to yield a crude pink solid. 
Purification by trituration (CH2Cl2) yielded (3aS*,4R*,4aS*,8aS*,9aS*)-1,9-
dioxododecahydronaphtho[2,3-c]furan-4-carboxylic acid (91) (441 mg, 1.75 mmol, 
49%) as a white solid; 1H NMR (600 MHz, CDCl3)  4.33 (1H, dd, J = 9.8, C3HH), 
4.27 (1H, dd, J = 9.8, 4.5, C3HH), 3.55 (1H, d, J = 7.9, C9aH), 3.22 (1H, ddd, J = 
11.8, 7.4, 4.5, C3aH), 2.57 (1H, t, J = 11.5, C3aH), 2.19-2.12 (1H, m, C8HH), 2.06-
2.01 (1H, m, C8aH), 1.89-1.82 (2H, m, C6HH & C7HH), 1.81-1.73 (2H, m, C5HH & 
C4aH), 1.26-1.18 (4H, m, C5HH, C6HH, C7HH & C8HH); 13C NMR (150 MHz, CDCl3) 
 201.5 (C9=O), 177.5 (C=OOH), 171.2 (C1=O), 70.6 (C3H2), 53.2 (C9aH), 51.1 
(C4H), 49.9 (C8aH), 42.5 (C3aH), 42.4 (C4aH), 31.8 (C5H2), 25.1 (C8H2), 25.0 (C6H2), 
24.7 (C7H2); IR (thin film) 2930 (C-H), 2869 (C-H), 1779 (C=O), 1705 (C=O), 1171, 
1166, 1018 cm-1; m/z (ES+) 253 (100%, [M+H]+); HRMS (EI) calcd for C13H16O5 
[M]+ 252.0992, observed 252.0982. 
 
 (3aR*,4R*,4aS*,8aS*,9aS*)-S-Ethyl 1,9-dioxododecahydronaphtho[2,3-
c]furan-4-carbothioate (92) 
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EDCl (502 mg, 2.62 mmol) was added to a stirred solution of 
(3aS*,4R*,4aS*,8aS*,9aS*)-1,9-dioxododecahydronaphtho[2,3-c]furan-4-carboxylic 
acid (91) (440 mg, 1.74 mmol), ethanethiol (0.52 mL, 6.98 mmol) and DMAP (21.3 
mg, 0.17 mmol) in CH2Cl2 (20 mL) under N2. The reaction mixture was stirred at 20 
°C for 2 h and then quenched with sat. aq. NH4Cl (10 mL). An extraction into 
CH2Cl2 (10 mL) was completed and the organic layer was dried (hydrophobic frit) 
and concentrated in vacuo to yield (3aR*,4R*,4aS*,8aS*,9aS*)-S-ethyl 1,9-
dioxododecahydronaphtho[2,3-c]furan-4-carbothioate (92) (482 mg, 1.62 mmol, 
93%) as an off-white solid; 1H NMR (600 MHz, CDCl3)  4.38 (1H, d, J = 9.6, 
C3HH), 4.18 (1H, dd, J = 9.6, 4.7, C3HH), 3.51 (1H, d, J = 7.5, C9aH), 3.21 (1H, 
ddd, J = 11.6, 7.4, 4.7, C3aH), 3.02-2.89 (2H, m, CH2CH3), 2.70 (1H, t, J = 11.1, 
C4H), 2.15-2.10 (1H, m, C8HH), 2.02 (1H, td, J = 11.2, 3.2, C8aH), 1.85-1.69 (4H, 
m, C4aH, C5HH, C6HH & C7HH), 1.30-1.27 (3H, m, CH2CH3), 1.27-1.09 (4H, m, 
C5HH, C6HH, C7HH & C8HH); 13C NMR (150 MHz, CDCl3)  201.9 (C9=O), 201.6 
(C=OSEt), 171.4 (C1=O), 70.6 (C3H2), 54.9 (C9aH), 51.1 (C4H), 49.7 (C8aH), 41.9 
(C4aH), 39.1 (C3aH), 31.8 (C5H2), 25.1 (C8H2), 25.0 (C6H2), 24.7 (C7H2), 24.6 
(CH2CH3), 14.2 (CH2CH3); IR (thin film) 2930 (C-H), 2876 (C-H), 1783 (C=O), 1706 
(C=O), 1671 (C=O), 1448, 1362, 1203, 1137, 1012, 981, 896 cm-1; m/z (ES+) 297 
(100%, [M+H]+); HRMS (EI) calcd for C15H20O4S [M]+ 296.1077, observed 
296.1076. 
 
 (3aS*,4aR*,8aS*,9aS*)-1,9-dioxododecahydronaphtho[2,3-c]furan-4-
carbaldehyde (93) 
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Neat triethylsilane (1.02 mL, 6.41 mmol) was added to a stirred solution of 
(3aR*,4R*,4aS*,8aS*,9aS*)-S-ethyl 1,9-dioxododecahydronaphtho[2,3-c]furan-4-
carbothioate (92) (475 mg, 1.60 mmol), palladium on carbon (171 mg, 1.60 mmol) 
and MgSO4 (to dry) in anhydrous, degassed acetone (25 mL) under N2. The 
reaction mixture was stirred at 20 °C for 16 h before being filtered over celite and 
concentrated in vacuo. Purification by flash column chromatography (0-100% 
EtOAc/cyclohexane) gave partial racemisation at C4 to yield 
(3aS*,4aR*,8aS*,9aS*)-1,9-dioxododecahydronaphtho[2,3-c]furan-4-carbaldehyde 
(93) (4S*:4R*; 1:6) (130 mg, 0.55 mmol, 34%) as a colourless oil; 1H NMR (600 
MHz, CDCl3)  9.90-9.89 (1H, m, 4S*-CHO), 9.83 (1H, d, J = 2.8, 4R*-CHO), 4.26 
(1H, dd, J = 9.8, 4.7, 4R-C3HH), 4.20 (1H, d, J = 9.6, 4R*-C3HH), 3.56 (1H, d, J = 
7.8, 4R*-C9aH), 3.22 (1H, ddd, J = 11.6, 7.5, 4.5, 4R*-C3aH), 2.57 (1H, td, J = 11.4, 
2.9, 4R*-C4H), 2.18-2.11 (2H, m, 4R*-C8HH & 4R*-C8aH), 2.04-1.97 (2H, m, 4R*-
C6HH & 4R*-C7HH), 1.89-1.77 (2H, m, 4R*-C5HH & 4R*-C4aH), 1.40-1.35 (1H, m, 
4R*-C8HH), 1.32-1.19 (3H, m, 4R*-C5HH, 4R*-C6HH & 4R*-C7HH); 13C NMR (150 
MHz, CDCl3)  201.6 (4R*-C9=O), 201.3 (4R*-CHO), 168.7 (4R*-C1=O), 70.4 (4R*-
C3H2), 54.8 (4R*-C4H), 52.9 (4R*-C9aH), 51.1 (4R*-C8aH), 41.8 (4R*-C4aH), 39.1 
(4R*-C3aH), 31.7 (4R*-C5H2), 24.9 (4R*-C8H2 & 4R*-C6H2), 24.5 (4R*-C7H2), 19.1 
(4R*-C3HCH3); IR (thin film) 2927 (C-H), 2855 (C-H), 1770 (C=O), 1713 (C=O), 
1125, 730 cm-1; m/z (ES+) 237 (100%, [M+H]+); HRMS (EI) calcd for C13H16O4 [M]+ 
236.1043, observed 236.1049. 
 
(3aS*,4R*,4aR*,8aS*,9aS*)-4-((E)-2-(5-(3-(Trifluoromethyl)phenyl)pyridin-
2-yl)vinyl)octahydronaphtho[2,3-c]furan-1,9(3H,9aH)-dione (94) 
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n-BuLi (2.7 M in heptanes) (0.25 mL, 0.66 mmol) was added dropwise to a stirred 
solution of diethyl (5-(3-(trifluoromethyl)phenyl)pyridin-2-yl)methylphosphonate (28) 
(226 mg, 0.60 mmol) in anhydrous 2-MeTHF (10 mL) at 0 °C, under N2. The 
solution was stirred at 0 °C for 10 min before a solution of (3aS*,4aR*,8aS*,9aS*)-
1,9-dioxododecahydronaphtho[2,3-c]furan-4-carbaldehyde (93) (130 mg, 0.55 
mmol) in anhydrous 2-MeTHF (10 mL) was added. The reaction mixture was 
stirred at 0 °C for a further 1 h and then quenched with sat. aq. NH4Cl (5 mL). An 
extraction into EtOAc (10 mL) was completed and the organic phase was washed 
with sat. aq. brine (5 mL), dried (hydrophobic frit) and concentrated in vacuo to 
yield a crude yellow gum. Purification by automated column chromatography (0-
100% EtOAc/cyclohexane) yielded (3aS*,4R*,4aR*,8aS*,9aS*)-4-((E)-2-(5-(3-
(trifluoromethyl)phenyl)pyridin-2-yl)vinyl)octahydronaphtho[2,3-c]furan-
1,9(3H,9aH)-dione (94) (76.0 mg, 0.17 mmol, 25 %) as a yellow glass; 1H NMR 
(600 MHz, CDCl3)  8.82 (1H, d, J = 2.0, CHN), 7.90 (1H, dd, J = 8.1, 2.4, 
CHCCHN), 7.83 (1H, s, CHCCF3), 7.78 (1H, d, J = 7.6, CHCCHCCF3), 7.69 (1H, d, 
J = 7.8, CHCHCCF3), 7.63 (1H, t, J = 7.6, CHCHCCF3), 7.36 (1H, dd, J = 8.2, 0.6, 
CHCN), 6.70 (1H, d, J = 15.4, CH=CH), 6.56 (1H, dd, J = 15.4, 9.4, CH=CH), 4.37 
(1H, d, J = 9.4, C3HH), 4.20 (1H, dd, J = 9.4, 4.8, C3HH), 3.58 (1H, d, J = 7.4, 
C9aH), 2.85 (1H, ddd, J = 11.1, 7.4, 4.8, C3aH), 2.34 (1H, td, J = 11.1, 9.4, C4H), 
2.20-2.08 (1H, m, C8aH & C8HH), 2.02-1.94 (1H, m, C5HH), 1.86-1.66 (2H, m, 
C6HH & C7HH), 1.56 (1H, qd, J = 11.2, 3.4, C4aH), 1.34-1.00 (4H, m, C5HH, C6HH,  
C7HH & C8HH); 13C NMR (150 MHz, CDCl3)  203.0 (C9=O), 172.1 (C1=O), 152.6 
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(CN), 147.8 (CHN), 138.2 (CCHCCF3), 134.7 (CHCCHN), 134.4 (CCHN), 134.3 
(CH=CH), 131.9 (CH=CH), 131.8 (q, J = 32.1, CCF3), 130.3 (CHCCHCCF3), 129.9 
(CHCHCCF3), 125.1 (q, J = 3.6, CHCHCCF3), 123.9 (q, J = 3.6, CCHCCF3), 124.0 
(d, J = 272.0, CF3), 122.5 (CHCN), 70.5 (C3H2), 53.9 (C9aH), 52.0 (C8aH), 48.2 
(C4H), 44.5 (C3aH), 44.4 (C4aH), 32.7 (C5H2), 25.4 (C8H2), 25.3 (C6H2), 24.9 (C7H2); 
IR (thin film) 2930 (C-H), 2858 (C-H), 1772 (C=O), 1706 (C=O), 1335, 1167, 1119, 
1072, 998, 971, 810 cm-1; m/z (ES+) 455 (100%, [M+H]+); HRMS (EI) calcd for 
C26H24O3F3N [M+H]+ 455.17028, observed 455.17029. 
 
Purification by chiral column chromatography gave (+)-(3aS,4R,4aR,8aS,9aS)-4-
((E)-2-(5-(3-(trifluoromethyl)phenyl)pyridin-2-yl)vinyl)octahydronaphtho[2,3-c]furan-
1,9(3H,9aH)-dione ((+)-94) with an [α]D25 = +31.4 (MeOH) and (-)-
(3aS,4R,4aR,8aS,9aS)-4-((E)-2-(5-(3-(trifluoromethyl)phenyl)pyridin-2-
yl)vinyl)octahydronaphtho[2,3-c]furan-1,9(3H,9aH)-dione ((-)-94) with an [α]D25 = -
31.3 (MeOH). 
 
Ethyl 3-cyclohexenyl-3-oxopropanoate (95) 
 
A solution of 1-(cyclohex-1-en-1-yl)ethanone (1.04 mL, 8.05 mmol) and diethyl 
carbonate (2.93 mL, 24.2 mmol) in t-BME (5 mL) was added dropwise to a stirred 
solution of KOt-Bu (1 M in THF) (16.1 mL, 16.1 mmol) under N2. The reaction 
mixture was stirred at 20 °C for 16 hr and then quenched with sat. aq. NH4Cl (10 
mL). An extraction into t-BME (2 x 30 mL) was completed and the combined 
organic layers were dried (hydrophobic frit) and concentrated in vacuo to yield a 
crude orange oil. Purification by automated column chromatography (0-100% t-
BME/cyclohexane) yielded ethyl 3-cyclohexenyl-3-oxopropanoate (95) (441 mg, 
2.25 mmol, 28%) as a yellow oil. Some of the product existed in the enol form; 1H 
NMR (400 MHz, CDCl3)  12.13 (<1H, s, Enol-OH), 6.92-6.89 (1H, m, C=CH), 
6.82-6.78 (<1H, m, Enol-C=CH), 5.13-5.11 (<1H, m, Enol-HC=COH), 4.22 (<2H, q, 
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J = 7.2, Enol-CH2CH3), 4.20 (2H, q, J = 7.2, CH2CH3), 3.68 (2H, s, C=OCH2C=O), 
2.32-2.20 (<6H, m, CH2C=CH, C=CHCH2 & Enol- CH2C=CH), 2.17-2.12 (<2H, m, 
Enol-C=CHCH2), 1.7-1.59 (<8H, m, 2 x CH2 & 2 x Enol-CH2), 1.31 (<3H, t, J = 7.1, 
Enol-CH2CH3), 1.28 (3H, t, J = 7.1, CH2CH3); 13C NMR (150 MHz, CDCl3)  193.6 
(C=O), 168.6 (C=OOEt), 142.6 (CH=C), 139.2 (CH=C), 62.0 (OCH2CH3), 44.9 
(C=OCH2C=O), 26.5 (C=CHCH2), 23.2 (CH2C=CH), 21.9 (CH2), 21.6 (CH2), 13.8 
(OCH2CH3); IR (thin film) 2933 (C-H), 2864 (C-H), 1731 (C=O), 1664 (C=O), 1187, 
1031 cm-1; m/z (ES+) 197 (100%, [M+H]+); HRMS (EI) calcd for C11H16O3 [M]+ 
196.1094, observed 196.1095. 
 
tert-Butyl 3-cyclohexenyl-3-oxopropanoate153 (96) 
 
n-BuLi (1.6 M in hexanes) (12.3 mL, 19.6 mmol) was added dropwise to a stirred 
solution of DIPA (2.80 mL, 19.6 mmol) in anhydrous 2-MeTHF (20 mL) at 0 °C, 
under N2. The reaction mixture was stirred at 0 °C for 20 min and then cooled to -
78 °C. Next, tert-butyl acetate (2.87 mL, 21.4 mmol) was added dropwise and 
stirring continued for 10 min at -78 °C. Finally, a solution of methyl cyclohex-1-
enecarboxylate (0.47 mL, 3.57 mmol) in anhydrous 2-MeTHF (20 mL) was added. 
The reaction mixture was stirred at -78 °C for 4 h and then quenched with sat. aq. 
NH4Cl (10 mL). An extraction into 2-MeTHF (2 x 30 mL) was completed and the 
combined organic layers were dried (hydrophobic frit) and concentrated in vacuo to 
yield a crude yellow oil. Purification by automated column chromatography (0-25% 
EtOAc/cyclohexane) yielded tert-butyl 3-cyclohexenyl-3-oxopropanoate (96) (757 
mg, 3.38 mmol, 95%) as a colourless oil; 1H NMR (400 MHz, Acetone-d6)  7.00-
6.95 (1H, m, C=CH), 3.61 (2H, s, C=OCH2C=O), 2.31-2.24 (2H, m, CHHC=CH & 
C=CHCHH), 2.22-2.16 (2H, m, 2 x CHH), 1.65-1.60 (4H, m, CHHC=CH, 
C=CHCHH & 2 x CHH), 1.43 (9H, s, C(CH3)3); 13C NMR (150 MHz, CDCl3)  194.1 
(C=O), 167.5 (C=OOEt), 142.1 (CH=C), 139.1 (CH=C), 81.6 (OC(CH3)3), 46.1 
(C=OCH2C=O), 28.0 (OC(CH3)3), 26.3 (C=CHCH2), 23.1 (CH2C=CH), 21.9 (CH2), 
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21.6 (CH2); IR (thin film) 2975 (C-H), 2933 (C-H), 2862 (C-H), 1728 (C=O), 1668 
(C=O), 1367, 1249, 1144, 962, 840 cm-1; m/z (ES+) 225 (100%, [M+H]+); HRMS 
(EI) calcd for C13H20O3 [M]+ 224.1407, observed 224.1412. Data agrees with that 
reported by Lavallée et al..153  
 
3-Cyclohexenyl-3-oxopropanoic acid (97) 
 
TFA (1.25 mL, 16.2 mmol) was added to a stirred solution of tert-butyl 3-
cyclohexenyl-3-oxopropanoate (96) (750 mg, 3.35 mmol) in CH2Cl2 (8 mL) under 
N2. The reaction mixture was stirred at 20 °C for 2 h before being concentrated in 
vacuo. Purification by automated column chromatography (0-100% 
EtOAc/cyclohexane) yielded 3-cyclohexenyl-3-oxopropanoic acid (97) (465 mg, 
2.77 mmol, 83%) as a colourless oil; 1H NMR (400 MHz, Acetone-d6)  4.87-4.80 
(1H, m, C=CH), 3.12-3.08 (2H, m, C=OCH2C=O), 2.88-2.81 (1H, m, CHHC=CH), 
2.26-2.19 (1H, m, C=CHCHH), 1.89-1.77 (3H, m, CHHC=CH & 2 x CHH), 1.56 
(1H, qt, J = 13.1, 3.6, CHH), 1.47-1.40 (1H, m, C=CHCHH), 1.33-1.20 (1H, m, 
CHH); m/z (ES+) 169 (100%, [M+H]+). 
 
(R)-Benzyl 4-hydroxypent-2-ynoate141 (98) 
 
HMDS (3.52 mL, 16.8 mmol) was added to a stirred solution of (R)-but-3-yn-2-ol 
(2.40 mL, 30.5 mmol) in anhydrous 2-MeTHF (15 mL), with a drop of H2SO4 added, 
under N2. The reaction mixture was stirred at 70 °C for 16 h. Once cool, the 
reaction mixture was further cooled to -40 °C, n-BuLi (2.7 M in heptanes) (11.3 mL, 
30.5 mmol) was added dropwise and stirring was continued for 1.5 h at -40 °C. The 
solution was then added, via cannular, to a stirred solution of benzyl chloroformate 
(5.23 mL, 36.6 mmol) in anhydrous 2-MeTHF (15 mL) and stirring was continued 
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for a further 30 min. Finally, aq. H2SO4 (6N, 12 mL) was added dropwise. The 
reaction mixture was stirred at 20 °C for a further 1 h. An extraction into t-BME (2 x 
50 mL) was completed and the combined organic layers were washed with NH4OH 
(50 mL) and sat. aq. brine (50 mL), dried (hydrophobic frit) and concentrated in 
vacuo to yield a crude brown oil. Purification by automated column 
chromatography (0-25% EtOAc/cyclohexane) yielded (R)-benzyl 4-hydroxypent-2-
ynoate (98) (3.42 g, 16.8 mmol, 55%) as a colourless oil; 1H NMR (400 MHz, 
CDCl3)  7.41-7.38 (5H, m, 5 x Ar-CH), 5.23 (2H, s, Bz-CH2), 4.65 (1H, qd, J = 6.7, 
5.6, CHOH), 2.20 (1H, d, J = 5.6, CHOH), 1.52 (3H, d, J = 6.7, CH3); 13C NMR (150 
MHz, CDCl3)  153.4 (C=O), 134.8 (Ar-C), 128.8 (2 x Ar-CH), 128.8 (2 x Ar-CH), 
128.7 (Ar-CH), 89.0 (C≡C), 81.2 (CHOH), 75.8 (C≡C), 67.9 (Bz-CH2), 23.4 (CH3); 
IR (thin film) 2237, 1706 (C=O), 1373, 1232, 1056, 748, 697 cm-1; m/z (ES+) 222 
(100%, [M+H]+); HRMS (EI) calcd for C12H12O3 [M]+ 204.0781, observed 204.0740. 
Data agrees with that reported by Fu et al..141  
 
(R)-Benzyl 4-(3-cyclohexenyl-3-oxopropanoyloxy)pent-2-ynoate (99) 
 
NBS (72.6 mg, 0.41 mmol) was added to a stirred solution of (R)-benzyl 4-
hydroxypent-2-ynoate (98) (416 mg, 2.04 mmol) and ethyl 3-cyclohexenyl-3-
oxopropanoate (95) (400 mg, 2.04 mmol) in toluene (8 mL) under N2. The reaction 
mixture was stirred at 90 °C for 16 h, in a flask with a distillation arm attached, 
before being concentrated in vacuo. Purification by automated column 
chromatography (0-50% t-BME/cyclohexane) yielded a crude colourless oil. 
Further purification by MDAP (MeCN/H2O with a formic acid modifier) yielded (R)-
benzyl 4-(3-cyclohexenyl-3-oxopropanoyloxy)pent-2-ynoate (99) (27 mg, 0.076 
mmol, 4%) as a colourless oil; 1H NMR (400 MHz, CDCl3)  7.41-7.37 (5H, m, 5 x 
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Ar-CH), 6.90-6.87 (1H, m, C=CH), 5.61 (1H, q, J = 6.7, OCHCH3), 5.22 (2H, s, Bz-
CH2), 3.72 (2H, s, C=OCH2C=O), 2.31-2.23 (4H, m, 2 x CH2), 1.68-1.59 (4H, m, 2 x 
CH2), 1.58 (3H, d, J = 6.7, CH3); IR (thin film) 2938 (C-H), 2870 (C-H), 2856 (C-H), 
1721 (C=O), 1656 (C=O), 1258, 1216, 1161, 1081, 733 cm-1; m/z (ES+) 355 
(100%, [M+H]+); HRMS (CI) calcd for C21H23O5 [M+H]+ 355.1540, observed 
355.1542. 
 
(R)-Benzyl 4-hydroxypentanoate (100) 
 
A solution of (R)-benzyl 4-hydroxypent-2-ynoate (98) (1.50 g, 7.34 mmol) in EtOH 
(20 mL) was added to Lindlar catalyst (120 mg, 1.13 mmol) and quinoline (0.26 
mL, 2.20 mmol) under N2. The reaction mixture was stirred under H2 at 20 °C for 
16 h. The reaction mixture was diluted with EtOAc (20 mL), filtered over celite and 
concentrated in vacuo. Purifcation by automated column chromatography (0-50% t-
BME/cyclohexane) yielded (R)-benzyl 4-hydroxypentanoate (100) (712 mg, 3.42 
mmol, 47%) as a colourless oil; 1H NMR (400 MHz, CDCl3)  7.40-7.34 (5H, m, 5 x 
Ar-CH), 5.15 (2H, s, Bz-CH2), 3.91-3.81 (1H, m, CHOH), 2.53 (1H, dd, J = 7.2, 0.5, 
CHHC=O), 2.51 (1H, d, J = 7.1, CHHC=O), 1.88 (1H, td, J = 7.4, 4.3, COHCHH), 
1.84 (1H, td, J = 7.4, 4.3, COHCHH), 1.23 (3H, d, J = 6.2, CH3); 13C NMR (150 
MHz, CDCl3)  177.5 (C=O), 141.0 (Ar-C), 128.7 (2 x Ar-CH), 127.9 (Ar-CH), 127.2 
(2 x Ar-CH), 77.4 (CHOH), 65.5 (Bz-CH2), 29.9 (CH2), 29.2 (CH2), 21.2 (CH3); IR 
(thin film) 3409 (br, OH), 2977 (C-H), 2932 (C-H), 2874 (C-H), 1760 (C=O), 1453, 
1385, 1343, 1171, 1040, 1020, 940, 736, 698 cm-1; m/z (ES+) 209 (100%, [M+H]+); 
HRMS (CI) calcd for C12H17O3 [M+H]+ 209.1172, observed 209.1170. 
 
Benzyl 3-cyclohexenyl-3-oxopropanoate (101) 
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NEt3 (0.21 mL, 1.49 mmol) was added to a stirred solution of (R)-benzyl 4-
hydroxypent-2-ynoate (98) (153 mg, 0.74 mmol) and ethyl 3-(cyclohex-1-en-1-yl)-3-
oxopropanoate (95) (146 mg, 0.74 mmol) in toluene (3 mL) under N2. The reaction 
mixture was stirred at 110 °C for 18 h, in a flask attached to a distillation arm, 
before being quenched with H2O (10 mL). An extraction into EtOAc (2 x 20 mL) 
was completed and the combined organic layers were washed with sat. aq. brine 
(5mL), dried (hydrophobic frit) and concentrated in vacuo to yield a crude 
colourless oil. Purification by MDAP (MeCN/H2O with an (NH4)HCO3 modifier) 
yielded benzyl 3-cyclohexenyl-3-oxopropanoate (101) (125 mg, 0.46 mmol, 65%) 
as a colourless oil; 1H NMR (400 MHz, CDCl3)  7.41-7.34 (5H, m, 5 x Ar-CH), 
6.90-6.86 (1H, m, C=CH), 5.20 (2H, s, Bz-CH2), 3.75 (2H, s, C=OCH2C=O), 2.28-
2.22 (4H, m, CH2C=CH & C=CHCH2), 1.68-1.56 (2H, m, 2 x CH2); m/z (ES+) 259 
(100%, [M+H]+). 
 
(R,Z)-Dibenzyl 3-(1-(cyclohex-1-enecarbonyloxy)ethyl)pent-2-enedioate 
(102) 
 
Cs2CO3 (139 mg, 0.43 mmol) was added to a stirred solution of (R)-benzyl 4-
hydroxypent-2-ynoate (98) (87.0 mg, 0.43 mmol) and benzyl 3-cyclohexenyl-3-
oxopropanoate (101) (110 mg, 0.43 mmol) in EtOAc (10 mL) under N2. The 
reaction mixture was stirred at 20 °C for 16 h and then quenched with H2O (25 mL) 
and extracted into EtOAc (50 mL). The organic layer was washed with sat. aq. 
brine (25 mL), dried (hydrophobic frit) and concentrated in vacuo to yield a crude 
orange oil. Purification by automated column chromatography (0-25% 
EtOAc/cyclohexane) yielded a crude red oil. Further purification by MDAP 
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(MeCN/H2O with an (NH4)HCO3 modifier) yielded (R,Z)-dibenzyl 3-(1-(cyclohex-1-
enecarbonyloxy)ethyl)pent-2-enedioate (102) (13 mg, 0.028 mmol, 7%) as a yellow 
solid; 1H NMR (400 MHz, CDCl3)  7.40-7.32 (10H, m, 10 x Ar-CH), 7.00 (1H, 
dquin, J = 3.8, 2.1, C=CH), 6.16 (1H, s, C=CHC=O), 5.47 (1H, qd, J = 6.5, 1.0, 
OCHCH3), 5.14 (2H, s, Bz-CH2), 5.12 (2H, s, Bz-CH2), 3.84 (1H, d, J = 16.6, 
CHHC=CH), 3.74 (1H, d, J = 16.6, CHHC=CH), 2.27-2.15 (4H, m, 2 x CH2), 1.69-
1.56 (4H, m, 2 x CH2), 1.40 (3H, d, J = 6.5, CHCH3); 13C NMR (100 MHz, CDCl3)  
169.5 (C=CHC=O), 166.1 (CC=OO), 165.7 (CCH2C=O), 152.3 (C=CHC=O), 140.6 
(Cyc-C=CH), 135.8 (2 x Bz-C), 130.0 6 (Cyc-C=CH), 128.6, 128.5, 128.4, 128.3, 
128.2, 128.1 (10 x Ar-CH), 119.1 (C=CHC=O), 72.6 (CHCH3), 66.7 (Bz-CH2), 66.2 
(Bz-CH2), 34.5 (CCH2C=O), 25.8 (CH2), 24.0 (CH2), 22.0 (CH2), 21.4 (CH2), 19.3 
(CHCH3); IR (thin film) 2936 (C-H), 1715 (C=O), 1233, 1149, 744, 698 cm-1; m/z 
(ES+) 462 (100%, [M+H]+); HRMS (EI) calcd for C28H30O6 [M]+ 462.2034, observed 
462.2035. 
 
(R,Z)-1-Benzyl 5-ethyl 3-(1-(cyclohex-1-enecarbonyloxy)ethyl)pent-2-
enedioate (103) 
 
Cs2CO3 (498 mg, 1.53 mmol) was added to a stirred solution of (R)-benzyl 4-
hydroxypent-2-ynoate (98) (312 mg, 1.53 mmol) and ethyl 3-cyclohexenyl-3-
oxopropanoate (95) (300 mg, 1.53 mmol) in EtOAc (12 mL) under N2. The reaction 
mixture was stirred at 20 °C for 16 h and then quenched with H2O (15 mL). An 
extraction into EtOAc (2 x 30 mL) was completed and the combined organic layers 
were washed with sat. aq. brine (10 mL), dried (hydrophobic frit) and concentrated 
in vacuo to yield a crude orange oil. Purification by automated column 
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chromatography (0-50% EtOAc/cyclohexane) yielded a crude yellow oil. Further 
purification by MDAP (MeCN/H2O with a formic acid modifier) yielded a 1:1 mixture 
of (R,Z)-1-benzyl 5-ethyl 3-(1-(cyclohex-1-enecarbonyloxy)ethyl)pent-2-enedioate 
(103) and (R,E)-5-benzyl 1-ethyl 3-(1-(cyclohex-1-enecarbonyloxy)ethyl)pent-2-
enedioate (104) (42 mg, 0.10 mmol, 7%) and (R)-benzyl 4-(2-cyclohexenyl-2-
oxoethyl)-5-methyl-2-oxo-2,5-dihydrofuran-3-carboxylate (105) (12 mg, 0.03 mmol, 
2%). The 1:1 mixture was purified further by chiral column chromatography to yield 
(R,Z)-1-benzyl 5-ethyl 3-(1-(cyclohex-1-enecarbonyloxy)ethyl)pent-2-enedioate 
(103) (18 mg, 0.04 mmol, 3%) and (R,E)-5-benzyl 1-ethyl 3-(1-(cyclohex-1-
enecarbonyloxy)ethyl)pent-2-enedioate (104) (18 mg, 0.04 mmol, 3%) as white 
solids. 
 
Data for (R,Z)-1-benzyl 5-ethyl 3-(1-(cyclohex-1-enecarbonyloxy)ethyl)pent-2-
enedioate (103): 
 
1H NMR (400 MHz, CDCl3)  7.40-7.32 (5H, m, 5 x Ar-CH), 7.02 (1H, dt, J = 3.8, 
2.0, C=CH), 6.15 (1H, s, C=CHC=O), 5.47 (1H, qd, J = 6.8, 0.8, OCHCH3), 5.17 
(2H, s, Bz-CH2), 4.13 (2H, q, J = 7.2, OCH2CH3), 3.78 (1H, d, J = 16.4, 
CHHC=CH), 3.68 (1H, d, J = 16.4, CHHC=CH), 2.30-2.18 (4H, m, 2 x CH2), 1.72-
1.57 (4H, m, 2 x CH2), 1.42 (3H, d, J = 6.5, CHCH3), 1.25 (3H, t, J = 7.2, CH2CH3); 
13C NMR (150 MHz, CDCl3)  169.6 (CCH2C=O), 166.1 (CC=OO), 165.7 
(C=CHC=O), 152.6 (C=CHC=O), 140.5 (Cyc-C=CH), 135.8 (Bz-C), 130.1 (Cyc-
C=CH), 128.6 (2 x Ar-CH), 128.4 (Ar-CH), 128.3 (2 x Ar-CH), 118.9 (C=CHC=O), 
72.6 (CHCH3), 66.1 (Bz-CH2), 60.9 (CH2CH3), 34.6 (CCH2C=O), 25.8 (CH2), 24.1 
(CH2), 22.0 (CH2), 21.4 (CH2), 19.0 (CHCH3), 14.1 (CH2CH3); IR (thin film) 2933 
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(C-H), 1708 (C=O), 1648 (C=O), 1230, 1146, 1033, 743, 697 cm-1; m/z (ES+) 401 
(100%, [M+H]+); HRMS (EI) calcd for C23H28O6 [M]+ 400.1880, observed 400.1885. 
 
Data for (R,E)-5-benzyl 1-ethyl 3-(1-(cyclohex-1-enecarbonyloxy)ethyl)pent-2-
enedioate (104): 
 
1H NMR (400 MHz, CDCl3)  7.41-7.32 (5H, m, 5 x Ar-CH), 7.01 (1H, tt, J = 3.8, 
1.8, C=CH), 6.10 (1H, s, C=CHC=O), 5.47 (1H, qd, J = 6.5, 1.0, OCHCH3), 5.14 
(2H, s, Bz-CH2), 4.15 (2H, qd, J = 7.1, 0.5, OCH2CH3), 3.82 (1H, d, J = 16.6, 
CHHC=CH), 3.72 (1H, d, J = 16.6, CHHC=CH), 2.29-2.16 (4H, m, 2 x CH2), 1.70-
1.56 (4H, m, 2 x CH2), 1.40 (3H, d, J = 6.8, CHCH3), 1.26 (3H, t, J = 7.2, CH2CH3); 
13C NMR (150 MHz, CDCl3)  169.6 (CCH2C=O), 166.2 (CC=OO), 165.9 
(C=CHC=O), 151.5 (C=CHC=O), 140.5 (Cyc-C=CH), 135.8 (Bz-C), 130.1 (Cyc-
C=CH), 128.5 (2 x Ar-CH), 128.1 (Ar-CH), 128.1 (2 x Ar-CH), 119.6 (C=CHC=O), 
72.7 (CHCH3), 66.7 (Bz-CH2), 60.3 (CH2CH3), 34.4 (CCH2C=O), 25.8 (CH2), 24.1 
(CH2), 22.0 (CH2), 21.4 (CH2), 19.0 (CHCH3), 14.2 (CH2CH3); IR (thin film) 2934 
(C-H), 1708 (C=O), 1648 (C=O), 1230, 1146, 1070, 1034, 742, 697 cm-1; m/z 
(ES+) 401 (100%, [M+H]+); HRMS (EI) calcd for C23H28O6 [M]+ 400.1880, 
observed 400.1885. 
 
Data for (R)-benzyl 4-(2-cyclohexenyl-2-oxoethyl)-5-methyl-2-oxo-2,5-dihydrofuran-
3-carboxylate (105): 
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1H NMR (600 MHz, CDCl3)  7.42-7.32 (5H, m, 5 x Ar-CH), 6.80-6.77 (1H, m, 
C=CH), 5.26 (1H, q, J = 6.8, OCHCH3), 5.16 (2H, s, Bz-CH2), 3.70 (1H, d, J = 17.0, 
CCHHC=O), 3.44 (1H, d, J = 17.0, CCHHC=O), 2.33-2.30 (2H, m, CH2C=CH), 
2.27-2.21 (2H, m, C=CHCH2), 1.71-1.61 (4H, m, 2 x CH2), 1.49 (3H, d, J = 6.9, 
CHCH3); 13C NMR (150 MHz, CDCl3)  190.3 (CH2C=O), 169.1 (CH=CC=O), 167.3 
(CC=OOCH2), 163.8 (C=CC=OO), 147.7 (Cyc-C=CH), 139.2 (Cyc-C=CH), 134.9 
(Bz-C), 130.5 (C=OCC=O), 128.8 (2 x Ar-CH), 128.7 (Ar-CH), 128.4 (2 x Ar-CH), 
78.9 (CHCH3), 67.6 (Bz-CH2), 32.7 (CCH2C=O), 26.4 (C=CHCH2), 22.5 
(CH2C=CH), 21.5 (CH2), 21.4 (CH2), 17.8 (CHCH3); IR (thin film) 2941 (C-H), 1722 
(C=O), 1230, 1154, 738, 697 cm-1; m/z (ES+) 401 (100%, [M+H]+); HRMS (CI) 
calcd for C21H23O5 [M+H]+ 355.1540, observed 355.1544. 
 
3-tert-Butyl 1,2-diethyl 4-oxodecahydronaphthalene-1,2,3-tricarboxylate 
(106) 
 
Cs2CO3 (291 mg, 0.89 mmol) was added to a stirred solution of diethyl maleate 
(0.13 mL, 0.89 mmol) and tert-butyl 3-cyclohexenyl-3-oxopropanoate (96) (200 mg, 
0.89 mmol) in EtOAc (4 mL) under N2. The reaction mixture was stirred at 20 °C for 
20 h and then quenched with H2O (10 mL). An extraction into EtOAc (2 x 20 mL) 
was completed and the combined organic layers were washed with sat. aq. brine 
(10 mL), dried (hydrophobic frit) and concentrated in vacuo to yield a crude yellow 
oil. Purification by automated column chromatography (0-25% t-BME/cyclohexane) 
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yielded a still crude colourless oil. Further purification by MDAP (MeCN/H2O with 
an (NH4)HCO3 modifier) yielded 3-tert-butyl 1,2-diethyl 4-
oxodecahydronaphthalene-1,2,3-tricarboxylate (106) (86 mg, 0.22 mmol, 24%) as 
a colourless oil and (1S*,2S*,3R*,4aS*,8aR*)-3-tert-butyl 1,2-diethyl 4-
oxodecahydronaphthalene-1,2,3-tricarboxylate (107) (13 mg, 0.03 mmol, 4%) as a 
white solid. 
 
Data for 3-tert-butyl 1,2-diethyl 4-oxodecahydronaphthalene-1,2,3-tricarboxylate 
(106): 
 
1H NMR (600 MHz, CDCl3)  4.24-4.13 (4H, m, 2 x OCH2H3), 3.66 (1H, t, J = 12.5, 
CHCO2Et), 3.32 (1H, dd, J = 12.5, 3.9, CHCO2Et), 3.26 (1H, d, J = 12.5, 
CHCO2tBu), 2.70-2.67 (1H, m, C=OCH), 2.60-2.55 (1H, m, CHCHCO2Et), 2.31-
2.27 (1H, m, CHH), 1.81-1.76 (1H, m, CHH), 1.53 (9H, s, C(CH3)3), 1.52-1.50 (1H, 
m, CHH), 1.49-1.41 (2H, m, CHH & CHH), 1.34-1.17 (8H, m, 2 x CHH & 2 x 
OCH2H3), 1.07 (1H, qd, J = 12.9, 3.3, CHH); 13C NMR (150 MHz, CDCl3)  204.2 
(C=O), 172.9 (C=OOEt), 171.8 (C=OOEt), 167.4 (C=OOtBu), 81.9 (C(CH3)3), 61.4 
(CO2CH2CH3), 61.0 (CO2CH2CH3), 59.1 (C=OCHC=O), 49.2 (C=OCHCH), 47.4 
(C=OCHCH), 42.9 (CHCO2CH2CH3), 40.8 (CHCO2CH2CH3), 28.0 (C(CH3)3), 25.9 
(CH2), 25.3 (CH2), 25.2 (CH2), 21.4 (CH2), 14.2 (CO2CH2CH3), 14.1 (CO2CH2CH3); 
IR (thin film) 2977 (C-H), 2933 (C-H), 1729 (C=O), 1671 (C=O), 1368, 1146, 1028, 
843 cm-1; m/z (ES+) 397 (100%, [M+H]+); HRMS (ES+) calcd for C21H33O7 [M+H]+ 
397.2226, observed 397.2228. 
 
Data for (1S*,2S*,3R*,4aS*,8aR*)-3-tert-butyl 1,2-diethyl 4-
oxodecahydronaphthalene-1,2,3-tricarboxylate (107): 
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1H NMR (600 MHz, CDCl3)  4.24-4.13 (4H, m, 2 x OCH2H3), 3.66 (1H, t, J = 12.5, 
CHCO2Et), 3.32 (1H, dd, J = 12.5, 3.9, CHCO2Et), 3.26 (1H, d, J = 12.5, 
CHCO2tBu), 2.70-2.67 (1H, m, C=OCH), 2.60-2.55 (1H, m, CHCHCO2Et), 2.31-
2.27 (1H, m, CHH), 1.81-1.76 (1H, m, CHH), 1.53 (9H, s, C(CH3)3), 1.52-1.50 (1H, 
m, CHH), 1.49-1.41 (2H, m, CHH & CHH), 1.34-1.17 (8H, m, 2 x CHH & 2 x 
OCH2H3), 1.07 (1H, qd, J = 12.9, 3.3, CHH); 13C NMR (150 MHz, CDCl3)  204.2 
(C=O), 172.9 (C=OOEt), 171.8 (C=OOEt), 167.4 (C=OOtBu), 81.9 (C(CH3)3), 61.4 
(CO2CH2CH3), 61.0 (CO2CH2CH3), 59.1 (C=OCHC=O), 49.2 (C=OCHCH), 47.4 
(C=OCHCH), 42.9 (CHCO2CH2CH3), 40.8 (CHCO2CH2CH3), 28.0 (C(CH3)3), 25.9 
(CH2), 25.3 (CH2), 25.2 (CH2), 21.4 (CH2), 14.2 (CO2CH2CH3), 14.1 (CO2CH2CH3); 
IR (thin film) 2936 (C-H), 1729 (C=O), 1368, 1264, 1144, 1058, 1031, 847 cm-1; 
m/z (ES+) 397 (100%, [M+H]+); HRMS (EI) calcd for C21H32O7 [M]+ 396.2143, 
observed 396.2142. 
 
Biology 
Biological testing of compounds was completed in collaboration with Prof. Rachel 
Chambers’ research group at the Centre for Inflammation and Tissue Repair (UCL, 
Division of Medicine). Calcium mobilisation assay work was assisted by Dr. Natalia 
Smoktunowicz and Dr. Manuela Plate. 
 
Materials and Methods 
Reagents: 
Thrombin, extracted from human plasma, was purchased from Calbiochem (Merck 
Biosciences, UK). PAR-1 agonist peptide and reverse peptide were supplied by 
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Bachem. The RWJ-58259 sample used as standard was synthesised by Dr. Eifion 
Robinson (University College London). 
 
Cell Culture: 
Primary human lung fibroblasts (pHLFs), grown from explant cultures of normal 
adult lung tissue, were a gift from Dr Robin J McAnulty (University College 
London). Cells were maintained in DMEM at 37 °C (10% CO2) supplemented with 
glutamine (4 mM), penicillin, streptomycin, and 10% (v/v) FBS (all from Invitrogen) 
and were below passage 10 when used for experiments. 
 
Measurement of Intracellular Ca2+ Levels: 
pHLFs were seeded in clear-bottom, black, 96-well microplates at a density of 
10,000 cells/well for 48 h and then quiesced for 24 h. Intracellular Ca2+ levels were 
assessed using the Fluo-4 AM kit (Invitrogen, UK) according to the manufacturer’s 
instructions. The dye was dissolved in assay buffer (20 mM HEPES in HBSS) 
supplemented with 2.5 mM probenecid. Wells were aspirated and solutions of test 
compounds (3 mM in DMSO) were added. Serial dilution using dye buffer solution 
was done to give the desired final concentrations (100 μL per well). For positive 
controls, the equivalent volume of DMSO only was diluted in the dye buffer solution 
and added to the relevant wells. The cells were then incubated again at 37 °C 
(10% CO2) for 30 min and at ambient conditions, in the dark, for 30 min. Cells were 
then stimulated by addition of a solution of thrombin in assay buffer (50 μL, 10 nM). 
Change in intracellular Ca2+ concentration was monitored in real-time using a 
fluorescent imaging plate reader (FLIPR® Tetra System, Molecular Devices, Inc). 
Measurements were taken every 1 sec for 1 min, then every 6 sec for a further 2 
min. Experiments were performed in three replicates, on the same plate, at least 
twice. The data was plotted as change in relative fluorescence units (RFU) or as 
percentage inhibition.154   
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